

CITATION REPORT

List of articles citing

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

DOI: 10.1212/wnl.44.12.2308
Neurology, 1994, 44, 2308-14.

Source: <https://exaly.com/paper-pdf/24892811/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2226	.		
2225	PHYSIOLOGICAL ONTOGENY : A. CHICKEN EMBRYOS. II. CATABOLISM. CHEMICAL CHANGES IN FERTILE EGGS DURING INCUBATION. SELECTION OF STANDARD CONDITIONS. 1925 , 9, 1-37		38
2224	The depressions of Alzheimer's disease: sorting, pharmacotherapy, and clinical advice. 1995 , 8 Suppl 1, S40-51		5
2223	Neuropsychiatric aspects of progressive supranuclear palsy. <i>Neurology</i> , 1996 , 47, 1184-9	6.5	208
2222	Behavioural Disorders in Demented Elderly Patients. 1996 , 6, 280-300		18
2221	Frontal Behavioral Syndromes in Cortical and Subcortical Dementia. 1996 , 3, 327-337		47
2220	The spectrum of behavioral changes in Alzheimer's disease. <i>Neurology</i> , 1996 , 46, 130-5	6.5	863
2219	Cerebral blood flow correlates of apathy in Alzheimer disease. 1996 , 53, 1116-20		184
2218	Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. 1996 , 9, 1-6		129
2217	Alzheimer disease and frontotemporal dementias. Behavioral distinctions. 1996 , 53, 687-90		251
2216	Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD). 1996 , 169, 293-307		62
2215	A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations. <i>Neurology</i> , 1997 , 48, 937-42	6.5	189
2214	Apolipoprotein E ?4 Associated With Chronic Traumatic Brain Injury in Boxing. 1997 , 278, 136		359
2213	Aggressive, socially disruptive and antisocial behaviour associated with fronto-temporal dementia. 1997 , 170, 150-4		184
2212	The family caregiver's role in Alzheimer's disease. <i>Neurology</i> , 1997 , 48, S25-9	6.5	108
2211	The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. <i>Neurology</i> , 1997 , 48, S10-6	6.5	1317
2210	Psychotic symptoms and physically aggressive behavior in Alzheimer's disease. 1997 , 45, 1074-9		83

2209	Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. 1997 , 24, 29-36		378
2208	The assessment and management of behavioural manifestations of dementia: a review and results of a controlled trial. 1997 , 1, 157-68		6
2207	Surface dyslexia in an italian patient with semantic dementia. 1997 , 3, 307-312		19
2206	Memory disorders consultation service. 1997 , 54, 92, 95		
2205	Isolated dementia in two patients with posterior intraventricular meningiomas. 1997 , 4, 606-612		
2204	Managing the burden of Alzheimer's disease: a partnership between caregiver and physician. 1998 , 5, S1-S8		5
2203	Incidence and relationship between behavioural and psychological symptoms in Alzheimer's disease. 1998 , 13, 785-92		13
2202	The home environment modification program in the care of demented elderly: Some examples. 1998 , 26, 83-90		5
2201	Special care units for dementia in nursing homes: A controlled study of effectiveness. 1998 , 26, 215-224		21
2200	Effectiveness of an educational program for demented person's relatives. 1998 , 26, 531-538		15
2199	An integrated approach to the management of Alzheimer's disease: assessing cognition, function and behaviour. 1998 , 5, S9-S17		41
2198	Modification of clinical effects and tolerability of cholinergic therapy by preceding cerebrolysin treatment in Alzheimer's disease. 1998 , 8, S274-S275		
2197	Olanaapin for psychosis in patients with Parkinson's disease with and without dementia. 1998 , 8, S275		1
2196	Psychiatric disorders in a general hospital: HIV patients compared to non-HIV patients. 1998 , 8, S275		
2195	Effects of calcium channel blockers, MK-801 and nimodipine on the Na,K-ATPase activity in rats exposed to hypoxia and cerebral ischemia. 1998 , 8, S275-S276		
2194	Frontal lobe hypometabolism and depression in Alzheimer's disease. <i>Neurology</i> , 1998 , 50, 380-3	6.5	137
2193	Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?. <i>Neurology</i> , 1998 , 50, 1203-5	6.5	21
2192	Update on diagnostic methods, natural history and outcome variables in Alzheimer's disease. 1998 , 9 Suppl 3, 2-7		9

2191	Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. <i>Neurology</i> , 1998 , 50, 1222-30	6.5	273
2190	Frequency and clinical determinants of poststroke depression. 1998 , 29, 2311-7		226
2189	Factors associated with psychotic symptoms in Alzheimer's disease. 1998 , 64, 648-52		60
2188	Apathy, depression, and cognitive performance in HIV-1 infection. 1998 , 10, 320-9		75
2187	Apathy is not depression. 1998 , 10, 314-9		437
2186	Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. <i>Neurology</i> , 1998 , 51, 125-30	6.5	201
2185	Neuropsychiatric features of corticobasal degeneration. 1998 , 65, 717-21		110
2184	Special care units for demented patients: a multicenter study. 1998 , 38, 456-62		43
2183	Depression and dementia: comorbidities, identification, and treatment. 1998 , 11, 201-5		29
2182	Hallucinations. 1998 , 86, 851-77		41
2181	Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. 1998 , 55, 1313-9		103
2180	Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. 1998 , 46, 210-5		383
2179	Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. 1998 , 10, 55-63		43
2178	Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. 1998 , 9 Suppl 2, 8-14		37
2177	Behavioral disorders in Alzheimer disease: a transcultural perspective. 1998 , 55, 539-44		88
2176	Alteration of regional cerebral glucose utilization with delusions in Alzheimer's disease. 1998 , 10, 433-9		44
2175	The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT). 1998 , 9 Suppl 2, 2-7		37
2174	Author's reply. 1998 , 4, 372-373		

2173	Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia. 1999 , 56, 2245-6	8
2172	Metrifonate: a new agent for the treatment of Alzheimer's disease. 1999 , 56, 427-32	8
2171	Behavioral syndromes in Alzheimer's disease: description and correlates. 1999 , 10, 130-8	186
2170	Acetylcholinesterase inhibitors in the treatment of Alzheimer's disease. 1999 , 8, 1511-1520	13
2169	Assessment of mood states in aphasia. 1999 , 20, 33-49; quiz 49-50	23
2168	Advances in methodology and current prospects for primary drug therapies for Alzheimer's disease. 2000 , 32, 45-61	1
2167	Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease. 1999 , 2, 59-66	6
2166	APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. <i>Neurology</i> , 1999 , 53, 321-31	6.5 324
2165	Range of neuropsychiatric disturbances in patients with Parkinson's disease. 1999 , 67, 492-6	400
2164	Outcome Measures on Inpatient Cognitive and Behavioural Units: An Overview. 1999 , 9, 345-361	4
2163	Insight in dementia: when does it occur? Evidence for a nonlinear relationship between insight and cognitive status. 1999 , 54, P100-6	103
2162	Behavior Rating Scale for Dementia: development of test scales and presentation of data for 555 individuals with Alzheimer's disease. 1999 , 12, 211-23	51
2161	The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. 1999 , 56, 1388-93	193
2160	Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. 1999 , 8, 463-71	15
2159	Neuropsychiatric manifestations of multiple sclerosis. 1999 , 11, 51-7	147
2158	Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. 1999 , 11, 392-4	53
2157	Assessing frontal lobe behavioral syndromes with the frontal lobe personality scale. 1999 , 6, 269-84	223
2156	Acetylcholinesterase inhibitors in Alzheimer's disease. 1999 , 48, 471-80	220

2155	Challenging behaviour in dementia: A critical role for psychology. 1999 , 34, 144-148	5
2154	Neuropsychiatric aspects of Alzheimer's disease. 1999 , 1, 49-60	12
2153	Neuropsychiatric aspects of Parkinson's disease. 1999 , 1, 61-8	48
2152	Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders. 1999 , 1, 78-84	10
2151	Trazodone in the treatment of behaviour in frontotemporal dementia. 1999 , 14, 279-281	20
2150	Anti-dementia drugs. 1999 , 14, 239-43	9
2149	Olanzapine in dementia with Lewy bodies: a clinical study. 1999 , 14, 459-466	100
2148	Mental symptoms in Parkinson's disease are important contributors to caregiver distress. 1999 , 14, 866-874	377
2147	A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. 1999 , 14, 973-982	37
2146	Measuring Outcomes in Alzheimer's Disease Research. 1999 , 5, 1-12	5
2145	Alzheimer's Disease. 1999 ,	
2144	Assessing the impact of neuropsychiatric symptoms on distress in professional caregivers. 1999 , 3, 241-245	32
2143	Principles of neuropsychiatry: Towards a neuropsychiatric epistemology. 1999 , 5, 181-188	8
2142	Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease. 1999 , 45, 422-5	62
2141	Assessing quality of life in dementia. 1999 , 3, 101-111	45
2140	Contrasting results between caregiver's report and direct assessment of activities of daily living in patients affected by mild and very mild dementia: the contribution of the caregiver's personal characteristics. 1999 , 47, 196-202	152
2139	New drugs for Alzheimer's disease. 1999 , 174, 476-9	34
2138	Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). 1999 , 10, 1903-7	117

2137	Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer's disease. 1999 , 11, 66-70	41
2136	The cholinergic deficit in Alzheimer's disease: impact on cognition, behaviour and function. 2000 ,	
2135	Galantamine: therapeutic effects beyond cognition. 2000 , 11 Suppl 1, 28-34	50
2134	Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. 2000 , 11, 314-21	25
2133	Impact of white matter changes on clinical manifestation of Alzheimer's disease: A quantitative study. 2000 , 31, 2182-8	146
2132	Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. 2000 , 31, 1263-8	64
2131	Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. 2000 , 12, 209-18	43
2130	Clinical issues in current drug therapy for dementia. 2000 , 14 Suppl 1, S103-8	9
2129	Detecting and managing depression and anxiety in people with dementia. 2000 , 13, 55-59	13
2128	Behavioral differences between white matter lacunar dementia and Alzheimer's disease: a comparison on the neuropsychiatric inventory. 2000 , 11, 294-8	48
2127	Neuropsychiatric disturbance is associated with executive dysfunction in HIV-1 infection. 2000 , 6, 336-47	61
2126	The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. 2000 , 6, 460-8	213
2125	Assessment by nurses of mood, general behaviour and functional ability in patients with dementia receiving nursing home care. 2000 , 14, 52-61	10
2124	Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. 2000 , 57, 861-6	108
2123	Measurement of progression in Alzheimer's disease: a clinician's perspective. 2000 , 19, 1393-400	14
2122	Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. 2000 , 19, 1401-9	55
2121	Donepezil for behavioural disorders associated with Lewy bodies: a case series. 2000 , 15, 338-45	68
2120	Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. 2000 , 15, 387-92	101

2119	Neuropsychologic assessment of patients for movement disorder surgery. 2000 , 15, 771-83		80
2118	Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. 2000 , 15, 713-20		86
2117	A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer's disease. 2000 , 15, 1028-33		145
2116	Dementia with lewy bodies: findings from an international multicentre study. 2000 , 15, 1034-45		92
2115	Predictors of severity of behavioral disturbance among community-dwelling elderly individuals with Alzheimer's disease: a 6-year follow-up study. 2000 , 54, 673-7		10
2114	Fall-related injuries in dementia with Lewy bodies (DLB) and Alzheimer's disease. 2000 , 7, 77-9		32
2113	Antipsychotic agents in patients with dementia. 2000 , 20, 23-33		22
2112	Nurturing syndrome: a form of pathological bereavement with delusions in Alzheimer's disease. 2000 , 38, 213-24		34
2111	A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. <i>Neurology</i> , 2000 , 54, 2269-76	6.5	756
2110	Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents. 2000 , 2, 473-8		46
2109	Personality in frontal lobe disorders. 2000 , 2, 446-51		48
2108	Neuropsychiatric Aspects of Traumatic Brain Injury. 2000 , 2, 169-186		65
2107	Guidelines for the diagnosis of dementia and Alzheimer's disease. The Dementia Study Group of the Italian Neurological Society. 2000 , 21, 187-94		33
2106	The evaluation of mood and behavior in patients with focal brain lesions. 2000 , 21-47		
2105	Methodological issues in studying secondary mood disorders. 2000 , 48-64		
2104	Deficits in decision-making in patients with aneurysms of the anterior communicating artery. 2000 , 123 (Pt 10), 2109-17		76
2103	Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. 2000 , 11, 202-11		21
2102	The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. 2000 ,		

2101 . 2000,

2

2100 The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. **2000**, 3, 21-29

40

2099 . 2000,

2098 Assessing the Benefits of Drug Treatment in Dementia. 21-36

2097 Cholinesterase inhibitors: A new class of psychotropic compounds. **2000**, 157, 4-15

310

2096 Acquired personality disturbances associated with bilateral damage to the ventromedial prefrontal region. **2000**, 18, 355-81

277

2095 Psychosis in Parkinson's disease: 'Between a rock and a hard place'**2000**, 12, 319-334

23

2094 Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of behavior and mood scales. **2000**, 13, 181-96

35

2093 Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. **2000**, 57, 968-76

448

2092 A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. *Neurology*, **2000**, 55, 1613-20

6.5 721

2091 Prevalence of symptoms on the CERAD behavior rating scale for dementia in normal elderly subjects and Alzheimer's disease patients. **2000**, 12, 472-9

16

2090 Disorders of frontal lobe functioning. **2000**, 20, 427-37

77

2089 The cognitive management of daily life activities in patients with mild to moderate Alzheimer's disease in a day care centre: A case report. **2000**, 10, 485-509

55

2088 [Expressions of depression in Alzheimer's disease. The current scientific debate]. **2000**, 9, 126-39

1

2087 Changes in emotional and behavioral symptoms of Alzheimer's disease. **2000**, 15, 176-179

1

2086 Visuoperceptual impairment in dementia with Lewy bodies. **2000**, 57, 489-93

186

2085 Affective behavioural disturbances in Alzheimer's disease and ischaemic vascular disease. **2000**, 68, 41-6

33

2084 Cerebral correlates of psychotic symptoms in Alzheimer's disease. **2000**, 69, 167-71

127

2083	Temporal lobe asymmetry in patients with Alzheimer's disease with delusions. 2000 , 69, 187-91	49
2082	Botulinum toxin and spasticity. 2000 , 69, 143-7	25
2081	Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. 2000 , 12, 233-9	944
2080	Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. 2000 , 157, 708-14	867
2079	Functional correlates of musical and visual ability in frontotemporal dementia. 2000 , 176, 458-63	180
2078	Negative symptoms: the 'pathology' of motivation and goal-directed behaviour. 2000 , 23, 412-7	217
2077	Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. 2000 , 21, 845-61	166
2076	Part VI. Primary drug therapies for Alzheimer's disease. 2000 , 46, 745-60	1
2075	Cholinesterase inhibitors: expanding applications. 2000 , 356, 2024-5	29
2074	Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. 2000 , 356, 2031-6	952
2073	Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors. 2000 , 13, 385-395	11
2072	Metrifonate. 2000 , 13, 443-467	4
2071	Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease?. 2000 , 69, 178-86	432
2070	Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. 2000 , 18, 829-46	127
2069	The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. 2000 , 8, 75-83	294
2068	Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. 2000 , 8, 29-34	252
2067	Evaluation of the supervisory system in elderly subjects with and without disinhibition. 2000 , 15, 407-15	10
2066	Galantamine: a review of its use in Alzheimer's disease. 2000 , 60, 1095-122	241

2065	Rivastigmine for Alzheimer's disease. 2000 , CD001191	88
2064	Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer's Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability. 2001 , 16 Suppl 1, 5s-24s	39
2063	Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. 2001 , 16, 439-45	68
2062	Acetylcholinesterase inhibitors in severe dementia. 2001 , 11, S162	
2061	Atypical antipsychotics in behavioral disturbances in Alzheimer's disease. 2001 , 11, S162	
2060	Neuropsychiatric aspects of Huntington's disease. 2001 , 71, 310-4	298
2059	Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. 2001 , 49, 289-99	206
2058	La risperidona en el tratamiento de los síntomas psicóticos y trastornos de la conducta en pacientes con demencia. 2001 , 36, 94-101	2
2057	Agitación/agresividad en la demencia de tipo Alzheimer. 2001 , 36, 156-162	1
2056	Alzheimer's disease and related disorders. 2001 , 85, 803-17	15
2055	Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia. 2001 , 18, 527-50	22
2054	Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in Alzheimer's disease and nondemented patients. 2001 , 13, 896-902	141
2053	Open-label study of donepezil in traumatic brain injury. 2001 , 82, 896-901	106
2052	Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis. 2001 , 7, 121-127	18
2051	Activities of Daily Living in Alzheimer's Disease: Neuropsychiatric, Cognitive, and Medical Illness Influences. 2001 , 9, 81-86	60
2050	The Impact of Behavioral Symptoms on Activities of Daily Living in Patients With Dementia. 2001 , 9, 41-48	72
2049	National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. 2001 , 9, 346-360	103
2048	Assessing quality of life in dementia: Preliminary psychometric testing of the Quality of Life Assessment Schedule (QOLAS). 2001 , 11, 219-243	77

2047	Neuropsychiatric assessment of Alzheimer's disease and related dementias. 2001 , 13, 240-6		28
2046	Alzheimer's Disease: Antidementive Drugs. 2001 , 418-423		
2045	Impaired affective prosody in AD: relationship to aphasic deficits and emotional behaviors. <i>Neurology</i> , 2001 , 57, 1474-81	6.5	44
2044	Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. 2001 , 13, 121-8		100
2043	Recommendations for the management of behavioral and psychological symptoms of dementia. 2001 , 28 Suppl 1, S96-107		70
2042	Brief review: rivastigmine, a second cholinesterase inhibitor. 2001 , 28 Suppl 1, S122-3		0
2041	An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. 2001 , 15, 162-5		27
2040	Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. 2001 , 24, 31-42		59
2039	Alteration of rCBF in Alzheimer's disease patients with delusions of theft. 2001 , 12, 2473-6		37
2038	Asia regional meeting of the International Working Group for the Harmonization of Dementia Drug Guidelines: meeting report. 2001 , 15, 66-8		4
2037	Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. 2001 , 13, 42-9		104
2036	The Alzheimer's Disease Centers' Neuropsychological Database Initiative: A Resource for Alzheimer's Disease Prevention Trials. 129-140		
2035	Frontotemporal lobar degeneration: a study in Japan. 2001 , 12, 393-9		20
2034	Abstracts of Posters. 2001 , 47, 260-303		
2033	Chapter 8 Dementia. 2001 , 25, 147-172		
2032	Alzheimer disease therapeutics. 2001 , 60, 923-8		33
2031	Benefits of Donepezil on Cognition, Function and Neuropsychiatric Symptoms in Patients with Mild and Moderate Alzheimer's Disease over One Year. 725-738		
2030	Applying Bradford Hill's criteria for causation to neuropsychiatry: challenges and opportunities. 2001 , 13, 318-25		34

2029	Motor neurone disease, dementia and aphasia: coincidence, co-occurrence or continuum?. 2001 , 248, 260-70	93
2028	Apathy in Alzheimer's disease. 2001 , 49, 1700-7	269
2027	Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. 2001 , 8, 361-2	77
2026	Gabapentin as a possible treatment of behavioral alterations in Alzheimer disease (AD) patients. 2001 , 8, 501-2	24
2025	Impairment of eyeblink classical conditioning in progressive supranuclear palsy. 2001 , 16, 240-51	10
2024	Voluntary palatal tremor is associated with hyperactivation of the inferior olive: a functional magnetic resonance imaging study. 2001 , 16, 1193-5	19
2023	Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. 2001 , 16, 1171-4	245
2022	Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): placebo-controlled, polysomnographic case report. 2001 , 16, 1177-9	15
2021	Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. 2001 , 16, 1176-7	79
2020	Action hand dystonia after cortical parietal infarction. 2001 , 16, 1183-5	22
2019	Hand orthosis as a writing aid in writer's cramp. 2001 , 16, 1185-9	30
2018	Stiff leg syndrome: case report. 2001 , 16, 1189-93	12
2017	Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders. 2001 , 16, 1098-104	36
2016	Unilateral periodic limb movements during sleep in corticobasal degeneration. 2001 , 16, 1180-3	37
2015	Poetic talent unmasked by treatment of Parkinson's disease. 2001 , 16, 1175-6	58
2014	Evaluation of tiapride in agitated elderly outpatients: an open study. 2001 , 16, 417-422	0
2013	An investigation of visual hallucinosis and visual sensory status in dementia. 2001 , 16, 709-13	66
2012	Validation study of the Chinese version of the neuropsychiatric inventory (CNPI). 2001 , 16, 789-93	105

2011	An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease. 2001 , 16, 1037-42	79
2010	Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. 2001 , 16, 1043-53	221
2009	Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?. 2001 , 16, 653-66	97
2008	The evolving typology of neuropsychiatric complications of Alzheimer's disease: the use of latent trait analysis. 2001 , 16, 1030-2	3
2007	Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. 2001 , 49, 355-361	222
2006	Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. 2001 , 16, 39-44	248
2005	Relationship of psychosis to aggression, apathy and function in dementia. 2001 , 16, 123-30	55
2004	Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. 2001 , 16, 184-91	122
2003	Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. 2001 , 16 Suppl 1, S71-7	28
2002	Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. 2001 , 16 Suppl 1, S62-70	57
2001	Geriatric Neuropsychopharmacology: Unmet Needs. 2001 , 1, 14-26	
2000	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting. 2001 , 49, 1590-1599	269
1999	Differential diagnosis of dementia: clinical examination and laboratory assessment. 2001 , 3, 1-14	
1998	Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?. 2001 , 21, 74-102	17
1997	Prospective analysis of risk factors for nursing home placement of dementia patients. <i>Neurology</i> , 2001 , 57, 1467-73	6.5 101
1996	Use of acetylcholinesterase inhibitors in Alzheimer's disease. 2001 , 1, 61-9	24
1995	Plasticity after acute ischaemic stroke studied by transcranial magnetic stimulation. 2001 , 71, 713-5	17
1994	Treatment of behavioral/psychological symptoms in Alzheimer's disease. 2001 , 1, 70-80	3

1993	A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. <i>Neurology</i> , 2001 , 57, 489-95	6.5	621
1992	Increased prevalence of vascular dementia in Japan: a community-based epidemiological study. <i>Neurology</i> , 2001 , 57, 839-44	6.5	137
1991	The Gottfries-Br�ie-Steen scale: validity, reliability and application in anti-dementia drug trials. 2001 , 12, 1-14		62
1990	Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. 2001 , 71, 589-95		160
1989	Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. 2001 , 13, 277-88		87
1988	Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. 2001 , 70, 165-73		132
1987	Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. <i>Neurology</i> , 2001 , 57, 467-73	6.5	137
1986	A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. <i>Neurology</i> , 2001 , 57, 613-20	6.5	552
1985	Leitlinien zur Diagnostik bei Patienten mit Demenz. 2001 , 28, 201-207		0
1984	Complex cognitive disruption in frontal dementia related to motor neuron disease. 2001 , 92, 1213-29		3
1983	Staged bilateral pallidotomy for treatment of Parkinson disease. 2001 , 94, 437-44		45
1982	Donepezil in the treatment of patients with Alzheimer's disease. 2001 , 1, 11-9		6
1981	The needs and mental health of older people in 24-hour care residential placements. 2001 , 5, 253-7		14
1980	Measuring aggression in older adults: a latent variable modeling approach. 2002 , 6, 231-8		4
1979	Depression and Alzheimer's disease: symptom or comorbidity?. 2002 , 17, 338-44		45
1978	Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. 2002 , 73, 371-6		295
1977	Apathy in Parkinson's disease. 2002 , 73, 636-42		308
1976	The emergence of delusional companions in Alzheimer's disease: an unusual misidentification syndrome. 2002 , 7, 317-28		22

1975	Managing behavioural and psychological symptoms in dementia. 2002 , 181, 463-5	69
1974	Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. 2002 , 17, 267-72	51
1973	Functional ability in executive variant Alzheimer's disease and typical Alzheimer's disease. 2002 , 16, 331-40	26
1972	Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. 2002 , 125, 391-403	511
1971	[Difficulties in the evaluation of depressive symptoms in patients with dementia]. 2002 , 29, 76-82	4
1970	[Influence of treatment with acetyl-cholinesterase inhibitors on psychopathological symptoms in Alzheimer's disease]. 2002 , 70, 78-83	4
1969	Galantamin (Reminyl [®]) nützt Patienten mit leichtgradiger Alzheimer-Krankheit und deren Angehörigen. 2002 , 29, 402-408	1
1968	Behavioral change in persons with dementia: relationships with mental and physical health of caregivers. 2002 , 57, P453-60	90
1967	Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. 2002 , 59, 71-5	79
1966	Chromosome 3 linked frontotemporal dementia (FTD-3). <i>Neurology</i> , 2002 , 59, 1585-94	6.5 95
1965	A transcultural study of agitation in dementia. 2002 , 15, 171-4	9
1964	Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. 2002 , 159, 1306-14	99
1963	Rating scales in old age psychiatry. 2002 , 180, 161-7	87
1962	Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. 2002 , 288, 1475-83	1299
1961	Neuropsychiatric symptoms in the dementias. 2002 , 15, 445-50	125
1960	Frontotemporal dementia classification and neuropsychiatry. 2002 , 8, 263-9	22
1959	Apathy and executive function in Alzheimer's disease. 2002 , 8, 373-81	105
1958	Regional brain atrophy in patients with mild Alzheimer's disease and delusions. 2002 , 14, 365-78	20

1957	Frontotemporal dementia: a review. 2002 , 8, 566-83		116
1956	Endogenous estradiol in elderly individuals: cognitive and noncognitive associations. 2002 , 59, 385-9		43
1955	Predictors of cognitive improvement after reality orientation in Alzheimer's disease. 2002 , 31, 193-6		21
1954	Assessment of behavioral and psychological symptoms of dementia. 2002 , 7, 797-802		14
1953	Cholinesterase-inhibitor therapy for dementia: novel clinical substrates and mechanisms for treatment response. 2002 , 7, 742-50		6
1952	Complex cognitive disruption in motor neuron disease. 2002 , 14, 141-50		27
1951	Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. 2002 , 16, 128-30		38
1950	Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease. 2002 , 16, 248-53		140
1949	Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. <i>Neurology</i> , 2002 , 58, 209-18	6.5	260
1948	Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. 2002 , 72, 708-12		232
1947	Natural history of dementia associated with lacunar infarctions. 2002 , 203-204, 53-5		18
1946	Rivastigmine in subcortical vascular dementia: an open 22-month study. 2002 , 203-204, 141-6		66
1945	Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. 2002 , 52, 438-45		160
1944	Benefit-risk considerations in the treatment of dementia with Lewy bodies. 2002 , 25, 511-23		14
1943	Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. 2002 , 41, 719-39		252
1942	Assessment, measures and approaches to easing caregiver burden in Alzheimer's disease. 2002 , 19, 203-15		24
1941	Nonpharmacologic treatment of behavioral disturbance in dementia. 2002 , 86, 641-56, viii		57
1940	Enfermedad de Alzheimer: deterioro cognitivo y funcional asociado a polimorfismos de APOE y A2M. 2002 , 37, 111-119		

1939	Nota de la redacci3. 2002 , 37, 119	1
1938	Bristol Activities of Daily Living Scale: a critical evaluation. 2002 , 2, 669-76	14
1937	Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease: theoretical and practical implications. 2002 , 125, 752-64	639
1936	Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. 2002 , 18, 156-71	29
1935	Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. 2002 , 18, 347-54	64
1934	Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. 2002 , 24, 862-86; discussion 837	43
1933	Apathy syndrome in cocaine dependence. 2002 , 109, 97-100	27
1932	The Stereotypy Rating Inventory for frontotemporal lobar degeneration. 2002 , 110, 175-87	67
1931	Methodological Aspects of Comparative Research in the Epidemiology of Alzheimer Disease. 2002 , 10, 373-385	1
1930	Verification of Scale Sub-Domains in Elderly Patients With Dementia: A Confirmatory Factor-Analytic Approach. 2002 , 10, 706-714	3
1929	Pharmacologic treatments of dementia. 2002 , 86, 657-74	117
1928	Deterioro funcional del paciente con demencia: influencia del grado de deterioro cognitivo, la comorbilidad f3sica y las alteraciones neuropsiqui3tricas. 2002 , 37, 210-215	1
1927	Provisional Diagnostic Criteria for Depression of Alzheimer Disease: Rationale and Background. 2002 , 10, 129-141	161
1926	Assessment and treatment of apathy syndrome following head injury. 2002 , 17, 325-331	16
1925	Pharmacological Treatment of Dementia, with the Emphasis on Dementia of the Alzheimer Type. 393-400	
1924	Tratamento dos transtornos do comportamento de pacientes com dem3ncia. 2002 , 24, 15-21	4
1923	The neuropsychological assessment of dementia. 2002 , 7, 371-5	
1922	Maladie d'Alzheimer : vision d'ensemble, aspects cliniques, facteurs de risque et pr3vention. 2002 , 18, 689-696	

1921	Use of cholinesterase inhibitors in dementia. 2002 , 8, 89-96	37
1920	Behavioral Disorders Associated with Central Nervous System Dysfunction. 2002 , 813-840	
1919	Memory consolidation and the hippocampus: further evidence from studies of autobiographical memory in semantic dementia and frontal variant frontotemporal dementia. 2002 , 40, 633-54	99
1918	Face and emotion processing in frontal variant frontotemporal dementia. 2002 , 40, 655-65	197
1917	Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. 2002 , 54, 1567-77	58
1916	Differential diagnosis of dementia: clinical examination and laboratory assessment. 2002 , 4, 53-65	1
1915	Assessing cognitive function in clinical trials: latest developments and future directions. 2002 , 7, 29-35	18
1914	Brain perfusion in Alzheimer's disease with and without apathy: a SPECT study with statistical parametric mapping analysis. 2002 , 114, 103-11	73
1913	Neuropsychological assessment for management of patients with deep brain stimulation. 2002 , 17 Suppl 3, S116-22	35
1912	Neuropsychiatric symptoms of Alzheimer's disease differ in Chinese and American patients. 2002 , 17, 22-8	81
1911	Effect of neuropsychiatric symptoms of Alzheimer's disease on Chinese and American caregivers. 2002 , 17, 29-34	63
1910	The second Leicester survey of memory clinics in the British Isles. 2002 , 17, 41-7	66
1909	Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. 2002 , 17, 140-5	44
1908	Reducing the burden of caring for Alzheimer's disease through the amelioration of "delusions of theft" by drug therapy. 2002 , 17, 211-7	40
1907	A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study. 2002 , 17, 270-8	114
1906	A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. 2002 , 17, 343-6	29
1905	Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version. 2002 , 17, 438-43	31
1904	Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. 2002 , 17, 531-41	42

1903	The relationship between biological and environmental determinants of delusions in mild Alzheimer's disease patients. 2002 , 17, 687-8	5
1902	Frontotemporal dementia: patient characteristics, cognition, and behaviour. 2002 , 17, 914-8	69
1901	Improving clinical descriptions to understand the effects of dementia treatment: consensus recommendations. 2002 , 17, 1006-11	14
1900	The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. 2002 , 17, 1099-105	284
1899	Mild cognitive impairment with subcortical vascular features: clinical characteristics and outcome. 2002 , 249, 1423-32	132
1898	Major depressive disorder in Parkinson's disease: a register-based study. 2002 , 106, 202-11	87
1897	A literature review of dementia care mapping: methodological considerations and efficacy. 2002 , 9, 725-36	39
1896	Self-destructive behaviors in nursing home residents. 2002 , 50, 354-8	41
1895	Clinical features and assessment of severe dementia. A review. 2002 , 9, 125-36	83
1894	Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. 2002 , 29, 1342-8	82
1893	Neuroprotective properties of valproate: potential benefit for AD and tauopathies. 2002 , 19, 303-7	28
1892	Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. 2003 , 17, 567-73	63
1891	[Facial expression in severe dementia]. 2003 , 36, 447-53	4
1890	Short-term longitudinal evaluation of cerebral blood flow in mild Alzheimer's disease. 2003 , 24, 24-30	9
1889	Vascular cognitive impairment. 2003 , 2, 89-98	970
1888	The treatment of Alzheimer's disease: success short of cure. 2003 , 2, 630-3	23
1887	Dawn-dusk simulation light therapy of disturbed circadian rest-activity cycles in demented elderly. 2003 , 38, 207-16	119
1886	Managing anxiety in people with dementia. A case series. 2003 , 76, 261-5	20

1885	Language impairment in dementia: impact on symptoms and care needs in residential homes. 2003 , 18, 1002-6	71
1884	A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease. 2003 , 18, 1037-42	88
1883	Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: the Memory and Medical Care Study. 2003 , 18, 174-82	93
1882	Behavioural disturbances in dementia patients and quality of the marital relationship. 2003 , 18, 149-54	130
1881	Visuospatial impairment in dementia with Lewy bodies and Alzheimer's disease: a process analysis approach. 2003 , 18, 387-91	60
1880	Delusions of Japanese patients with Alzheimer's disease. 2003 , 18, 527-32	40
1879	Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. 2003 , 18, 740-7	42
1878	Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. 2003 , 18, 937-41	153
1877	Role of behavioural disturbance in the loss of autonomy for activities of daily living in Alzheimer patients. 2003 , 18, 977-82	15
1876	Parkinson's disease is associated with hippocampal atrophy. 2003 , 18, 784-90	245
1875	Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. 2003 , 18 Suppl 6, S72-9	59
1874	Current pharmacologic options for patients with Alzheimer's disease. 2003 , 2, 1	36
1873	Wandering behaviour in people with dementia. 2003 , 44, 173-82	116
1872	Prevention and early intervention for vascular dementia in community dwelling elderly: Findings from the Nakayama study. 2003 , 3, 17-20	2
1871	Age and sex do not bias the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction and congestive heart failure. 2003 , 51, 572-3	2
1870	Decrease of functional or cognitive capacity explains the lack of eye examination in visually impaired older persons. 2003 , 51, 573-4	2
1869	What is a geriatric syndrome anyway?. 2003 , 51, 574-6	88
1868	Dance/Movement Therapeutic methods in management of dementia. 2003 , 51, 576-7	21

1867	Possible model for successful care: burden of caregivers of centenarians. 2003 , 51, 577-8	6
1866	Interleukin-6-174 G/C promoter gene polymorphism C allele reduces Alzheimer's disease risk. 2003 , 51, 578-9	50
1865	Deep vein thrombosis in older patients. 2003 , 51, 579	1
1864	Lyme neuroborreliosis revealed as a normal pressure hydrocephalus: a cause of reversible dementia. 2003 , 51, 579-80	9
1863	The relationship between health and type of fracture in persons aged 65 and older. 2003 , 51, 580-2	0
1862	Satisfaction with primary care providers of older adults living in senior housing. 2003 , 51, 582-3	
1861	Training caregivers to change the sleep hygiene practices of patients with dementia: the NITE-AD project. 2003 , 51, 1455-60	62
1860	Psychiatric morbidity in a neurology-based memory clinic: the effect of systematic psychiatric evaluation. 2003 , 51, 1773-8	11
1859	Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. 2003 , 10, 633-40	36
1858	The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. 2003 , 12, 331-7	113
1857	Efficacy of combination treatment of fluvoxamine and tiapride for repetitive behaviors in frontotemporal lobar degeneration. 2003 , 3, 123-126	
1856	Mild cognitive impairment clinical trials. 2003 , 2, 646-53	119
1855	Cholinesterase Inhibitors in Non-Alzheimer Dementias. 2003 , 4, S165-S169	7
1854	Donepezil HCl (E2020) Maintains Functional Brain Activity in Patients With Alzheimer Disease: Results of a 24-Week, Double-Blind, Placebo-Controlled Study. 2003 , 11, 169-177	72
1853	Treatment-Related Decisional Capacity. 2003 , 11, 257-258	1
1852	Tratamiento de la agitación en el paciente mayor. 2003 , 203, 346-348	0
1851	Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations. 2003 , 11, 131-145	103
1850	Assessing Antipsychotic Effectiveness in Dementia with the Factor Structure of the Psychogeriatric Dependency Rating Scale (PGDRS). 2003 , 4, 61-66	2

1849	The Epidemiology of Psychosis in Dementia. 2003 , 11, 83-91	65
1848	A Structured, Open Trial of Risperidone Therapy for Delusions of Theft in Alzheimer Disease. 2003 , 11, 256-257	3
1847	Memantine in moderate-to-severe Alzheimer's disease. 2003 , 348, 1333-41	1517
1846	Psychotic Symptoms in Alzheimer Disease: Evidence for Subtypes. 2003 , 11, 406-413	48
1845	Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on. 2003 , 64, 216-35	163
1844	12th Annual Rotman Institute Abstracts. 2003 , 51, 160-248	7
1843	Inhibitory attentional control in patients with frontal lobe damage. 2003 , 52, 258-70	35
1842	Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. 2003 , 27, 549-53	44
1841	[The French network multicenter study. Predictive factors of hospitalization and management of Alzheimer's disease patients (REAL.FR)]. 2003 , 24 Suppl 3, 278s-282s	2
1840	[Clinical evaluation of dementia in a cohort of 358 patients with the French version of the Clinical Dementia Rating (CDR) scale]. 2003 , 24 Suppl 3, 283s-287s	8
1839	[Patients with Alzheimer's disease living alone at home in the cohort of REAL.FR]. 2003 , 24 Suppl 3, 301s-306s	1
1838	[Clinical features of ambulatory patients over 80 years of age followed for Alzheimer's disease. French prospective multicenter study REAL.FR]. 2003 , 24 Suppl 3, 307s-313s	2
1837	[Nutritional status and Alzheimer's disease: preliminary results of the REAL.FR study]. 2003 , 24 Suppl 3, 314s-318s	13
1836	[Behavioral and psychologic symptoms in Alzheimer's disease: results of the REAL.FR study]. 2003 , 24 Suppl 3, 319s-324s	46
1835	An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. 2003 , 25, 1765-82	63
1834	Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. 2003 , 25, 1806-25	43
1833	Delusions and hallucinations in Alzheimer's disease: review of the brain decade. 2003 , 44, 388-401	103
1832	Factor analysis of the frontal systems behavior scale (FrSBe). 2003 , 10, 79-85	145

1831	Music therapy for people with dementia. 2004 , CD003477	133
1830	Cuidados informales en la demencia: predicción de sobrecarga en cuidadoras familiares. 2003 , 38, 212-218	9
1829	Challenges in the Management of Psychotic Symptoms in Long-Term Care. 2003 , 4, H17-H20	
1828	Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation. 2003 , 20, 1035-40	24
1827	A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. 2003 , 20, 777-89	139
1826	Nutritional assessment of demented patients: a descriptive study. 2003 , 15, 148-53	43
1825	The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach. 2003 , 17, 1045-57	17
1824	Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. 2003 , 18, 205-14	75
1823	Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. 2003 , 289, 210-6	346
1822	Health status and assessed need for a cohort of older people admitted to nursing and residential homes. 2003 , 32, 303-9	29
1821	A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. 2003 , 160, 857-66	213
1820	Familial dementia with Lewy bodies with an atypical clinical presentation. 2003 , 16, 59-64	24
1819	Non-pharmacological interventions in cognitively impaired and demented patients--a comparison with cholinesterase inhibitors. 2003 , 14, 343-68	17
1818	Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. 2003 , 60, 1385-9	512
1817	Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. 2003 , 60, 737-46	296
1816	Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. 2003 , 74, 1215-20	163
1815	Analysis of probabilistic classification learning in patients with Parkinson's disease before and after pallidotomy surgery. 2003 , 10, 226-36	39
1814	HSP70-2 (HSPA1B) is associated with noncognitive symptoms in late-onset Alzheimer's disease. 2003 , 16, 146-50	30

1813	Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. 2003 , 58, 548-54	65
1812	Assessment of Stimulus Preferences in Multisensory Environment Therapy for Older People with Dementia. 2003 , 66, 542-550	30
1811	Caregiver attribution and resentment in dementia care. 2003 , 18, 366-74	31
1810	Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. 2003 , 49, 13-9	164
1809	A study of stereotypic behaviours in Alzheimer's disease and frontal and temporal variant frontotemporal dementia. 2003 , 74, 1398-402	111
1808	Music therapy with Alzheimer's patients and their family caregivers: a pilot project. 2003 , 40, 138-50	68
1807	Patients with Alzheimer's disease living at home in France: costs and consequences of the disease. 2003 , 16, 140-5	36
1806	Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. 2003 , 9, 393-6	244
1805	Defining "early dementia" and monitoring intervention: what measures are useful in family caregiving?. 2003 , 7, 7-14	10
1804	Neuropsychiatric symptoms in Latino elders with dementia or cognitive impairment without dementia and factors that modify their association with caregiver depression. 2003 , 43, 669-77	59
1803	The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. <i>Neurology</i> , 2003 , 61, 944-9	6.5 52
1802	Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study. 2003 , 60, 1740-4	56
1801	The incidence of mental and behavioral disturbances in dementia: the cache county study. 2003 , 15, 340-5	57
1800	Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. 2003 , 15, 180-6	97
1799	Evaluation of dementia in the cardiovascular health cognition study. 2003 , 22, 1-12	184
1798	[Overview of standardised diagnostic instruments of dementia]. 2003 , 71, 187-98	9
1797	Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. 2003 , 3, 99-106	16
1796	An electronic memory aid to support prospective memory in patients in the early stages of Alzheimer's disease: a pilot study. 2003 , 7, 22-7	63

1795	Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. 2003 , 29, 57-72	46
1794	Dopamine and cognitive function. 2003 , 16 Suppl 2, S17-22	50
1793	The impact of depressive symptoms on patients with Alzheimer disease. 2003 , 17, 61-2	7
1792	The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia. 2003 , 26, 239-51	52
1791	Differential diagnosis and clinical assessment of patients with severe Alzheimer disease. 2003 , 17 Suppl 3, S92-5	8
1790	2nd Asia-Pacific regional meeting of the International Working Group on Harmonization of Dementia Drug Guidelines: meeting report. 2003 , 17, 129-31	4
1789	Evolution of depressive symptoms in Alzheimer disease: one-year follow-up. 2003 , 17, 77-85	38
1788	A new measurement of activities of daily living for Thai elderly with dementia. 2003 , 15, 135-48	15
1787	Donepezil for mild and moderate Alzheimer's disease. 2000 , CD001190	48
1786	A review of cholinergic agents in the treatment of neurobehavioral deficits following traumatic brain injury. 2003 , 15, 17-26	38
1785	Cholinesterase inhibitors for dementia with Lewy bodies. 2003 , CD003672	30
1784	Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine. 2003 , 26, 602-6	31
1783	A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. 2003 , 22, 265-74	113
1782	Progression of dementia associated with lacunar infarctions. 2003 , 16, 71-7	12
1781	Chapter 6 Cognitive Impairment in the Motor Neuron Disorders. 2003 , 28, 145-cp1	
1780	A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. 2003 , 26, 893-901	313
1779	Aroma therapy for dementia. 2003 , CD003150	33
1778	A Pilot Open-Label Trial of Citalopram for Restless Activity and Aberrant Motor Behaviors in Alzheimer Disease. 2003 , 11, 687-691	9

1777 23 Antidementive Therapie. **2003**,

1776 Diagnosis and Treatment of Dementia. **2003**, 311-325

1775 Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. **2004**, 20, 517-24 31

1774 Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease. **2004**, 20, 931-8 15

1773 Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. **2004**, 4, 5-16 28

1772 Pharmacologic treatment of adolescent and child schizophrenia. **2004**, 4, 53-60 23

1771 Delayed discharge--a solvable problem? The place of intermediate care in mental health care of older people. **2004**, 8, 34-9 11

1770 Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. **2004**, 17, 29-34 29

1769 Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. **2004**, 61, 1249-53 107

1768 Donepezil: a clinical review of current and emerging indications. **2004**, 5, 161-80 32

1767 The use of assessment scales in Old Age Psychiatry Services in England and Northern Ireland. **2004**, 8, 249-55 32

1766 Subacute dementia and imaging correlates in a case of Fahr's disease. **2004**, 75, 1163-5 50

1765 Bupropion in the management of apathy. **2004**, 18, 133-5 60

1764 Domain-Specific Anosognosia in Alzheimer's Disease and Vascular Dementia. **2004**, 5, 187-197 5

1763 Psychosis in Parkinson's disease. **2004**, 17, 127-36 38

1762 Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil. **2004**, 47, 1149-63 105

1761 Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. *Neurology*, **2004**, 63, 2348-53 6.5 218

1760 DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. *Neurology*, **2004**, 62, 181-7 6.5 310

1759	Nuclear Medicine in Psychiatry. 2004,		3
1758	Frontotemporal dementia: behavioral symptoms and caregiver distress. 2004, 18, 299-306		91
1757	Olanzapine as a possible treatment for anxiety due to vascular dementia: an open study. 2004, 19, 81-8		7
1756	Similar early clinical presentations in familial and non-familial frontotemporal dementia. 2004, 75, 1743-5		19
1755	Donepezil therapy for neuropsychiatric symptoms in AD: methods make the message. <i>Neurology</i> , 2004, 63, 200-1	6.5	4
1754	An attempt to determine the benefits of a 'home-for-life' principle in residential care for people with dementia and behavioural problems: a comparative cohort study. 2004, 18, 6-14		5
1753	Frontotemporal dementia: a randomised, controlled trial with trazodone. 2004, 17, 355-9		245
1752	Mechanism of disorientation in Alzheimer's disease. 2004, 52, 193-7		17
1751	Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients. 2004, 18, 215-20		21
1750	Impact of APOE in mild cognitive impairment. <i>Neurology</i> , 2004, 63, 1898-901	6.5	167
1749	Pharmacologic management of agitation in Alzheimer's disease. 2004, 17, 65-77		22
1748	Treating apathy in Alzheimer's disease. 2004, 17, 91-9		67
1747	Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. 2004, 17, 14-20		81
1746	Medial temporal hypoperfusion and aggression in Alzheimer disease. 2004, 61, 1731-7		39
1745	Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. 2004, 329, 75		135
1744	Nonpharmacological and pharmacological interventions for symptoms in Alzheimer's disease. 2004, 4, 809-21		13
1743	A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care--the LASER-AD Study. 2004, 20, 1007-16		41
1742	Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. <i>Neurology</i> , 2004, 63, 2341-7	6.5	122

1741	The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. <i>Neurology</i> , 2004 , 63, 214-9	6.5	261
1740	Levetiracetam in the treatment of idiopathic hemifacial spasm. <i>Neurology</i> , 2004 , 62, 2134-5	6.5	16
1739	Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). 2004 , 17, 32-5		54
1738	A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease. 2004 , 58, 144-8		12
1737	Characteristics of behavioral and psychological symptoms in the oldest patients with Alzheimer's disease. 2004 , 4, 11-16		2
1736	Incidence and prevalence of dementia in the Cardiovascular Health Study. 2004 , 52, 195-204		302
1735	Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. 2004 , 52, 1070-6		48
1734	Nutritional intervention in special care units for dementia. 2004 , 52, 1216-7		17
1733	Ethical issues in end-of-life geriatric care: the approach of three monotheistic religions-Judaism, Catholicism, and Islam. 2004 , 52, 1224-5; author reply 1225		
1732	Guidelines for dementia diagnosis: neuroimaging. 2004 , 52, 1225		0
1731	Pyothorax-associated lymphoma in an elderly woman with a history of lung tuberculosis. 2004 , 52, 1226-7		1
1730	Propoxyphene use in the elderly. 2004 , 52, 1227		3
1729	Advanced dementia and feeding tubes: do physician factors contribute to state variation?. 2004 , 52, 1217-8		8
1728	Pet peeves. 2004 , 52, 1218		
1727	Case report: mental confusion, diplopia, and inability to stand in an 82-year-old-man. 2004 , 52, 1218-9		1
1726	Adverse reactions to influenza vaccine alone or with pneumococcal vaccine in the elderly. 2004 , 52, 1219-20		20
1725	Giant cell arteritis presenting with dizziness and a normal erythrocyte sedimentation. 2004 , 52, 1220-1		1
1724	Squamous cell carcinoma occurring at site of prior herpes zoster of the scalp: case report of Marjolin ulcer. 2004 , 52, 1221-2		10

1723	High response to intravenous immunoglobulin in the treatment of acquired hemophilia in an elderly patient. 2004 , 52, 1222-3	
1722	Over-the-counter product line extensions: have we reached the limit yet?. 2004 , 52, 1223-4	1
1721	The Maryland Assisted Living Study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland. 2004 , 52, 1618-25	122
1720	Response to Zorowitz. 2004 , 52, 1224-1225	
1719	Development of neuropsychiatric symptoms in poststroke patients: a cross-sectional study. 2004 , 110, 55-63	132
1718	Correlating Brain Atrophy With Cognitive Dysfunction, Mood Disturbances, and Personality Disorder in Multiple Sclerosis. 2004 , 14, 36S-45S	120
1717	Ethnic differences in the prevalence and pattern of dementia-related behaviors. 2004 , 52, 1277-83	97
1716	Growth hormone response to clonidine predicts aggression in Alzheimer's disease. 2004 , 29, 1192-7	19
1715	Dementia with Lewy bodies. 2004 , 3, 19-28	560
1714	Psychosis of Alzheimer's disease: clinical characteristics and history. 2004 , 38, 105-11	49
1713	Depression and vascular disease: what is the relationship?. 2004 , 79, 81-95	194
1712	Psychiatric issues in non-Alzheimer dementias. 2004 , 3, 397-412	3
1711	The cognitive pattern of vascular dementia and its assessment. 2004 , 4, 79-86	2
1710	Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease. 2004 , 251, 688-95	66
1709	Italian Neurological Society guidelines for the diagnosis of dementia: revision I. 2004 , 25, 154-82	6
1708	Neuropsychological profile of Alzheimer's disease in women: moderate and moderately severe cognitive decline. 2004 , 7, 27-36	2
1707	Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. 2004 , 172, 400-8	138
1706	Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. 2004 , 124B, 50-3	46

1705	Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. 2004 , 19, 115-26	142
1704	Do caregiver management strategies influence patient behaviour in dementia?. 2004 , 19, 85-92	152
1703	Validity and reliability of the newly translated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer's disease: a study of disturbing behaviors among referrals to a memory clinic. 2004 , 19, 203-8	66
1702	Psychometric properties and factor structure of the Neuropsychiatric Inventory Nursing Home version in an elderly neuropsychiatric population. 2004 , 19, 440-8	66
1701	Memantine enhances autonomy in moderate to severe Alzheimer's disease. 2004 , 19, 458-64	29
1700	A counseling intervention for caregivers: effect on neuropsychiatric symptoms. 2004 , 19, 781-8	26
1699	Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey. 2004 , 19, 954-60	31
1698	The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease. 2004 , 19, 1040-6	36
1697	A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. 2004 , 19, 1087-94	107
1696	A pilot study of behavioural and psychological signs and symptoms of dementia in patients of Indian sub-continent origin admitted to a dementia day hospital in the United Kingdom. 2004 , 19, 1195-204	18
1695	A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. 2004 , 19, 9-18	112
1694	Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. 2004 , 19, 29-35	85
1693	A polar diagram for comprehensive geriatric assessment. 2004 , 38, 139-44	5
1692	Visual perception in Parkinson disease dementia and dementia with Lewy bodies. <i>Neurology</i> , 2004 , 63, 2091-6	6.5 251
1691	Long-term cholinesterase inhibitor treatment of Alzheimer's disease. 2004 , 18, 757-68	42
1690	Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease. 2004 , 12, 473-482	26
1689	Effect of High Climate Temperature on the Behavioral and Psychological Symptoms of Dementia. 2004 , 5, 161-166	15
1688	Psychiatric issues in non-Alzheimer dementias. 2004 , 3, 397-397	0

1687	Psychoactive Medications and Actigraphically Scored Sleep Quality in Frail Nursing Home Patients. 2004 , 5, 223-227	7
1686	[Hallucinations and dementia. Prevalence, clinical presentation and pathophysiology]. 2004 , 160, S31-43	11
1685	The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. 2004 , 5, 242-248	8
1684	The Use, Benefits, and Costs of Cholinesterase Inhibitors for Alzheimer's Dementia in Long-Term Care: Are the Data Relevant and Available?. 2004 , 5, 249-255	9
1683	Dimensions of Sexual Dysfunction in Parkinson Disease. 2004 , 12, 221-226	27
1682	Syndrome d'émietiel. 2004 , 1, 55-64	3
1681	Efficacy and tolerability of memantine in the treatment of dementia. 2004 , 2, 303-12	19
1680	Rivastigmine in frontotemporal dementia: an open-label study. 2004 , 21, 931-7	108
1679	Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. 2004 , 225, 135-41	38
1678	Emerging therapies for vascular dementia and vascular cognitive impairment. 2004 , 35, 1010-7	173
1677	Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions. 2004 , 21, 415-26	12
1676	Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. 2004 , 21, 453-78	223
1675	Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias. 2004 , 20, 59-68	7
1674	Managing agitation and difficult behavior in dementia. 2004 , 20, 69-82	10
1673	A 6-Month Observational Study of the Relationship Between Weight Loss and Behavioral Symptoms in Institutionalized Alzheimer's Disease Subjects. 2004 , 5, 89-97	73
1672	[Frontal dysexecutive syndromes]. 2004 , 160, 899-909	30
1671	Dières non schizophrhiques du sujet g. 2004 , 4, 13-19	
1670	[Cost relation between severity of Alzheimer's disease and cognitive and functional impairment]. 2004 , 122, 767-72	22

1669	[Diagnosis of dementia]. 2004 , 25, 363-75	0
1668	Prepulse inhibition in patients with Alzheimer's disease. 2004 , 25, 1045-50	43
1667	[Mmantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease]. 2004 , 30, 69-79	5
1666	The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. <i>Neurology</i> , 2004 , 62, 912-9	6.5 283
1665	Rivastigmine for dementia associated with Parkinson's disease. 2004 , 351, 2509-18	919
1664	Clinical effectiveness of atypical antipsychotics in elderly patients with psychosis. 2004 , 14 Suppl 4, S461-9	6
1663	Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. 2004 , 21, 714-24	135
1662	The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. 2004 , 23, 956-66	51
1661	Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. 2004 , 363, 2105-15	702
1660	Anorgasmia in a patient treated with bupropion SR for smoking cessation. 2004 , 24, 460-1	4
1659	Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. 2004 , 24, 467-9	10
1658	Mutation analysis of the ryanodine receptor gene isoform 3 (RYR3) in recurrent neuroleptic malignant syndrome. 2004 , 24, 471-3	3
1657	Panic attacks with spontaneous ejaculation successfully treated with citalopram and clonazepam. 2004 , 24, 463-4	5
1656	QT interval prolongation in patients on methadone with concomitant drugs. 2004 , 24, 446-8	28
1655	Further comments on the effects of nitrous oxide treatment on alcohol withdrawal. 2004 , 24, 473-5	
1654	Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine. 2004 , 24, 464-7	2
1653	Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. 2004 , 24, 456-9	71
1652	The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies. 2004 , 16, 409-25	14

1651	The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs. 2004 , 24, 452-4	6
1650	Dementia with lewy bodies: implications for clinical trials. 2004 , 27, 281-92	4
1649	Prevalence and clinical correlates of disinhibition in dementia. 2004 , 17, 139-47	33
1648	Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder. 2004 , 24, 454-6	9
1647	Comments on article by Harrigan et al: "A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition". 2004 , 24, 456	3
1646	Gabapentin and behavioral disorders in severe Alzheimer disease. 2004 , 24, 459-60	9
1645	A follow-up study of male sexual disorders: the neurophysiological assessments, anxiety-depression levels, and response to fluoxetine treatment. 2004 , 24, 461-3	
1644	Cognitive impairments in cerebellar degeneration: a comparison with Huntington's disease. 2004 , 16, 176-84	17
1643	Amoxapine in schizophrenia: a negative double-blind controlled trial. 2004 , 24, 448-50	5
1642	Construct validity and frequency of euphoria sclerotica in multiple sclerosis. 2004 , 16, 350-6	32
1641	Differential time course efficacy on dysphoric and physical symptoms of the intermittent dosing of fluoxetine in the premenstrual dysphoric disorder. 2004 , 24, 469-71	3
1640	Trazodone for agitation in dementia. 2004 , CD004990	30
1639	Galantamine for Alzheimer's disease. 2004 , CD001747	30
1638	A comparative study of behavioral and psychological signs and symptoms of dementia in patients with dementia referred to psychogeriatric services in Korea and the United Kingdom. 2004 , 16, 219-36	14
1637	Traitements non pharmacologiques des troubles cognitifs et comportementaux chez le sujet âgé. 2004 , 1, 1-6	
1636	Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. 2004 , 18, 17-21	188
1635	Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations. 2004 , 2, 239-252	0
1634	Understanding the latest advances in pharmacologic interventions for Alzheimer's disease. 2004 , 9, 24-8	24

1633	Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia. <i>Neurology</i> , 2004 , 62, 407-10	6.5	42
1632	A guide to diagnosis of Alzheimer's disease. 2004 , 9, 16-9		9
1631	Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates. 2004 , 49, 164-71		26
1630	Cryptococcal meningitis mimicking vascular dementia. <i>Neurology</i> , 2004 , 62, 2135	6.5	26
1629	Canadian Outcomes Study in Dementia: study methods and patient characteristics. 2004 , 49, 417-27		21
1628	Comparisons between Alzheimer disease, frontotemporal lobar degeneration, and normal aging with brain mapping. 2005 , 16, 409-25		65
1627	Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial. 2005 , 187, 450-5		117
1626	Reduction of caregiver burden in Alzheimer's disease by treatment with galantamine. 2005 , 10, 481-8		14
1625	Added Value of the Neuropsychological Evaluation for Diagnosis and Research of Atypical Parkinsonian Disorders. 2005 , 185-195		2
1624	A review of rating scales for measuring behavior change due to frontal systems damage. 2005 , 18, 18-27		96
1623	Assessing age of dementia onset: validity of informant reports. 2005 , 19, 128-34		17
1622	The emotional impact of psychiatric symptoms in dementia on partner caregivers: do caregiver, patient, and situation characteristics make a difference?. 2005 , 19, 195-201		38
1621	Use of ziprasidone in parkinsonian patients with psychosis. 2005 , 28, 111-4		47
1620	Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. 2005 , 19, 23-8		87
1619	Donepezil in the treatment of dementia. 2005 , 1, 7-17		2
1618	Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. 2005 , 28, 215-9		58
1617	The use of olanzapine in the treatment of negative symptoms in Alzheimer's disease. 2005 , 17, 423-4		1
1616	Memantine for dementia. 2005 , CD003154		27

1615	Syndromes majeurs de l'hémisphère mineur. 2005 , 2, 1-21		
1614	Disorders of diminished motivation. 2005 , 20, 377-88		137
1613	Troubles psychiques des personnes âgées. 2005 , 2, 1-15		1
1612	Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. 2005 , 11, 574-83		78
1611	Is there a need to study behavioral and psychological signs and symptoms of dementia across cultures?. 2005 , 17, 513-8		1
1610	Depression in Long-Term Care.. 2005 , 12, 280-299		24
1609	Frontotemporal dementia progresses to death faster than Alzheimer disease. <i>Neurology</i> , 2005 , 65, 719-25		219
1608	Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. <i>Neurology</i> , 2005 , 65, 1863-72	6.5	3921
1607	Nighttime insomnia treatment and education for Alzheimer's disease: a randomized, controlled trial. 2005 , 53, 793-802		236
1606	Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. 2006 , 60, 110-8		74
1605	Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients. 2005 , 59, 274-9		55
1604	Dementia caregivers' burdens and use of public services. 2005 , 5, 94-98		31
1603	Acceptance of memory impairment and satisfaction with life in patients with mild to moderate Alzheimer's disease. 2005 , 5, 122-126		
1602	Symptoms of sleep disturbance in persons with Alzheimer's disease and normal elderly. 2005 , 14, 177-85		83
1601	Apolipoprotein E genotype and mortality: findings from the Cache County Study. 2005 , 53, 935-42		47
1600	Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. 2005 , 53, 1101-7		340
1599	Brief checklist for non-cognitive symptoms of dementia. 2005 , 24, 88-93		
1598	The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials. 2005 , 4, 129-33		14

1597	A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia. 2005 , 111, 403-9	10
1596	Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. 2005 , 112, 201-7	60
1595	Neuropsychiatric symptoms in patients with multiple sclerosis. 2005 , 112, 463-8	78
1594	Behavioural changes and psychological symptoms in dementia disorders. 2005 , 4, 735-42	164
1593	Representation of attitudinal knowledge: role of prefrontal cortex, amygdala and parahippocampal gyrus. 2005 , 43, 249-59	28
1592	Impaired recognition of negative facial emotions in patients with frontotemporal dementia. 2005 , 43, 1673-87	124
1591	Apathy predicts hedonic but not craving response to cocaine. 2005 , 82, 236-40	7
1590	Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. 2005 , 139, 79-88	48
1589	Frontotemporal dementia. 2005 , 4, 55-58	3
1588	Components of behavioral pathology in dementia. 2005 , 20, 137-45	23
1587	Predictors of high level of burden and distress in caregivers of demented patients: results of an Italian multicenter study. 2005 , 20, 168-74	126
1586	Depressive symptom quality and neuropsychological performance in dementia. 2005 , 20, 479-84	14
1585	The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. 2005 , 20, 523-30	187
1584	The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables. 2005 , 20, 531-6	67
1583	Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. 2005 , 20, 559-69	94
1582	Self-injurious behaviour in nursing home residents with dementia. 2005 , 20, 651-7	17
1581	Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. 2005 , 20, 459-64	150
1580	Repetitive behaviour in Alzheimer's disease: description, correlates and functions. 2005 , 20, 686-93	34

1579	The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey. 2005 , 20, 744-8	27
1578	A SPECT study of wandering behavior in Alzheimer's disease. 2005 , 20, 816-20	35
1577	Sleep disturbances in the elderly residing in assisted living: findings from the Maryland Assisted Living Study. 2005 , 20, 956-66	40
1576	A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. 2005 , 20, 938-44	82
1575	Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. 2005 , 20, 1028-37	91
1574	Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. 2005 , 20, 1020-7	31
1573	Assessing early to late stage dementia: the TSI and BANS-S scales in the nursing-home. 2005 , 20, 1138-45	18
1572	Behavioural and psychological signs and symptoms of dementia across cultures: current status and the future. 2005 , 20, 1187-95	28
1571	Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. 2005 , 57, 216-25	142
1570	Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. 2005 , 20, 208-12	34
1569	Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. 2005 , 20, 1571-6	90
1568	Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. 2005 , 32, 1176-85	77
1567	Global cognitive impairment should be taken into account in SPECT-neuropsychology correlations: the example of verbal memory in very mild Alzheimer's disease. 2005 , 32, 1186-92	9
1566	A cross-cultural study on expressed emotion in carers of people with dementia and schizophrenia: Japan and England. 2005 , 40, 564-70	27
1565	[The Heidelberg instrument for the assessment of quality of life in dementia (H. I. L. DE.)--dimensions of quality of life and methods of organization]. 2005 , 38, 108-21	23
1564	Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study. 2005 , 252, 1186-93	29
1563	Alzheimer's disease and frontal variant of frontotemporal dementia-- a very brief battery for cognitive and behavioural distinction. 2005 , 252, 1238-44	51
1562	Behavioral and psychologic symptoms of dementia: How does this conceptualization help us?. 2005 , 3, 32-37	

1561	Hebben verzorgende familieleden invloed op probleemgedrag bij dementie?. 2005 , 36, 10-17	1
1560	Een Ontmoetingscentrum voor Surinamers met dementie en hun mantelzorgers. 2005 , 36, 251-262	1
1559	Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: etiology and management. 2005 , 5, 345-54	15
1558	Treatment approaches to symptoms associated with frontotemporal degeneration. 2005 , 7, 376-80	27
1557	Proxy completion of EQ-5D in patients with dementia. 2005 , 14, 107-18	69
1556	Der DemTect in der klinischen Anwendung. 2005 , 18, 121-130	4
1555	Perfiles diagnsticos y epidemiolgicos en una Unidad de Memoria. 2005 , 133, 789	1
1554	[Charles Bonnet syndrome: visual hallucinations in patients with ocular diseases--case report]. 2005 , 68, 129-32	1
1553	Geriatric psychiatry 2050?. 2005 , 17, 518-520	0
1552	[An update on the treatment of psychological and behavioral symptoms associated to dementia]. 2005 , 133, 1242-51	
1551	Clinical Aspects of Alzheimer's Disease. 1083-1093	
1550	Other Dementias. 1111-1133	
1549	Anhang. 2005 , 161-222	
1548	Naturalistic audit of NICE criteria for the use of cholinesterase inhibitors. 2005 , 29, 410-412	11
1547	Clinical Diagnosis of Dementia With Lewy Bodies. 2005 , 361-373	1
1546	Role of Neuropsychiatric Assessment in Diagnosis and Research. 2005 , 163-183	
1545	A evolu de longo prazo pode diferenciar dois subtipos de psicose de incio tardio. 2005 , 32, 37-42	
1544	[Diagnosis of Alzheimer's disease in Brazil: cognitive and functional evaluation. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology]. 2005 , 63, 720-7	92

1543	The association of neuropsychiatric symptoms and environment with quality of life in assisted living residents with dementia. 2005 , 45 Spec No 1, 19-26		109
1542	Training community consultants to help family members improve dementia care: a randomized controlled trial. 2005 , 45, 802-11		139
1541	Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. <i>Neurology</i> , 2005 , 64, 1539-47	6.5	83
1540	The Caregivers for Alzheimer's disease Problems Scale (CAPS): development of a new scale within the LASER-AD study. 2005 , 34, 287-90		18
1539	STAR: a dementia-specific training program for staff in assisted living residences. 2005 , 45, 686-93		105
1538	A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease. 2005 , 2, 553-8		32
1537	Prevalence of apathy, dysphoria, and depression in relation to dementia severity in Alzheimer's disease. 2005 , 17, 342-9		81
1536	Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. 2005 , 62, 721-8		104
1535	Behavioural and Psychiatric Symptoms in Patients With Neurodegenerative Diseases. 2005 , 6, 181-190		
1534	Prevalence and clinical correlates of neuropsychiatric symptoms in dementia. 2005 , 20, 367-73		47
1533	Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. 2005 , 62, 1728-33		227
1532	Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. <i>Neurology</i> , 2005 , 64, 861-5	6.5	175
1531	Underreporting of behavioral problems in older hospitalized patients. 2005 , 45, 535-8		4
1530	Subjective appraisal of Alzheimer's disease caregiving: the role of self-efficacy and depressive symptoms in the experience of burden. 2005 , 20, 273-80		51
1529	Antipsychotic dose-sparing effect with addition of memantine. 2005 , 39, 1573-6		10
1528	Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. 2005 , 162, 2022-30		264
1527	Two aspects of impaired consciousness in Alzheimer's disease. 2005 , 150, 287-98		27
1526	Use of the ten-point clock test to compare executive functioning across 24 months in patients with subcortical vascular dementia. 2005 , 100, 207-16		3

1525	Apathy: why care?. 2005 , 17, 7-19	195
1524	Treatable comorbid conditions and use of VA health care services among patients with dementia. 2005 , 56, 70-5	15
1523	Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. 2005 , 21, 1631-9	18
1522	[New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?]. 2005 , 130, 408-12	0
1521	Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. 2005 , 20, 120-32	77
1520	Atypical Parkinsonian Disorders. 2005 ,	10
1519	Behavioral problems in dementia patients and salivary cortisol patterns in caregivers. 2005 , 17, 201-7	84
1518	Frontotemporal dementia, semantic dementia, and Alzheimer's disease: the contribution of standard neuropsychological tests to differential diagnosis. 2005 , 18, 39-44	63
1517	Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. 2005 , 331, 321-7	315
1516	Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski's description of PSP 40 years ago and Albert's delineation of the subcortical dementia 30 years ago. 2005 , 11, 250-62	16
1515	Anosognosia in very mild Alzheimer's disease but not in mild cognitive impairment. 2005 , 19, 349-56	110
1514	Behavioral and psychological symptoms in Alzheimer's disease: frequency and relationship with duration and severity of the disease. 2005 , 19, 276-81	72
1513	Glutathione S-transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprotein E epsilon4 allele. 2005 , 51, 944-51	42
1512	Distinctive clinical features of mild cognitive impairment with subcortical cerebrovascular disease. 2005 , 19, 196-203	75
1511	Prevalence of psychiatric function disorders in psychogeriatric patients at referral to nursing home care--the relation to cognition, activities of daily living and general details. 2005 , 20, 215-24	19
1510	Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia. 2005 , 76, 1337-41	110
1509	Neurotransmitter Dysfunction and Neurotransmitter Replacement Therapy as Part of Frontotemporal Dementia Treatment. 2005 , 1, 345-351	0
1508	Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia. 2005 , 19, 82-5	27

1507	Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. 2005 , 102, 15647-52	258
1506	Family caregivers and caregiving in dementia. 2005 , 15, 263-271	10
1505	Use of the QOL-AD for measuring quality of life in people with severe dementia--the LASER-AD study. 2005 , 34, 130-5	161
1504	Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. 2005 , 128, 570-83	144
1503	Neuroanatomical predictors of response to donepezil therapy in patients with dementia. 2005 , 62, 1718-22	39
1502	Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. 2005 , 128, 752-72	51
1501	Eficacia de un programa psicosocial con cuidadores de enfermos de Alzheimer: análisis de los resultados al año de seguimiento. 2005 , 40, 46-54	3
1500	Frontal lobe dementia and subcortical vascular dementia: a neuropsychological comparison. 2005 , 96, 141-51	14
1499	Identification of VaD and AD prodromes: the Cache County Study. 2005 , 1, 19-29	14
1498	Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. 2005 , 20, 490-6	143
1497	Neural correlates of semantic and behavioural deficits in frontotemporal dementia. 2005 , 24, 1042-51	158
1496	Rivastigmine for Alzheimer's disease. 2005 , 5, 563-80	24
1495	Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies. 2005 , 128, 1267-76	164
1494	Inhibitory control of saccadic eye movements and cognitive impairment in Alzheimer's disease. 2005 , 57, 1052-60	126
1493	[Behavioral and psychological symptoms in dementia: description and management]. 2005 , 161, 357-66	13
1492	Echelles d'évaluation de la dépression en consultation gériatrique. 2005 , 5, 44-51	1
1491	Galantamine Treatment of Problematic Behavior in Alzheimer Disease: Post-Hoc Analysis of Pooled Data From Three Large Trials. 2005 , 13, 527-534	38
1490	[A global intervention program for institutionalized demented patients]. 2005 , 161, 290-8	9

1489	Anxiety and Depression in Family Caregivers of People With Alzheimer Disease: The LASER-AD Study. 2005 , 13, 795-801	263
1488	Effects of Previous Major Depressive Illness on Cognition in Alzheimer Disease Patients. 2005 , 13, 312-318	15
1487	[Self-evaluation of physical, cognitive and mood symptoms in a cohort of traumatic and vascular brain injury patients participating in social and neuropsychological remediation programmes]. 2005 , 161, 67-73	1
1486	Clinical Features of Argyrophilic Grain Disease: A Retrospective Survey of Cases With Neuropsychiatric Symptoms. 2005 , 13, 1083-1091	32
1485	Tratamiento de la demencia. 2005 , 9, 1-5	
1484	Neuropsychiatric assessment. 2005 , 28, 507-47, 45	2
1483	Risperidone in the treatment of behavioural and psychological symptoms of dementia in patients diagnosed with vascular or mixed-type dementia. 2005 , 9, 45-51	3
1482	Neuropsychiatric Symptoms and Quality of Life in Alzheimer Disease. 2005 , 13, 469-474	164
1481	Methylphenidate may treat apathy independent of depression. 2005 , 39, 1947-9	29
1480	Donepezil: a review. 2005 , 1, 527-36	61
1479	apoE isoforms and measures of anxiety in probable AD patients and Apoe ^{-/-} mice. 2005 , 26, 637-43	65
1478	¹ H MRS in stroke patients with and without cognitive impairment. 2005 , 26, 873-82	16
1477	A pilot study of associated factors of weight changes in community-dwelling patients with Alzheimer's disease. 2005 , 25, 111-118	6
1476	Neuropsychological functioning of dementia patients with psychosis. 2005 , 20, 771-83	14
1475	[Assessment of disability and quality of life in patients with cognitive disorders]. 2005 , 48, 376-91	7
1474	Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer's disease : results of a 52-week open-label study. 2005 , 25, 507-15	14
1473	Open-label, observational study of the effects of risperidone on the behavioral and psychological symptoms of dementia and caregiver stress in the community setting. 2005 , 3, 8-16	5
1472	Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression. 2005 , 57, 412-21	147

1471	Prise en charge thérapeutique de la démence. 2005 , 2, 145-151	
1470	Syndromes majeurs de l'hémisphère mineur. 2005 , 2, 475-504	0
1469	Troubles psychiques des personnes âgées. 2005 , 2, 259-281	5
1468	Survival following dementia onset: Alzheimer's disease and vascular dementia. 2005 , 229-230, 43-9	94
1467	Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. 2005 , 231, 29-34	378
1466	Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia. 2005 , 236, 43-8	169
1465	Self-rated executive function: development of the executive function index. 2005 , 115, 649-67	108
1464	Persistence of and Changes in Neuropsychiatric Symptoms in Alzheimer Disease Over 6 Months. 2005 , 13, 976-983	7
1463	Comparison of Olanzapine and Risperidone in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients With Dementia. 2005 , 13, 722-730	79
1462	[Consensus statement on severe dementia]. 2005 , 161, 868-77	9
1461	[Preliminary pilot study of cyproterone acetate for the treatment of aggressive behavior associated with severe dementia]. 2005 , 161, 1071-8	8
1460	The Caregiver Burden Inventory in evaluating the burden of caregivers of elderly demented patients: results from a multicenter study. 2005 , 17, 46-53	88
1459	Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. 2005 , 21, 1317-27	167
1458	Galantamine for Alzheimer's disease and mild cognitive impairment. 2006 , CD001747	134
1457	Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review. 2006 , 23, 957-67	15
1456	Risperidone for the treatment of neuropsychiatric features in dementia. 2006 , 23, 887-96	2
1455	Management of Parkinson's disease dementia : practical considerations. 2006 , 23, 807-22	16
1454	A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia. 2006 , 23, 241-9	10

1453	Psychiatry for Neurologists. 2006,	1
1452	Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. 2006, 355, 1525-38	875
1451	Évaluation des fonctions neuropsychologiques du patient atteint de sclérose latérale amyotrophique (SLA). 2006, 162, 151-157	
1450	Difficult behaviors in long-term care patients with dementia. 2006, 7, 180-92	47
1449	Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. 2006, 14, 605-12	106
1448	Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease. 2006, 14, 343-51	23
1447	Antipsychotic drug use among nursing home residents taking rivastigmine. 2006, 7, 12-6	15
1446	Design of Depression in Alzheimer's Disease Study-2. 2006, 14, 920-30	33
1445	Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. 2006, 14, 438-45	94
1444	Galantamine for vascular cognitive impairment. 2006,	26
1443	Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. 2006, 20, 311-25	42
1442	The scale for emotional blunting in patients with frontotemporal dementia. 2006, 12, 242-6	23
1441	Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. 2006, 22, 483-94	52
1440	Assessment of anxiety in dementia: an investigation into the association of different methods of measurement. 2006, 19, 202-8	29
1439	Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy. 2006, 20, 157-60	34
1438	Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. 2006, 367, 1057-1065	294
1437	Mild cognitive impairment. 2006, 367, 1262-70	1703
1436	Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. 2006, 77, 1323-8	83

1435	[Bipolar affective disorders and cerebral degeneration: an observation]. 2006 , 32 Pt 2, S48-50	1
1434	Decomposition of metabolic brain clusters in the frontal variant of frontotemporal dementia. 2006 , 30, 871-8	43
1433	3D mapping of ventricular and corpus callosum abnormalities in HIV/AIDS. 2006 , 31, 12-23	108
1432	Relationship between antisocial behavior and regional cerebral blood flow in frontotemporal dementia. 2006 , 32, 301-6	28
1431	In vivo neuropathology of the hippocampal formation in AD: a radial mapping MR-based study. 2006 , 32, 104-10	108
1430	In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. 2006 , 33, 423-9	48
1429	[Cholinesterase inhibitor therapy in long term care settings]. 2006 , 27, 588-94	4
1428	Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach. 2006 , 2, 303-13	11
1427	Predictors of institutionalization in demented patients discharged from a rehabilitation unit. 2006 , 7, 345-9	36
1426	Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies. 2006 , 14, 153-60	118
1425	A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. 2006 , 14, 428-37	45
1424	Neuropsychiatric Features of Dementia: What is the Big Picture?. 2006 , 14, 557-560	1
1423	Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. 2006 , 14, 191-210	595
1422	Comparison of different clinical diagnostic criteria for depression in Alzheimer disease. 2006 , 14, 589-97	58
1421	[Measurement instruments and assessment scales for frontotemporal dementia]. 2006 , 162, 244-52	6
1420	Effects of group-home care on behavioral symptoms, quality of life, and psychotropic drug use in patients with frontotemporal dementia. 2006 , 7, 335-7	10
1419	Progression of white matter hyperintensities in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia: a comparison with normal aging. 2006 , 14, 842-9	85
1418	Frontal dysfunction underlies depressive syndrome in Alzheimer disease: a FDG-PET study. 2006 , 14, 625-8	38

1417	Antipsychotic drug use among nursing home residents taking rivastigmine. 2006 , 7, 337-8	1
1416	Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. 2006 , 14, 767-76	95
1415	Factors associated with caregiver reports of sleep disturbances in persons with dementia. 2006 , 14, 112-20	66
1414	Évaluation cognitive et comportementale. 2006 , 162, 145-150	1
1413	Transition to nursing home from assisted living is not associated with dementia or dementia-related problem behaviors. 2006 , 7, 73-8	20
1412	Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: application to mild and moderate dementia. 2006 , 41, 105-17, vii	6
1411	Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease. 2006 , 26, 303-14	7
1410	Donepezil for dementia due to Alzheimer's disease. 2006 , CD001190	188
1409	Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. 2006 , 14, 704-15	213
1408	Memantine for dementia. 2006 , CD003154	315
1407	Caregiver burden, health-related quality of life and coping in dementia caregivers: a comparison of frontotemporal dementia and Alzheimer's disease. 2006 , 22, 405-12	143
1406	Current pharmacotherapy for Alzheimer's disease. 2006 , 57, 513-33	243
1405	Predicting neuropsychological abnormalities in multiple sclerosis. 2006 , 245, 67-72	49
1404	Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review. 2006 , 248, 104-14	25
1403	Practice effects on motor control in healthy seniors and patients with mild cognitive impairment and Alzheimer's disease. 2006 , 13, 385-410	53
1402	Components of depression in HIV-1 infection: their differential relationship to neurocognitive performance. 2006 , 28, 420-37	53
1401	Dementia Neuropsychiatric Symptom Severity, Help-Seeking Patterns, and Family Caregiver Unmet Needs in the Sacramento Area Latino Study on Aging (SALSA). 2006 , 29, 1-15	18
1400	Recommendations for best practices in the treatment of Alzheimer's disease in managed care. 2006 , 4 Suppl A, S9-S24; quiz S25-S28	67

1399	[Ecologic evaluation in the cognitive assessment of brain injury patients: generation and execution of script]. 2006 , 49, 234-41	8
1398	Heterogeneity of posterior limbic perfusion in very early Alzheimer's disease. 2006 , 55, 285-91	12
1397	Central nervous system effects in acute thallium poisoning. 2006 , 27, 291-5	49
1396	[Medical comorbidity in Alzheimer's disease: baseline characteristics of the REAL.FR Cohort]. 2006 , 27, 91-7	9
1395	LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. 2006 , 12, 410-9	85
1394	Lewy body disease: thalamic cholinergic activity related to dementia and parkinsonism. 2006 , 27, 433-8	56
1393	Cortical rhythms reactivity in AD, LBD and normal subjects: a quantitative MEG study. 2006 , 27, 1100-9	72
1392	Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms. 2006 , 27, 1595-603	68
1391	Behavioural and Psychological Symptoms of Dementia â Agitation. 2006 , 51-61	4
1390	Absence of dementia in late-onset schizophrenia: a one year follow-up of a Brazilian case series. 2006 , 64, 946-9	22
1389	Cerebral emboli and depressive symptoms in dementia. 2006 , 189, 260-3	12
1388	Assessment and Diagnosis of Severe Dementia. 2006 , 1-20	
1387	. 2006 ,	4
1386	Depression in Severe Dementia. 2006 , 63-74	1
1385	Physical Aspects of Severe Alzheimer's Disease. 2006 , 75-82	
1384	. 2006 ,	3
1383	Front Matter. 2006 , i-xiii	
1382	Cholinesterase inhibitors for Parkinson's disease dementia. 2006 , CD004747	38

1381	Melatonin for cognitive impairment. 2006 , CD003802	28
1380	Use of the Neuropsychiatric Inventory in traumatic brain injury: A pilot investigation.. 2006 , 51, 232-238	27
1379	The primary care of Alzheimer disease. 2006 , 332, 314-33	7
1378	Prise en charge thérapeutique de la démence. 2006 , 1, 1-5	
1377	Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia. 2006 , 20, 133-7	16
1376	Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors. 2006 , 26, 685-7	32
1375	Alcohol abuse in an elderly woman taking donepezil for Alzheimer disease. 2006 , 26, 683-5	7
1374	Reply to Comments by Dr. Hanna. 2006 , 26, 690-691	
1373	Anxiety and regional cortical glucose metabolism in patients with Alzheimer's disease. 2006 , 18, 521-8	29
1372	Level of cognitive impairment predicts mortality in high-risk community samples: the memory and medical care study. 2006 , 18, 543-6	13
1371	Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. 2006 , 29, 331-7	110
1370	The development and validation of a dementia behavior disturbance inventory. 2006 , 18, 95-110	3
1369	Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary. 2006 , 33, 6-26	14
1368	Self-conscious emotion deficits in frontotemporal lobar degeneration. 2006 , 129, 2508-16	140
1367	Impulsivity, reward sensitivity, and decision-making in subarachnoid hemorrhage survivors. 2006 , 12, 697-706	10
1366	Rivastigmine in the Treatment of Dementia Associated with Parkinson's Disease: A Randomized, Double-blind, Placebo-controlled Study. 2006 , 1, 13-25	1
1365	Correlates of caregiver-rated quality of life in assisted living: the Maryland Assisted Living study. 2006 , 61, P311-4	18
1364	Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. 2006 , 29, 59	8

1363	ADCS Prevention Instrument Project: overview and initial results. 2006 , 20, S109-23	53
1362	Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. 2006 , 26, 671-3	14
1361	Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. 2006 , 20, 263-8	55
1360	Behavioral alterations and vascular dementia. 2006 , 12, 43-7	24
1359	Methadone and the QT interval: relations to the serum concentrations of methadone and its enantiomers (R)-methadone and (S)-methadone. 2006 , 26, 687-9	12
1358	Urinary obstruction with citalopram and aripiprazole combination in an elderly patient. 2006 , 26, 667-8	11
1357	Workshop reports from the third Asia-pacific regional meeting of the international working group on harmonization of dementia drug guidelines. 2006 , 20, 313	1
1356	Clozapine augmented with aripiprazole in 5 patients with schizophrenia. 2006 , 26, 669-71	14
1355	Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. 2006 , 20, 93-100	204
1354	Third Asia-pacific regional meeting of the international working group on harmonization of dementia drug guidelines: meeting report summary. 2006 , 20, 311-2	0
1353	The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. 2006 , CD003476	227
1352	Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. 2006 , 26, 666-7	11
1351	Inhaled cocaine used to relieve "off" periods in patients with Parkinson disease and unpredictable motor fluctuations: a report of 2 cases. 2006 , 26, 689-90	5
1350	Quetiapine-induced erythema multiforme minor: a case report. 2006 , 26, 668-9	4
1349	Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine. 2006 , 26, 681-3	23
1348	Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status. 2006 , 26, 679-81	9
1347	Use of a serotonin 1A receptor agonist to treat restless legs syndrome. 2006 , 26, 673-5	4
1346	A case of hyponatremia induced by duloxetine. 2006 , 26, 675-6	19

1345	Cognitive change in Parkinson disease. 2006 , 20, 302-10	45
1344	Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine. 2006 , 26, 676-7	10
1343	Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine. 2006 , 26, 677-9	11
1342	Comments on guest editorial, "Chronic fatigue syndrome, mast cells, and tricyclic antidepressants". 2006 , 26, 690; author reply 690-1	
1341	Efficacy of recreational and occupational activities associated to psychologic support in mild to moderate Alzheimer disease: a multicenter controlled study. 2006 , 20, 275-82	34
1340	Neuropsychiatric inventory workshop: behavioral and psychologic symptoms of dementia in Asia. 2006 , 20, 314-7	13
1339	The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. 2006 , 20, 210-6	568
1338	ADCS Prevention Instrument Project: behavioral measures in primary prevention trials. 2006 , 20, S147-51	11
1337	Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease. 2006 , 23, 421-5	43
1336	Demência fronto-temporal: aspectos clínicos e terapêuticos. 2006 , 28, 69-76	1
1335	Alzheimer's Disease and Other Disorders Associated With Dementia. 266-298	1
1334	Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. 2006 , 60, 190-5	56
1333	Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer's disease with late onset. 2006 , 13, 176-82	29
1332	A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. 2006 , 13, 43-54	87
1331	Subcortical deficit pattern after brain abscess: a neuropsychological study. 2006 , 13, 599-603	9
1330	The evaluation of behavioral disturbances in epilepsy. 2006 , 47 Suppl 2, 3-8	31
1329	A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. 2006 , 54, 354-61	77
1328	Caregiver characteristics are associated with neuropsychiatric symptoms of dementia. 2006 , 54, 796-803	121

1327	Education, cognitive test scores, and black-white differences in dementia risk. 2006 , 54, 898-905	73
1326	Amygdalar volume and psychiatric symptoms in Alzheimer's disease: an MRI analysis. 2006 , 113, 40-5	29
1325	Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease. 2006 , 114, 97-101	15
1324	Association between apolipoprotein E epsilon4 allele and apathy in probable Alzheimer's disease. 2006 , 113, 59-63	30
1323	Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. 2006 , 5, 64-74	34
1322	Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. 2006 , 6, 246-54	563
1321	A nonpharmacological intervention to improve sleep in nursing home patients: results of a controlled clinical trial. 2006 , 54, 38-47	88
1320	Mild cognitive impairment subtypes and vascular dementia in community-dwelling elderly people: a 3-year follow-up study. 2006 , 54, 580-6	116
1319	Exercise, cognition and Alzheimer's disease: more is not necessarily better. 2006 , 30, 562-75	108
1318	Cholinesterase inhibitors for Alzheimer's disease. 2006 , CD005593	849
1317	[Assessment of pain in advanced dementia. Construct validity of the German PAINAD]. 2006 , 20, 519-26	91
1316	[The impact of different reference groups for the assessment of quality of life in people suffering from dementia-determination of competence groups with HILDE]. 2006 , 39, 350-7	7
1315	Regional cerebral blood flow change in a case of Alzheimer's disease with musical hallucinations. 2006 , 256, 236-9	19
1314	Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. 2006 , 185, 524-8	122
1313	Delusions in the nonclinical population. 2006 , 8, 191-204	104
1312	Prevalentie van probleemgedrag bij een groep dementerende verpleeghuispatiënten. 2006 , 37, 18-23	6
1311	Coping strategies and anxiety in caregivers of people with Alzheimer's disease: the LASER-AD study. 2006 , 90, 15-20	110
1310	Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. 2006 , 23, 481-9	99

1309	Autobiographical memory in semantic dementia: implication for theories of limbic-neocortical interaction in remote memory. 2006 , 44, 2421-9	62
1308	Functional correlates of Apolipoprotein E genotype in Frontotemporal Lobar Degeneration. 2006 , 6, 31	13
1307	Assessing quality of life in Taiwanese patients with Alzheimer's disease. 2006 , 21, 103-7	62
1306	A longitudinal study regarding conversion from mild memory impairment to dementia in a Japanese community. 2006 , 21, 134-9	29
1305	Determinants of costs of care for patients with Alzheimer's disease. 2006 , 21, 449-59	169
1304	Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnesic mild cognitive impairment. 2006 , 21, 550-5	78
1303	Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. 2006 , 21, 824-30	83
1302	Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. 2006 , 21, 930-6	32
1301	The contribution of neuropsychiatric symptoms to the cost of dementia care. 2006 , 21, 972-6	167
1300	Neural correlates of anosognosia for cognitive impairment in Alzheimer's disease. 2006 , 27, 588-97	140
1299	Pharmacological management of behavioural and psychological disturbance in dementia. 2006 , 21, 1-12	22
1298	Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. 2006 , 21, 456-61	94
1297	Visual rating of white matter hyperintensities in Parkinson's disease. 2006 , 21, 223-9	84
1296	Deep brain stimulation: preoperative issues. 2006 , 21 Suppl 14, S171-96	208
1295	Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. 2006 , 21, 1899-907	236
1294	Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. 2006 , 21, 2078-81	116
1293	Congestive heart failure and Alzheimer's disease. 2006 , 28, 588-94	28
1292	Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. 2006 , 129, 3103-14	99

1291	Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. 2006 , 63, 177-85		146
1290	Socio-demographic variation of dementia subtypes in china: Methodology and results of a prevalence study in Beijing, Chengdu, Shanghai, and Xian. 2006 , 27, 177-87		75
1289	What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?. 2006 , 129, 729-35		196
1288	Psychosis in Parkinson's disease: how should we treat it?. 2006 , 6, 1243-6		4
1287	New-onset bipolar disorder in late life: a case of mistaken identity. 2006 , 163, 198-203		24
1286	Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics. <i>Neurology</i> , 2006 , 66, 523-8	6.5	43
1285	Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. <i>Neurology</i> , 2006 , 66, 1830-6	6.5	231
1284	Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine. 2006 , 9, 507-16		26
1283	Cognitive functioning in spousal caregivers of dementia patients: findings from the prospective MAASBED study. 2006 , 35, 160-6		72
1282	Caregivers' experience of risk in dementia: the LASER-AD study. 2006 , 10, 532-8		24
1281	Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the Sunnybrook dementia cohort. 2006 , 3, 147-56		21
1280	Caregivers' adaptation to change: the impact of increasing impairment of persons suffering from dementia on their caregivers' subjective well-being. 2006 , 10, 539-48		32
1279	Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. <i>Neurology</i> , 2006 , 66, 935-7	6.5	60
1278	Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. 2006 , 63, 1627-31		169
1277	Relationship of vascular risk to the progression of Alzheimer disease. <i>Neurology</i> , 2006 , 67, 1357-62	6.5	109
1276	Project CARE: a randomized controlled trial of a behavioral intervention group for Alzheimer's disease caregivers. 2006 , 46, 827-32		33
1275	The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. 2006 , 77, 579-84		307
1274	Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics. 2006 , 21, 101-8		23

1273	Risk factors for functional decline and institutionalisation among community-dwelling older adults with mild to severe Alzheimer's disease: one year of follow-up. 2006 , 35, 308-10		21
1272	Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. 2007 , 78, 356-62		60
1271	Symptoms underlying unawareness of memory impairment in patients with mild Alzheimer's disease. 2006 , 19, 3-12		31
1270	Sleep and its management in dementia. 2006 , 16, 59-70		3
1269	A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. 2007 , 78, 254-9		202
1268	Clinical features associated with impulse control disorders in Parkinson disease. <i>Neurology</i> , 2006 , 67, 1258-61	6.5	198
1267	National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. 2006 , 37, 2220-41		1179
1266	Neuropsychological characteristics of mild cognitive impairment subgroups. 2006 , 77, 159-65		112
1265	Orbitofrontal dysfunction related to both apathy and disinhibition in frontotemporal dementia. 2006 , 21, 373-9		147
1264	Neurological picture. Extensive brain calcification in idiopathic hypoparathyroidism. 2006 , 77, 1328		9
1263	The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. 2007 , 78, 233-9		61
1262	Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer's disease and frontotemporal dementia. 2006 , 22, 35-41		161
1261	The Cambridge Behavioral Inventory: validation and application in a memory clinic. 2006 , 19, 220-5		28
1260	A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. 2006 , 63, 49-54		147
1259	Therapeutic Uses of Cholinesterase Inhibitors in Neurodegenerative Diseases. 2006 , 25-33		1
1258	[Psychometric properties of a German version of the Apathy Evaluation Scale]. 2006 , 74, 714-22		50
1257	Behavioral disturbances in the course of frontotemporal dementia. 2006 , 22, 352-7		39
1256	Initial symptoms in frontotemporal dementia and semantic dementia compared with Alzheimer's disease. 2006 , 21, 74-80		54

1255	Family history of dementia does not influence the progression of Alzheimer's disease at two years: results from the REAL.FR Study. 2006 , 21, 131-6	5
1254	The "Protocole d'Examen Cognitif de la Personne Agê - Lausanne" (PECPA-L): a cognitive assessment tool for the French-speaking elderly in Switzerland. 2006 , 55, 22-30	4
1253	3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. 2006 , 21, 353-63	116
1252	Patterns of frontal lobe atrophy in frontotemporal dementia: a volumetric MRI study. 2006 , 22, 278-87	75
1251	Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias. 2006 , 22, 413-20	41
1250	Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. 2006 , 21, 1-8	22
1249	Relationship between delusions and regional cerebral blood flow in Alzheimer's disease. 2006 , 21, 16-21	47
1248	Neuropathologic correlates of apathy in Alzheimer's disease. 2006 , 21, 144-7	95
1247	Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life-Alzheimer's disease scale. 2006 , 21, 182-91	70
1246	Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. 2006 , 295, 2148-57	505
1245	Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's disease. 2006 , 21, 263-73	28
1244	Caregivers' perceptions of dementia patients' functional ability. 2006 , 21, 85-91	12
1243	Evaluating two group programmes of cognitive training in mild-to-moderate AD: is there any difference between a 'global' stimulation and a 'cognitive-specific' one?. 2006 , 10, 211-8	49
1242	The Overlooked Role of Deficit or Non-Productive Behaviors in Traditional Assessment of Long-Term Care Residents. 2006 , 29, 19-37	
1241	Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. 2006 , 77, 146-8	172
1240	Socially Assistive Robotics in the Treatment of Behavioural and Psychological Symptoms of Dementia.	49
1239	A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. <i>Neurology</i> , 2006 , 66, 17-22	6.5 233
1238	Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. 2006 , 22, 49-59	42

1237	Associations between delusion proneness and personality structure in non-clinical participants: comparison between young and elderly samples. 2006 , 39, 218-26		29
1236	Predictors of driving cessation in mild-to-moderate dementia. 2006 , 175, 591-5		60
1235	Effect of the Meeting Centres Support Program on informal carers of people with dementia: results from a multi-centre study. 2006 , 10, 112-24		51
1234	Neurological picture. Involvement of the recurrent artery of Heubner with contralateral middle cerebral artery infarction. 2007 , 78, 362		3
1233	Solitary pyogenic abscess of the medulla oblongata: survival after aspiration and antibiotics. <i>Neurology</i> , 2006 , 66, 1836	6.5	3
1232	Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. <i>Neurology</i> , 2006 , 66, 685-92	6.5	233
1231	Investigational treatment for vascular cognitive impairment. 2007 , 16, 647-58		6
1230	Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy. 2007 , 23, 3153-65		3
1229	Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. 2007 , 32, 171-9		35
1228	Feasibility study of the integrated circuit tag monitoring system for dementia residents in Japan. 2007 , 22, 129-36		24
1227	Behavioural and psychological symptoms of dementia associated with Parkinson's disease. 2007 , 78, 2-3		2
1226	Personality changes in Alzheimer's disease. 2007 , 11, 526-31		18
1225	Light treatment for neuropsychiatric behaviors in Alzheimer's disease. 2007 , 29, 961-75		79
1224	Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. 2007 , 4, 81-93		90
1223	Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. <i>Neurology</i> , 2007 , 68, 1800-8	6.5	277
1222	Donepezil preserves cognition and global function in patients with severe Alzheimer disease. <i>Neurology</i> , 2007 , 69, 459-69	6.5	176
1221	Current therapeutic options for Alzheimer's disease. 2007 , 8, 550-8		42
1220	¹¹ C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. <i>Neurology</i> , 2007 , 68, 1205-12	6.5	300

1219	A direct functional measure to help ascertain optimal level of residential care. 2007 , 22, 355-9		7
1218	Impact of adult day services on behavioral and psychological symptoms of dementia. 2007 , 47, 775-88		69
1217	IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. <i>Neurology</i> , 2007 , 69, S14-22	6.5	131
1216	Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. 2007 , 4, 277-93		56
1215	Radiotherapy for glioblastoma in the elderly. 2007 , 356, 1527-35		602
1214	Dysexecutive syndromes in neurologic disease. 2007 , 31, 119-27		67
1213	Prevalence of dementia subtypes in El Prat de Llobregat, Catalonia, Spain: the PRATICON study. 2007 , 28, 224-34		62
1212	The ICTUS Study: A Prospective longitudinal observational study of 1,380 AD patients in Europe. Study design and baseline characteristics of the cohort. 2007 , 29, 29-38		45
1211	Corticobasal syndrome associated with the A9D Progranulin mutation. 2007 , 66, 892-900		75
1210	Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia. 2007 , 164, 1577-84		21
1209	Donepezil for the treatment of agitation in Alzheimer's disease. 2007 , 357, 1382-92		240
1208	Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. 2007 , 164, 1491-8		83
1207	Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis. 2007 , 64, 330-4		79
1206	Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. 2007 , 64, 1259-68		45
1205	Apathy in dementia: an examination of the psychometric properties of the apathy evaluation scale. 2007 , 19, 57-64		74
1204	Multiple sclerosis. 2007 , 27, 78-85		50
1203	[Non-cognitive symptoms and psychopharmacological treatment in demented nursing home residents]. 2007 , 75, 720-7		15
1202	Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study. 2007 , 78, 25-9		31

1201	Clinical diagnosis of dementia, not behavioral and psychologic symptoms, is associated with psychotropic drug use in community-dwelling elders classified as having dementia. 2007 , 20, 100-6		4
1200	Clinical diagnosis of dementia, not presence of behavioral and psychological symptoms, is associated with psychotropic use in community-dwelling elders classified as having dementia. 2007 , 20, 50-7		3
1199	Telehealth home monitoring of solitary persons with mild dementia. 2007 , 22, 20-6		52
1198	Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. <i>Neurology</i> , 2007 , 68, 1356-63	6.5	162
1197	Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study. 2007 , 22, 42-7		20
1196	Validity and reliability of the Behavioural Assessment Tool for Cognition and Higher Function (BATCHE) in neuropsychiatric patients. 2007 , 41, 697-704		9
1195	Clinical Trials in Dementia. 2007 , 2, 39-78		
1194	Investigating the bias of space representations in patients with stroke. 2007 , 78, 3-4		1
1193	How do officially organized services meet the needs of elderly caregivers and their spouses with Alzheimer's disease?. 2007 , 22, 360-8		51
1192	Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia. 2007 , 20, 13-28		1
1191	A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. 2007 , 23, 116-9		67
1190	Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. 2007 , 23, 161-7		44
1189	Clinical characteristics of dementia associated with argyrophilic grain disease. 2007 , 24, 229-34		11
1188	Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. 2007 , 23, 219-24		157
1187	Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. 2007 , 23, 42-6		42
1186	Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. 2008 , 79, 652-5		69
1185	Impact of problem alcohol use on patient behavior and caregiver burden in a geriatric assessment clinic. 2007 , 20, 120-7		12
1184	Cognitive changes in Parkinson's disease patients with visual hallucinations. 2007 , 23, 281-8		77

1183	Behavioural measures in frontotemporal lobar dementia and other dementias: the utility of the frontal behavioural inventory and the neuropsychiatric inventory in a national cohort study. 2007 , 23, 406-15	24
1182	Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. 2007 , 24, 20-7	155
1181	Frequency and clinical characteristics of early-onset dementia in consecutive patients in a memory clinic. 2007 , 24, 42-7	45
1180	Incident occurrence of depressive symptoms among patients with mild cognitive impairment - the Italian longitudinal study on aging. 2007 , 24, 55-64	52
1179	The spectrum of dementia: frequency, causes and clinical profile. A national referral hospital-based study in Oman. 2007 , 24, 280-7	14
1178	Relationship between behavioural and psychological symptoms of dementia and cognition in Alzheimer's disease. 2007 , 24, 343-7	25
1177	Institutional placement of persons with dementia: what predicts occurrence and timing?. 2007 , 13, 253-77	54
1176	Atlas of Alzheimer's Disease. 2007 ,	6
1175	Galantamine treatment of vascular dementia: a randomized trial. <i>Neurology</i> , 2007 , 69, 448-58	6.5 136
1174	Greater impairment of ability in the divided attention task is seen in Alzheimer's disease patients with depression than in those without depression. 2007 , 23, 231-40	21
1173	Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. 2007 , 23, 401-5	60
1172	Metabolic correlates of brain reserve in dementia with Lewy bodies: an FDG PET study. 2007 , 23, 416-22	24
1171	A SPECT study of apathy in Alzheimer's disease. 2007 , 24, 65-72	87
1170	Structural correlates of apathy in Alzheimer's disease. 2007 , 24, 91-7	120
1169	Neuropsychiatric symptoms in nursing home patients: factor structure invariance of the Dutch nursing home version of the neuropsychiatric inventory in different stages of dementia. 2007 , 24, 169-76	78
1168	Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. 2007 , 24, 247-52	39
1167	An estimate of the prevalence of dementia among community-dwelling elderly in Israel. 2007 , 24, 294-9	19
1166	Clusters of cognitive and behavioral disorders clearly distinguish primary progressive aphasia from frontal lobe dementia, and Alzheimer's disease. 2007 , 24, 317-26	27

1165	Screening for frontotemporal dementias and Alzheimer's disease with the Philadelphia Brief Assessment of Cognition: a preliminary analysis. 2007 , 24, 441-7	37
1164	Vascular risk factors in mild cognitive impairment subtypes. Findings from the ReGAl project. 2007 , 24, 448-56	21
1163	Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. 2007 , 24, 457-63	230
1162	Chapter 5 Frontotemporal Dementia Syndromes. 2007 , 112-140	1
1161	Pharmacotherapy of Alzheimer disease. 2007 , 52, 620-9	20
1160	Behavioral and Psychological Symptoms of Dementia of Psychogeriatric Inpatients on Admission to a Psychiatric Hospital. 2007 , 30, 53-63	4
1159	Chapter 3 Mild Cognitive Impairment. 2007 , 59-87	2
1158	Chapter 16 Behavioral Syndromes and Their Treatment. 2007 , 30, 411-427	
1157	Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. 2007 , 26, 40-9	203
1156	Depression after stroke. 548-570	3
1155	The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients. 2007 , 27, 182-7	12
1154	Cerebral ventricular changes associated with transitions between normal cognitive function, mild cognitive impairment, and dementia. 2007 , 21, 14-24	81
1153	Rehabilitating Patients With Dementia Who Have Had a Hip Fracture. 2007 , 23, 161-173	22
1152	Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease. 2007 , 21, 150-4	96
1151	A case of late-onset obsessive compulsive disorder developing frontotemporal lobar degeneration. 2007 , 19, 487-8	10
1150	Amisulpride-induced neuroleptic malignant syndrome. 2007 , 19, 488-9	6
1149	Restorative Care With Cognitively Impaired Older Adults. 2007 , 23, 114-125	8
1148	PSYCHIATRIC MANIFESTATIONS IN DEMENTIA. 2007 , 13, 165-179	3

1147	Degenerative dementias and their medical care in the movies. 2007 , 21, 55-9	20
1146	Memantine for behavioral disturbances in frontotemporal dementia: a case series. 2007 , 21, 164-6	59
1145	Documentation, assessment, and treatment of aggression in patients with newly diagnosed dementia. 2007 , 21, 115-21	14
1144	Longitudinal tracking of FTLD: toward developing clinical trial methodology. 2007 , 21, S58-63	11
1143	Acetylcholinesterase inhibitors for Alzheimer's disease. 2007 , 3, 483-494	3
1142	Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. 2007 , 52, 630-46	49
1141	The influence of neuropsychological functioning on neuropsychiatric problems in dementia. 2007 , 19, 50-6	8
1140	Wandering behavior and Alzheimer disease. The REAL.FR prospective study. 2007 , 21, 31-8	33
1139	A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. 2007 , 21, 136-43	121
1138	Outcomes for assessment of symptomatic and stabilization/disease modifying drugs. 2007 , 34 Suppl 1, S23-6	1
1137	Assessment of behavioural and psychological symptoms associated with dementia. 2007 , 34 Suppl 1, S67-71	49
1136	Treatment of moderate to severe Alzheimer's disease: rationale and trial design. 2007 , 34 Suppl 1, S103-8	8
1135	Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies. 2007 , 34 Suppl 1, S109-17	6
1134	Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. 2007 , 34 Suppl 1, S118-24	20
1133	A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. 2007 , 10, 281-3	37
1132	Clustering of behavioural and psychological symptoms in dementia (BPSD): a European Alzheimer's disease consortium (EADC) study. 2007 , 62, 426-32	70
1131	Relationship between psychiatric status and frontal-subcortical systems in HIV-infected individuals. 2007 , 13, 549-54	32
1130	Magnetic resonance imaging correlates of set shifting. 2007 , 13, 386-92	37

1129	Meaning and measurement of caregiver outcomes. 2007 , 19, 363-81	38
1128	Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia. 2007 , 31, 205-9	12
1127	Successful treatment with Yi-Gan San for psychosis and sleep disturbance in a patient with dementia with Lewy bodies. 2007 , 31, 1543-5	37
1126	Haplotypes in catechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease. 2007 , 28, 1231-8	26
1125	Preliminary examination of progression of Alzheimer's disease in a rural Southern African American cohort. 2007 , 22, 405-14	3
1124	Review of ICT-based services for identified unmet needs in people with dementia. 2007 , 6, 223-46	194
1123	[Frontotemporal dementia: a review]. 2007 , 33, 933-40	4
1122	Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease. 2007 , 14, 850-5	12
1121	[Dementia syndromes in the elderly: diagnostic procedures]. 2007 , 36, 1442-52	1
1120	[Clinical aspects of Alzheimer disease]. 2007 , 36, 1491-9	3
1119	Extrapyramidal symptoms in Frontotemporal Dementia: prevalence and clinical correlations. 2007 , 422, 39-42	34
1118	No effect of DC brain polarization on verbal fluency in patients with advanced frontotemporal dementia. 2007 , 118, 1417-8	32
1117	Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. 2007 , 22, 395-403	36
1116	Meta-analysis of six-month memantine trials in Alzheimer's disease. 2007 , 3, 7-17	65
1115	Management of mild to moderate Alzheimer's disease and dementia. 2007 , 3, 355-84	58
1114	Clinical practice guidelines for severe Alzheimer's disease. 2007 , 3, 385-97	42
1113	Atrophy is associated with posterior cingulate white matter disruption in dementia with Lewy bodies and Alzheimer's disease. 2007 , 36, 1-7	78
1112	[Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]. 2007 , 33, 211-5	11

1111	Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. 2007 , 64, 354-62		343
1110	Judgment in older adults: development and psychometric evaluation of the Test of Practical Judgment (TOP-J). 2007 , 29, 752-67		32
1109	Acetylcholinesterase inhibitors and depressive symptoms in patients with mild to moderate Alzheimer's disease. 2007 , 19, 220-3		20
1108	Donepezil: an update. 2007 , 8, 1011-23		132
1107	Self report on quality of life in dementia with modified COOP/WONCA charts. 2007 , 11, 734-42		14
1106	Corticobasal degeneration. 2007 , 84, 351-72		1
1105	Neurobehavioral disorders in Parkinson's disease. 2007 , 83, 435-55		4
1104	Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. <i>Neurology</i> , 2007 , 69, 747-54	6.5	135
1103	Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. 2007 , 78, 36-42		307
1102	Alzheimer's disease and mild cognitive impairment. 2007 , 25, 577-609, v		184
1101	A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease. 2007 , 15, 888-98		33
1100	Amygdala in stroke/transient ischemic attack patients and its relationship to cognitive impairment and psychopathology: the Sydney Stroke Study. 2007 , 15, 487-96		26
1099	Difficult behaviors in long-term care patients with dementia. 2007 , 8, e101-13		25
1098	Epidemiology of apathy in older adults: the Cache County Study. 2007 , 15, 365-75		120
1097	New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins. 2007 , 7, 1731-50		25
1096	Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease. 2007 , 15, 314-27		62
1095	A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. 2007 , 15, 942-52		174
1094	Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. 2007 , 15, 918-31		103

1093	Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. 2007 , 78, 1097-102	109
1092	Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia. 2006 , 21, 448-53	11
1091	Premorbid personality and behavioral and psychological symptoms in probable Alzheimer disease. 2007 , 15, 202-13	56
1090	Development of a short version of the Apathy Evaluation Scale specifically adapted for demented nursing home residents. 2007 , 15, 376-85	59
1089	Frontotemporal dementia in Oman: cognitive behavioural profile and neuroimaging characteristics; a prospective hospital-based study. 2007 , 260, 167-74	4
1088	Clinical and molecular genetic assessment of a chorea-acanthocytosis pedigree. 2007 , 263, 124-32	38
1087	Asymptomatic spontaneous cerebral emboli predict cognitive and functional decline in dementia. 2007 , 62, 339-44	42
1086	The effects of prolonged stress and APOE genotype on memory and cortisol in older adults. 2007 , 62, 472-8	73
1085	Neuropsicología de las demencias. 2007 , 206-285	
1084	Neuroimaging and other investigative findings. 134-160	2
1083	Alzheimer's Disease. 2007 ,	
1082	The effects of a comprehensive rehabilitation program of Alzheimer's Disease in a hospital setting. 2007 , 18, 1-6	50
1081	Profile of caregivers of Alzheimer's disease patients attended at a reference center for cognitive disorders. 2007 , 1, 412-417	6
1080	[Correlation between burden on caregiver and clinical characteristics of patients with dementia]. 2007 , 53, 497-501	19
1079	Antipsychotic prescribing for behavioural and psychological symptoms of dementia. 2007 , 31, 176-178	3
1078	The dementias of schizophrenia. 2007 , 1, 124-130	3
1077	Behavior disorders and subjective burden among caregivers of demented patients. 2007 , 1, 190-195	3
1076	Tratando os sintomas comportamentais e psicológicos da demência (SCPD). 2007 , 56, 83-87	9

1075	Anosognosia in Alzheimer's disease: A neuropsychological approach. 2007 , 1, 81-88	1
1074	Reports by caregivers of behavioral and psychological symptoms of dementia. 2007 , 1, 97-103	1
1073	Clinical evaluation of patients with moderate to severe Alzheimer disease. 2007 , 1, 296-302	
1072	The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease. 2007 , 22, 754-62	14
1071	[Neuropsychiatric symptoms in dementias: preliminary report of a prospective outpatient evaluation in Brazil]. 2007 , 65, 498-502	13
1070	CLINICAL ASSESSMENT OF MENTAL STATUS. 2007 , 2-21	3
1069	Efficacy and safety of galantamine in the treatment of Alzheimer's Disease and Alzheimer's Disease with cerebrovascular (Mixed Dementia) (GAL-DEM-402). 2007 , 94	1
1068	Multiple sclerosis, bipolar affective disorder and euphoria. 66-81	
1067	Overview of frontotemporal dementia. 1-24	1
1066	Clinical presentations of frontotemporal dementia. 38-79	6
1065	Psychological interventions in frontotemporal dementia. 277-325	
1064	Effectiveness and acceptability of non-pharmacological interventions to reduce wandering in dementia: a systematic review. 2007 , 22, 9-22	96
1063	A comparison of small and large assisted living facilities for the diagnosis and care of dementia: the Maryland Assisted Living Study. 2007 , 22, 224-32	22
1062	Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study. 2007 , 22, 312-9	18
1061	Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. 2007 , 22, 356-60	170
1060	Prevalence of neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia. 2007 , 22, 632-8	194
1059	Patients with Lewy body dementia use more resources than those with Alzheimer's disease. 2007 , 22, 713-9	73
1058	Improving the quality of care for mild to moderate dementia: an evaluation of the Croydon Memory Service Model. 2007 , 22, 782-8	118

1057	The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. 2007 , 22, 843-9	275
1056	Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. 2007 , 22, 890-5	36
1055	Comparison of behavioral and psychological symptoms in early-onset and late-onset Alzheimer's disease. 2007 , 22, 896-901	61
1054	Reliability and validity of the Japanese version of the Dysexecutive Questionnaire (DEX) in Alzheimer's disease: validation of a behavioral rating scale to assess dysexecutive symptoms in Japanese patients with Alzheimer's disease. 2007 , 22, 951-6	23
1053	Subthreshold depression in patients with Parkinson's disease and dementia--clinical and demographic correlates. 2007 , 22, 980-5	14
1052	Quality of life in dementia: care recipient and caregiver perceptions of quality of life in dementia: the LASER-AD study. 2007 , 22, 1031-6	100
1051	A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. 2007 , 22, 456-67	219
1050	The relationship between severity of Alzheimer's disease and prevalence of comorbid depressive symptoms and depression: a systematic review. 2007 , 22, 1063-86	62
1049	Diagnosing Alzheimer's disease--non-clinicians and computerised algorithms together are as accurate as the best clinical practice. 2007 , 22, 1154-63	18
1048	Conversion of amnesic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration. 2007 , 22, 1217-22	131
1047	Depression or apathy and functional recovery after stroke. 2007 , 22, 1046-51	122
1046	Do family caregivers perceive more difficulty when they look after patients with early onset dementia compared to those with late onset dementia?. 2007 , 22, 1255-61	87
1045	Depression rating scales in Parkinson's disease: critique and recommendations. 2007 , 22, 1077-92	490
1044	Clinical diagnostic criteria for dementia associated with Parkinson's disease. 2007 , 22, 1689-707; quiz 1837	1968
1043	Assessment of psychiatric complications in Parkinson's disease: The SCOPA-PC. 2007 , 22, 2221-8	86
1042	A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. 2007 , 22, 2418-25	65
1041	Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. 2007 , 22, 2314-24	708
1040	An appraisal of the psychometric properties of the Clinician version of the Apathy Evaluation Scale (AES-C). 2007 , 16, 97-110	16

1039	Outcomes from a program of home care attendance in very frail elderly subjects. 2007 , 44, 95-103	8
1038	Effectiveness of validation therapy (VT) in group: preliminary results. 2007 , 44, 113-7	21
1037	Drug adverse events and drop-out risk: a clinical case. 2007 , 44 Suppl 1, 359-64	3
1036	Clinical outcomes in elderly demented patients and caregiver's stress: a 2-year follow-up study. 2007 , 44 Suppl 1, 401-6	1
1035	Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study. 2007 , 45, 19-26	17
1034	Occupational therapy and dementia: the experience of an Alzheimer special care unit. 2007 , 44 Suppl 1, 49-54	10
1033	The daily center care on impact of family burden. 2007 , 44 Suppl 1, 55-9	8
1032	Multidimensional evaluation of home-dwelling elderly: the impact of medical and social factors on health status indices. 2007 , 44 Suppl 1, 75-81	9
1031	Effectiveness of a cognitive rehabilitation program in mild dementia (MD) and mild cognitive impairment (MCI): a case control study. 2007 , 44 Suppl 1, 391-9	149
1030	Validation therapy (VT) in nursing home: a case-control study. 2007 , 44 Suppl 1, 407-11	33
1029	Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease. 2007 , 55, 800-1	39
1028	Sitting balance as an early predictor of functional improvement in association with depressive symptoms in stroke patients. 2007 , 61, 543-51	28
1027	Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study. 2007 , 61, 622-9	31
1026	Two dimensions of anosognosia in patients with Alzheimer's disease: reliability and validity of the Japanese version of the Anosognosia Questionnaire for Dementia (AQ-D). 2007 , 61, 672-7	12
1025	Exercise program for nursing home residents with Alzheimer's disease: a 1-year randomized, controlled trial. 2007 , 55, 158-65	469
1024	Community-dwelling nondisabled nonagenarians: two-year follow-up: the NonaSantfeliu Study. 2007 , 55, 801-3	4
1023	Effect of dementia and treatment of dementia on time to discharge from assisted living facilities: the Maryland assisted living study. 2007 , 55, 1031-7	21
1022	Quality indicators for the care of dementia in vulnerable elders. 2007 , 55 Suppl 2, S293-301	28

1021	Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. 2007 , 14, e1-26	400
1020	Cognitive and behavioural predictors of progression rates in Alzheimer's disease. 2007 , 14, 440-6	36
1019	Cerebral atrophy in Parkinson's disease patients with visual hallucinations. 2007 , 14, 750-6	137
1018	Assessment of hallucinations in Parkinson's disease using a novel scale. 2008 , 117, 35-40	8
1017	Can health workers diagnose dementia in the community?. 2007 , 116, 125-8	27
1016	Assessment of insomnia in high level residential aged care facility residents. 2007 , 26, 201-204	1
1015	A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. 2007 , 61, 403-10	9
1014	Latent profile analysis in frontotemporal lobar degeneration and related disorders: clinical presentation and SPECT functional correlates. 2007 , 7, 9	9
1013	Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. 2007 , 27, 399-411	23
1012	Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. 2007 , 29, 349-56	70
1011	Structure factorielle de l'Inventaire d'agitation de Cohen-Mansfield. 2007 , 57, 167-174	3
1010	Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease. 2007 , 155, 135-45	56
1009	Diffuse axonal injury due to traumatic brain injury alters inhibition of imitative response tendencies. 2007 , 45, 3149-56	15
1008	Mobilization-Observation-Behavior-Intensity-Dementia Pain Scale (MOBID): development and validation of a nurse-administered pain assessment tool for use in dementia. 2007 , 34, 67-80	97
1007	Disease-modifying trials in Alzheimer's disease: a European task force consensus. 2007 , 6, 56-62	118
1006	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. 2007 , 6, 305-13	488
1005	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study. 2007 , 6, 501-12	260
1004	Deep brain stimulation of the subthalamic nucleus improves set shifting but does not affect dual task performance in Parkinson's disease. 2007 , 15, 198-206	17

1003	Apathy and its treatment. 2007 , 9, 363-370	1
1002	De relatie van psychiatrische functiestoornissen met cognitie, activiteiten dagelijks leven (ADL) en biografische gegevens. 2007 , 38, 69-78	
1001	Ontwikkeling van de Gedragsobservatieschaal Psychomotorische therapie voor demente ouderen (GPMT-dem).. 2007 , 38, 79-90	
1000	Lichte Cognitieve Stoornissen (MCI): Prodromen van dementie?. 2007 , 38, 104-110	1
999	[Dementia with Lewy bodies. Clinical improvement under treatment with an acetylcholinesterase inhibitor]. 2007 , 78, 1052-7	4
998	Brain bank of the Brazilian aging brain study group - a milestone reached and more than 1,600 collected brains. 2007 , 8, 151-62	100
997	Actigraphy in agitated patients with dementia. Monitoring treatment outcomes. 2007 , 40, 178-84	62
996	Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. 2007 , 254, 351-8	30
995	Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT. 2007 , 254, 907-13	27
994	Reliability and validity of neuropsychological screening and assessment strategies in MS. 2007 , 254 Suppl 2, II22-II25	23
993	The Frontal Behavioural Inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease. 2007 , 28, 80-6	52
992	Hallucinations and sleep-wake cycle in Alzheimer's disease: a questionnaire-based study in 218 patients. 2007 , 28, 96-9	34
991	Apathy and its treatment. 2007 , 9, 363-370	39
990	Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease. 2007 , 21, 257-65	29
989	Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. 2008 , 117, 198-202	126
988	Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). 2008 , 38, 937-45	95
987	The Geriatric Minimum Data Set for clinical trials (GMDS). 2008 , 12, 197-200	28
986	A randomized trial of the impact of a specific care plan in 1120 Alzheimer's patients (PLASA Study) over a two-year period: design and baseline data. 2008 , 12, 263-71	12

985	Rapid correction of low vitamin D status in nursing home residents. 2008 , 19, 1621-8	110
984	Principal component analysis of FDG PET in amnesic MCI. 2008 , 35, 2191-202	64
983	Maladie d'Alzheimer et troubles psychiatriques. 2008 , 6, 76-81	2
982	Prise en charge des complications de la maladie d'Alzheimer: mise au point. 2008 , 6, 91-98	
981	Acute care utilization by dementia caregivers within urban primary care practices. 2008 , 23, 1736-40	71
980	A comprehensive evaluation of elderly people discharged from an Emergency Department. 2008 , 3, 245-9	28
979	Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. 2008 , 10, 377-84	27
978	Severity of explicit memory impairment due to Alzheimer's disease improves effectiveness of implicit learning. 2008 , 255, 502-9	23
977	The accuracy of the MMSE in detecting cognitive impairment when administered by general practitioners: a prospective observational study. 2008 , 9, 29	69
976	(Cost)-effectiveness of family meetings on indicated prevention of anxiety and depressive symptoms and disorders of primary family caregivers of patients with dementia: design of a randomized controlled trial. 2008 , 8, 2	25
975	The use of advanced tracking technologies for the analysis of mobility in Alzheimer's disease and related cognitive diseases. 2008 , 8, 7	87
974	Mood disorder following DBS of the left amygdaloid region in a dystonia patient with a dislodged electrode. 2008 , 23, 147-50	22
973	Scales to assess psychosis in Parkinson's disease: Critique and recommendations. 2008 , 23, 484-500	143
972	Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. 2008 , 23, 2004-14	242
971	Anxiety rating scales in Parkinson's disease: critique and recommendations. 2008 , 23, 2015-25	182
970	Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. 2008 , 23, 2335-43	65
969	Carer burden in dementia--assessing the impact of behavioural and psychological symptoms via self-report questionnaire. 2008 , 23, 60-4	27
968	Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. 2008 , 23, 161-9	132

967	Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. 2008 , 23, 170-7	453
966	Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention. 2008 , 23, 178-84	7
965	Insomnia and daytime sleepiness in people with dementia residing in assisted living: findings from the Maryland Assisted Living Study. 2008 , 23, 199-206	28
964	Special acute care unit for older adults with Alzheimer's disease. 2008 , 23, 215-9	14
963	Screening for elder abuse in dementia in the LASER-AD study: prevalence, correlates and validation of instruments. 2008 , 23, 283-8	71
962	Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis. 2008 , 23, 364-9	6
961	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. 2008 , 23, 387-92	24
960	Apathy and depression in Alzheimer's disease are associated with functional deficit and psychotropic prescription. 2008 , 23, 409-14	61
959	A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort). 2008 , 23, 460-5	13
958	The association between activity participation and time to discharge in the assisted living setting. 2008 , 23, 586-91	18
957	Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. 2008 , 23, 537-45	165
956	Neuropsychiatric symptoms are associated with disability in cognitively impaired Latino elderly with and without dementia: results from the Sacramento Area Latino study on Aging. 2008 , 23, 102-8	28
955	Development of a Korean version of the behavior rating scale for dementia (BRSD-K). 2008 , 23, 677-84	6
954	Neuropsychiatric symptoms in the community-based patients with mild cognitive impairment and the influence of demographic factors. 2008 , 23, 699-703	51
953	A feasibility and tolerability study of lithium in Alzheimer's disease. 2008 , 23, 704-11	112
952	A semi-structured interview to assess visual hallucinations in older people. 2008 , 23, 712-8	85
951	Clinical correlates of Parkinsonian signs in community- dwelling Chinese older persons: a population based study. 2008 , 23, 719-25	4
950	A 6-month, open-label study of memantine in patients with frontotemporal dementia. 2008 , 23, 754-9	75

949	Coping strategies, anxiety and depression in caregivers of people with Alzheimer's disease. 2008 , 23, 929-36	181
948	Reasons for psychiatric consultation referrals in Dutch nursing home patients with dementia: a comparison with normative data on prevalence of neuropsychiatric symptoms. 2008 , 23, 1014-9	5
947	The pattern of depressive symptoms and factor analysis of the Cornell Scale among patients in Norwegian nursing homes. 2008 , 23, 1058-65	35
946	Day Care for older dementia patients: favorable effects on behavioral and psychological symptoms and caregiver stress. 2008 , 23, 1066-72	57
945	Co-occurrence of neuropsychiatric syndromes in demented and psychotic institutionalized elderly. 2008 , 23, 1182-90	18
944	Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. 2008 , 23, 1222-30	60
943	Treatment Target Test Dementia (3TD). 2008 , 23, 1239-44	0
942	Determinants of burden in those who care for someone with dementia. 2008 , 23, 1078-85	171
941	Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. 2008 , 46, 101-6	58
940	Cognitive and behavioral assessment in the early stages of neurodegenerative extrapyramidal syndromes. 2008 , 47, 53-61	36
939	Trazodone for Alzheimer's disease: a naturalistic follow-up study. 2008 , 47, 207-15	25
938	Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. 2008 , 25, 559-63	40
937	Controversies in behavioral neurology: the use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia. 2008 , 8, 471-4	12
936	Cambridge Behavioural Inventory for the diagnosis of dementia. 2008 , 12, 23-25	15
935	Frontal Behavioural Inventory in the differential diagnosis of dementia. 2008 , 117, 260-5	38
934	Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types. 2008 , 117, 455-64	57
933	Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease. 2008 , 84, 63-8	31
932	Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: the Hisayama study. 2008 , 18, 317-25	58

931	Relationship between psychiatric symptoms and regional cerebral blood flow in patients with mild Alzheimer's disease. 2008 , 8, 108-113	4
930	Sociodemographic and clinical correlates of utility scores in Alzheimer's disease. 2008 , 11, 1120-30	6
929	Psychiatric and behavioural symptoms and the use of psychotropic medication in Special Care Units and Regular Units in Norwegian nursing homes. 2008 , 22, 568-73	22
928	Azelastine hydrochloride on behavioral and psychological symptoms and activities of daily living in dementia patients. 2008 , 8, 59-61	4
927	Quality of life of the community-based patients with mild cognitive impairment. 2008 , 8, 80-5	43
926	Lavender aroma therapy for behavioral and psychological symptoms in dementia patients. 2008 , 8, 136-8	42
925	Quality of private personal care for elderly people with a disability living at home: correlates and potential outcomes. 2008 , 16, 354-62	16
924	Programa de estimulación multisensorial para enfermos de Alzheimer: alteraciones de la conducta. 2008 , 30, 122-130	1
923	A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. 2008 , 8, 21	56
922	Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. 2008 , 7, 41-9	113
921	Endpoints for trials in Alzheimer's disease: a European task force consensus. 2008 , 7, 436-50	123
920	Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. 2008 , 7, 779-86	577
919	Emotion recognition impairment and apathy after subthalamic nucleus stimulation in Parkinson's disease have separate neural substrates. 2008 , 46, 2796-801	71
918	A functional neuroimaging study of appetite loss in Alzheimer's disease. 2008 , 271, 97-103	28
917	Physical activity programs for persons with dementia. 2008 , CD006489	84
916	Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. 2008 , 64, 850-5	143
915	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. 2008 , 24, 2561-74	106
914	Psychotic symptoms in frontotemporal dementia: prevalence and review. 2008 , 25, 206-11	79

913	Late-life anxiety and cognitive impairment: a review. 2008 , 16, 790-803	181
912	Development of a cell phone-based video streaming system for persons with early stage Alzheimer's disease. 2008 , 2008, 5330-3	11
911	The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes--a 12-month follow-up study. 2008 , 16, 528-36	97
910	Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals. 2008 , 16, 136-44	19
909	Relationship between quality of life and cognitive decline in dementia. 2008 , 25, 564-72	37
908	[Symptomatic antidementia drugs: methodological considerations and clinical relevance in the population]. 2008 , 37, 1261-7	
907	The relationship between depressive symptoms and prefrontal hypoperfusion demonstrated by eZIS in patients with DAT. 2008 , 441, 328-31	21
906	Les troubles anxiodépressifs dans la maladie de Parkinson: une revue de la littérature. 2008 , 166, 85-92	1
905	Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease. 2008 , 29, 341-7	54
904	Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease. 2008 , 29, 1524-32	18
903	Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. 2008 , 29, 1830-8	91
902	Metabolic correlates of clinical heterogeneity in questionable Alzheimer's disease. 2008 , 29, 1823-9	14
901	A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. 2008 , 14, 37-42	109
900	Prevalence, patterns, service needs, and assessment of neuropsychiatric disorders among people with epilepsy in residential care: validation of the Neuropsychiatric Inventory as a caregiver-rated measure of neuropsychiatric functioning in epilepsy. 2008 , 13, 223-8	12
899	Current and future management of the corticobasal syndrome and corticobasal degeneration. 2008 , 89, 533-48	15
898	Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction. 2008 , 110, 19-24	84
897	Anxiety in dementia: a critical review. 2008 , 28, 1071-82	199
896	The impact of apathy on glycemic control in diabetes: a cross-sectional study. 2008 , 79, 37-41	35

895	Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. 2008 , 7, 483-93	204
894	Frontotemporal dementia. 2008 , 7, 24-28	7
893	Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. 2008 , 40, 1056-63	47
892	Assessing apathy: the use of the Apathy Evaluation Scale in first episode psychosis. 2008 , 23, 33-9	54
891	Behavioral effects of current Alzheimer's disease treatments: a descriptive review. 2008 , 4, 49-60	77
890	Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study. 2008 , 4, 22-9	62
889	Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials. 2008 , 4, 390-4	30
888	[Efficacy of a psychological intervention program at home for the caregivers of dependent elderly people]. 2008 , 43, 229-34	2
887	Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. 2008 , 372, 207-15	373
886	Demographic, structural and genetic predictors of late cognitive decline after penetrating head injury. 2008 , 131, 543-58	75
885	Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. 2008 , 16, 469-77	66
884	Neuropsychiatric symptom patterns in hospice-eligible nursing home residents with advanced dementia. 2008 , 9, 509-15	22
883	Early frontal executive impairment as a predictor of subsequent behavior disturbance in dementia. 2008 , 16, 102-8	18
882	Concurrent validity of neuropsychiatric subgroups on caregiver burden in Alzheimer disease patients. 2008 , 16, 594-602	10
881	Apathy associated with Alzheimer disease: use of dextroamphetamine challenge. 2008 , 16, 551-7	28
880	The demented elder with insomnia. 2008 , 24, 69-81, vii	14
879	Facial emotion recognition deficit in amnesic mild cognitive impairment and Alzheimer disease. 2008 , 16, 389-98	88
878	Cognitive and behavioral impairment in amyotrophic lateral sclerosis. 2008 , 19, 607-17, xi	27

877	Le syndrome dysexécutif dans la maladie d'Alzheimer: ^ propos de 95 cas. 2008 , 8, 23-29		
876	Neuropsychiatric problems in Parkinson's disease: comparisons between self and caregiver report. 2008 , 12, 647-53		58
875	Serum albumin level interferes with the effect of donepezil in Alzheimer's disease. 2008 , 20, 509-12		6
874	Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine*. 2008 , 24, 3357-67		34
873	Pharmacological treatment in moderate-to-severe Alzheimer's disease. 2008 , 9, 2575-82		17
872	A comparison of unawareness in frontotemporal dementia and Alzheimer's disease. 2008 , 79, 176-9		55
871	A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. 2008 , 24, 157-66		32
870	Stroke-related psychiatric disorders. 2009 , 93, 623-51		1
869	Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. 2008 , 42, 32-8		74
868	Weight loss in patients with Alzheimer's disease. 2007 , 26, 21-38		28
867	Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. <i>Neurology</i> , 2008 , 71, 1342-9	6.5	168
866	Executive function and metacognitive self-awareness after severe traumatic brain injury. 2008 , 14, 862-8		75
865	Prevalence of neuropsychiatric symptoms in elderly patients with dementia in Mungialde County (Basque Country, Spain). 2008 , 25, 103-8		31
864	The cerebrovascular pathology in Alzheimer's disease and its influence on clinical variables. 2008 , 23, 91-6		12
863	Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer's disease. 2008 , 26, 257-60		15
862	Identification of responders to rivastigmine: a prospective cohort study. 2008 , 25, 60-6		3
861	Neuroanatomical correlates of unawareness of memory deficits in early Alzheimer's disease. 2008 , 25, 347-53		35
860	Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. 2008 , 14, 1084-90		31

859	Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. 2008 , 25, 1-8	135
858	Neuropsychiatric symptoms in amnesic and nonamnesic mild cognitive impairment. 2008 , 25, 32-6	53
857	Patterns of loss of abilities in instrumental activities of daily living in Alzheimer's disease: the REAL cohort study. 2008 , 25, 46-53	18
856	Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations. 2008 , 25, 531-8	75
855	Neural correlates of caregiver burden in cortical basal syndrome and frontotemporal dementia. 2008 , 26, 467-74	17
854	Activities of daily living, cerebral glucose metabolism, and cognitive reserve in Lewy body and Parkinson's disease. 2008 , 26, 475-81	27
853	Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. 2008 , 67, 649-56	116
852	Relationship between measures of dementia severity and observation of daily life functioning as measured with the Assessment of Motor and Process Skills (AMPS). 2008 , 25, 81-7	26
851	Multi-center comparison of medial temporal atrophy in patients with Alzheimer's disease--data from the ICTUS study. 2008 , 26, 314-22	5
850	Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. 2008 , 131, 2957-68	270
849	The importance of Alzheimer disease assessment scale-cognitive part in predicting progress for amnesic mild cognitive impairment to Alzheimer disease. 2008 , 21, 261-7	20
848	Frontotemporal dementia: Its definition, differential diagnosis, and management. 2008 , 22, 422-444	4
847	Group living homes for older people with dementia: the effects on psychological distress of informal caregivers. 2008 , 12, 761-8	18
846	Self-, collateral- and clinician assessment of depression in persons with cognitive impairment. 2008 , 12, 675-83	17
845	Behavioral and psychological symptoms, neurocognitive performance, and functional independence in mild dementia. 2008 , 7, 397-413	8
844	The use of legal guardians and financial powers of attorney among home-dwellers with Alzheimer's disease living with their spousal caregivers. 2008 , 34, 882-6	7
843	Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. 2008 , 5, 83-9	198
842	Economical aspects of dementia. 2008 , 89, 137-46	3

841	Temporal patterns of movements in institutionalized elderly with dementia during 12 consecutive days of observation in Seoul, Korea. 2008 , 23, 200-6		17
840	Neuropsychological Issues in Deep Brain Stimulation of Neurological and Psychiatric Disorders. 2008 , 399-452		1
839	Neuropsychological testing: bedside approaches. 2008 , 88, 137-54		3
838	The Neuropsychiatric Inventory--NPI. Validation of the Danish version. 2008 , 62, 481-5		10
837	No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. 2008 , 3, e1475		102
836	Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. 2008 , 65, 1193-8		280
835	Neuropsychiatric evaluation in dementia. 2008 , 89, 53-61		
834	A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). 2008 , 5, e76		144
833	Prevalence of neuropsychiatric symptoms in Alzheimer's disease and vascular dementia. 2008 , 5, 61-9		49
832	The clinical significance of plasmatic amyloid A{beta}-40 peptide levels in Alzheimer's disease patients treated with galantamine. 2008 , 23, 286-90		1
831	Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates. <i>Neurology</i> , 2008 , 71, 736-42	6.5	213
830	Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. 2008 , 131, 2455-63		245
829	Measuring progression in frontotemporal dementia: implications for therapeutic interventions. <i>Neurology</i> , 2008 , 70, 2046-52	6.5	53
828	Zarit burden inventory and activities of daily living in the behavioral variant of frontotemporal dementia. 2008 , 25, 272-7		66
827	Environmental control interventions for frontotemporal dementia with reversed sleep-wake cycles. 2008 , 23, 470-6		19
826	Efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia. 2008 , 22, 158-62		186
825	Neuropsychiatric symptoms in behavioral variant frontotemporal dementia and primary progressive aphasia. 2008 , 21, 133-41		54
824	Imaging amyloid deposition in Lewy body diseases. <i>Neurology</i> , 2008 , 71, 903-10	6.5	376

823	The progression of behavior in dementia: an in-office guide for clinicians. 2008 , 23, 242-9	3
822	Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. 2008 , 165, 844-54	230
821	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. 2008 , 131, 732-46	275
820	Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. <i>Neurology</i> , 2008 , 70, 1664-71	6.5 125
819	Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. 2008 , 12, 1367-76	7
818	Neuropsychology of frontotemporal dementia. 2008 , 88, 527-48	5
817	A European consensus on outcome measures for psychosocial intervention research in dementia care. 2008 , 12, 14-29	272
816	The MDS Challenging Behavior Profile for long-term care. 2008 , 12, 116-23	11
815	Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. 2008 , 42, 162-70	108
814	Apathy in late-life depression among Taiwanese patients. 2008 , 20, 328-37	12
813	Mild parkinsonian signs and psycho-behavioral symptoms in subjects with mild cognitive impairment. 2008 , 20, 86-95	17
812	Reliability of the Brazilian Portuguese version of the Neuropsychiatric Inventory (NPI) for patients with Alzheimer's disease and their caregivers. 2008 , 20, 383-93	94
811	Association between apathy/depression and executive function in patients with Alzheimer's disease. 2008 , 20, 964-75	21
810	Attachment style and anxiety in carers of people with Alzheimer's disease: results from the LASER-AD study. 2008 , 20, 494-507	20
809	Clinical correlates of functional performance in community-dwelling Chinese older persons with mild cognitive impairment. 2008 , 20, 1059-70	11
808	Validity and reliability of the Dutch version of the Camberwell Assessment of Need for the Elderly in community-dwelling people with dementia. 2008 , 20, 1273-90	50
807	Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. 2008 , 20, 538-53	50
806	Behavioral and psychological symptoms of dementia in relation to level of cognitive impairment. 2008 , 20, 777-89	69

805	The reliability and validity of the Norwegian version of the Neuropsychiatric Inventory, nursing home version (NPI-NH). 2008 , 20, 375-82	74
804	Factor structure and reliability of the brain impairment behavior scale. 2008 , 40, 40-7	14
803	Role of cerebral microemboli in the causation of Alzheimer's disease and vascular dementia. 2008 , 3, 391-397	
802	Diminished self-conscious emotional responding in frontotemporal lobar degeneration patients. 2008 , 8, 861-9	81
801	Beyond the "C" in MCI: noncognitive symptoms in amnesic and non-amnesic mild cognitive impairment. 2008 , 13, 66-72	41
800	Neuropsychological testing. 2008 , 7-18	
799	Behavioral and psychological symptoms of dementia and bipolar spectrum disorders: review of the evidence of a relationship and treatment implications. 2008 , 13, 796-803	16
798	Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. 2008 , 28, 296-301	94
797	Progressive supranuclear palsy: a current review. 2008 , 14, 79-88	36
796	Apathy in dementia: clinical and sociodemographic correlates. 2008 , 20, 337-47	39
795	Outcome measurement in cognitive neurorehabilitation. 91-105	3
794	Management of behavioural and psychological symptoms of dementia and acquired brain injury. 187-216	4
793	Cognitive function, neuropsychological evaluation, and syndromes of cognitive impairment. 6-38	
792	Mapping cerebellar degeneration in HIV/AIDS. 2008 , 19, 1655-9	31
791	Cognitive-behavioral treatment for anxiety in patients with dementia: two case studies. 2008 , 14, 186-92	45
790	Nutritional status is associated with disease progression in very mild Alzheimer disease. 2008 , 22, 66-71	48
789	Impact of depression on insight into memory capacity in patients with Alzheimer disease. 2008 , 22, 369-74	8
788	The psychiatry of old age. 350-382	

787	Long Term Care in Health Services. 2008 , 127-132	4
786	Short IQCODE as a screening tool for MCI and dementia: Preliminary results. 2008 , 2, 300-304	11
785	The Cambridge Behavioural Inventory revised. 2008 , 2, 102-107	119
784	Perfil neuropsiquiátrico na doena de Alzheimer e na deméncia mista. 2008 , 57, 117-121	
783	Effects of functional physical activity on the maintenance of motor function in Alzheimer's disease. 2008 , 2, 233-240	4
782	Errorless learning and spaced retrieval techniques to relearn instrumental activities of daily living in mild Alzheimer's disease: A case report study. 2008 , 4, 987-99	37
781	Non-pharmacological treatments of challenging behaviours: part 2. 2008 , 10, 290-292	2
780	Association of caregiver demographic variables with neuropsychiatric symptoms in Alzheimer's disease patients for distress on the Neuropsychiatric Inventory (NPI). 2008 , 2, 211-216	6
779	Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis. 2008 , 3, 719-28	44
778	Cognitive Assessment in Traumatic Brain Injury. 2008 , 1, 148	1
777	Towards a cognitive stimulation program using an errorless learning paradigm in amnesic mild cognitive impairment. 2007 , 3, 975-85	15
776	Features associated with the development of non-motor manifestations in Parkinson's disease. 2008 , 66, 22-5	9
775	Effektivit einer optimierten Ergotherapie bei Demenz im huslichen Setting (ERGODEM). 2008 , 21, 185-189	4
774	Die Berliner Studie zu Versorgungsstrukturen und Versorgungsergebnissen von Wohngemeinschaften fur Menschen mit Demenz (DeWeGE). 2008 , 21, 179-183	3
773	Positirelin (l-pyro-2-aminoadipyl-l-leucyl-l-prolinamide) treatment for persons with dementia. 2008 ,	
772	Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole. 2008 , 3, 491-501	10
771	Neurobiology of apathy in Alzheimer's disease. 2008 , 66, 436-43	42
770	Behavioral and activities of daily living inventories in the diagnosis of frontotemporal lobar degeneration and Alzheimer's disease. 2008 , 2, 108-113	7

769	Care for the person with dementia, 2: How to know what the person needs or wants. 2008 , 4, 22-29	
768	Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease. 2009 , 5, 553-61	10
767	Treatment of behavioral symptoms in vascular dementia. 206-219	
766	Alzheimer's disease. 56-73	1
765	Neuropsychiatric features of dementia. 85-100	2
764	Cognition in corticobasal degeneration and progressive supranuclear palsy. 288-301	2
763	Update on the use of memantine in Alzheimer's disease. 2009 , 5, 237-47	66
762	Neurological soft signs in nursing home residents with Alzheimer's disease. 2009 , 18, 525-32	13
761	Accuracy of neuropsychological tests and the Neuropsychiatric Inventory in differential diagnosis between Frontotemporal dementia and Alzheimer's disease. 2009 , 3, 332-336	4
760	Brazilian caregiver version of the Apathy Scale. 2009 , 3, 321-326	16
759	Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. 2009 , 2, 77-82	41
758	A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. 2009 , 5, 327-32	92
757	Pour la'pratique clinique.... 2009 , 1, 79	2
756	Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association. 2009 , 16, 173-80	16
755	The abbreviated form of the Brief Cognitive Battery in the diagnosis of dementia in Alzheimer's disease. 2009 , 3, 327-331	8
754	Diagnosis and Treatment for Behavioral and Psychological Symptoms of Dementia. 2009 , 52, 1048	19
753	Dementia caregiver burden in a Brazilian sample: Association to neuropsychiatric symptoms. 2009 , 3, 132-135	11
752	Clinical characteristics in subcortical ischemic white matter disease. 2009 , 67, 173-8	12

751	Psychologische Interventionen bei demenziellen Erkrankungen. 2009 , 57, 195-206	2
750	Mental status examination. 74-84	1
749	Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. 2009 , 1	1
748	A pilot study on the effects of music therapy on frontotemporal dementia âdeveloping a research protocol1View all notes. 2009 , 18, 103-132	15
747	Longitudinal assessment of psychotherapeutic day hospital treatment for neuropsychiatric symptoms in dementia. 2009 , 13, 92-8	15
746	Understanding social dysfunction in the behavioural variant of frontotemporal dementia: the role of emotion and sarcasm processing. 2009 , 132, 592-603	195
745	The determinants and longitudinal course of post-stroke mild cognitive impairment. 2009 , 15, 915-23	60
744	An abnormal "one-leg balance" test predicts cognitive decline during Alzheimer's disease. 2009 , 16, 525-31	32
743	Memantine for dementia in people with Down syndrome. 2009 , CD007657	20
742	Galantamine for dementia in people with Down syndrome. 2009 , CD007656	14
741	Rivastigmine for dementia in people with Down syndrome. 2009 , CD007658	16
740	Donepezil for dementia in people with Down syndrome. 2009 , CD007178	21
739	Assessment of patient and caregiver experiences of dementia-related symptoms: development of the Multidimensional Assessment of Neurodegenerative Symptoms questionnaire. 2009 , 27, 260-72	8
738	Neuropsychological patterns in magnetic resonance imaging-defined subgroups of patients with degenerative dementia. 2009 , 15, 459-70	11
737	Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. 2009 , 21, 813-24	154
736	Neuropsychological assessment in the diagnosis of Alzheimer's disease. 2009 , Chapter 10, Unit10.3	8
735	Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study. 2009 , 64, 560-8	84
734	Therapy for Alzheimer's Disease: How Effective are Current Treatments?. 2009 , 2, 163-80	69

733	A comprehensive neuropsychiatric study of elderly twins: the Older Australian Twins Study. 2009 , 12, 573-82	52
732	Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease. 2009 , 28, 244-51	36
731	Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type. 2009 , 66, 888-93	89
730	Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey. 2009 , 25, 3059-68	21
729	The neuropsychiatric mental status examination. 2009 , 29, 185-93	4
728	[Frontotemporal dementia: neurotransmitter and clinical symptoms with focus on therapeutic targets]. 2009 , 77, 289-94	3
727	Störungen des Erlebens und Verhaltens bei Demenzen. 2009 , 3, 149-164	
726	Adaptation and Validation of the Memory Alteration Test (M@T) in Greek Middle-Aged, Older, and Older-Old Population with Subjective Cognitive Decline and Mild Cognitive Impairment. 2021 , 84, 1219-1232	0
725	Subtypes of delirium after ischaemic stroke-predisposing factors and outcomes: a prospective observational study (PROPOLIS). 2021 ,	0
724	A nursing mentoring programme on non-pharmacological interventions against BPSD: Effectiveness and use of antipsychotics-A retrospective, before-after study. 2021 , 9, 181	1
723	Demenz. 2000 , 303-316	2
722	References. 2000 , 257-302	
721	Diagnosis and management of Alzheimer's disease. 2000 , 2, 129-38	0
720	Dementia: Trial Design and Experience with Large Multicentre Trials. 2001 , 183-198	
719	Neuropsychiatry in the Elderly. 2001 , 107-115	
718	Behavioral Manifestations of Alzheimer's Disease. 2001 , 84-88	
717	Evaluaci3n del sistema supervisor en sujetos ancianos con y sin desinhibici3n. 2001 , 8, 27-37	
716	Frontotemporal dementia deficit in Theory of Mind assessed with Happ3 Test. 2011 , 19, 413-422	

715 Verhaltensauffälligkeiten und andere Störungen. **2002**, 457-483

714 Organische psychische Störungen. **2002**, 89-279

1

713 Untersuchungsverfahren. **2002**, 67-88

712 Enfermedad de Huntington: una revisión de las publicaciones sobre la prevalencia y el tratamiento de los fenómenos neuropsiquiátricos. **2002**, 9, 147-153

711 Adopting dementia assessments for international application. **2002**, 87-96

710 Frontotemporal lobar degeneration. **2003**, 217-241

709 Dementia with Lewy bodies. **2003**, 117-132

708 Parkinson's disease and related parkinsonian syndromes. **2003**, 133-182

707 Die Aufgaben des Psychologen im multiprofessionellen Team. **2003**, 257-297

706 Neurobiology of neuropsychiatric symptoms in dementias. **2003**, 255-280

705 Management of neuropsychiatric aspects of dementia. **2003**, 281-300

704 Vascular dementia. **2003**, 183-215

703 Neuroepidemiology: Fundamental Considerations. **2004**, 2-22

702 Functional Neuro-imaging in Apathy. **2004**, 531-538

701 Die Alzheimer-Krankheit: Molekulare Grundlagen und Therapieansätze. **2004**, 148-179

700 The relationship between delusions of theft and memory disturbance in Alzheimer's disease. **2004**, 24, 147-154

699 Cognitive rehabilitation in mild cognitive impairment and prodromal Alzheimer's disease. **2004**, 90-105

698 The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?. **2004**, 5, 249-55

3

- 697 Therapeutic strategies for vascular dementia. **2005**, 574-600 o
- 696 A Randomized, Placebo-Controlled Study of the Efficacy of Cognitive Intervention on Elderly People and on Patients with Alzheimer's Disease. **2006**, 759-765
- 695 Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer's Disease. **2007**, 28-35
- 694 Die Aufgaben des Psychologen im multiprofessionellen Team. **2007**, 197-237
- 693 La Paralyse Supranucléaire Progressive. **2007**, 103-116
- 692 Comparison of Roles and Training of Different Mental Health Specialists. **2007**, 23-30
- 691 Les Démences et les Troubles Cognitifs non Démentiels D'origine Vasculaire. **2008**, 137-152
- 690 Bibliographie. **2008**, 207-244
- 689 Organische psychische Störungen. **2008**, 1005-1013
- 688 Evaluació de la apatà: uso de la Escala de Evaluació de la Apatà en el primer episodio de psicosis. **2008**, 15, 145-151
- 687 Altersprobleme. **2009**, 583-616 2
- 686 7 Diagnostische instrumenten. **2009**, 59-102
- 685 Bibliographie. **2009**, 337-358
- 684 Diagnosis of psychiatric disorders of the elderly. **2010**, 53, 964
- 683 Leitliniensynopse zur S3-Leitlinie »Demenzen« (November 2009). **2010**, 125-226
- 682 Neuropsychiatric Assessment of Traumatic Brain Injury During Acute Neurorehabilitation*. **2010**, 123-146
- 681 Neuropsychologie der Motivation. **2010**, 67-88
- 680 Small Group Training for Patients with Higher Brain Dysfunction : A Rehabilitation Class to prepare them for their return to Society. **2010**, 47, 728-734

- 679 Clinical Trials in Dementia. 1
- 678 Clinical Trials on Cognitive Drugs. 1
- 677 Measurement of behaviour disturbance, non-cognitive symptoms and quality of life. **2010**, 75-85
- 676 Cognitive Domains Affected by Conditions of Ageing and the Role of Neuropsychological Testing. **2010**, 389-396
- 675 Behavioural Management in Alzheimer's Disease â Pharmacology. **2010**, 312-323
- 674 Grundlegendes zur Systematik organischer/symptomatischer psychischer Störungen. **2011**, 1212-1227
- 673 Konsil- und Liaisonpsychiatrie bei Demenz. **2011**, 395-418
- 672 Encyclopedia of Clinical Neuropsychology. **2011**, 871-873
- 671 Psychological Co-morbidities of Dementia. **2011**, 335-383
- 670 I disturbi psicotici. **2011**, 103-109
- 669 I disturbi dell'umore. **2011**, 75-102
- 668 Evaluating the behavioral and psychological symptoms of dementia. **2011**, 220-227
- 667 Neuropsychologische Diagnostik bei Alzheimerkrankheit im Frstadium: Status quo und Zukunftstrends. **2011**, 59, 95-102 4
- 666 Neuropsychologic Features of Parkinson's Dementias. 145-152
- 665 Demenzen (F00â03). **2012**, 207-223
- 664 Wirkungen tiergesttzter Interventionen auf demenziell erkrankte Pflegeheimbewohner. **2012**, 383-397
- 663 18 Ouderen. **2012**, 269-285
- 662 14 Gynaecologie en obstetrie. **2012**, 207-220

- 661 Rehabilitation for Parkinson Disease. **2012**, 49, 738-745 0
- 660 Affective and Behavioural Dysfunctions in Patients with Subcortical Stroke. **2012**, 03, 141-148
- 659 19 Dementie. **2012**, 287-304
- 658 De la maladie de Pick aux démences fronto-temporales. **2012**, 196, 431-443
- 657 The Current Status of Alzheimer's Disease Treatment. **2012**, 117-161
- 656 Psychosis. **2013**, 113-119
- 655 Bñfices de la rflexologie plantaire en Ehpad. **2012**, 17, 15-18
- 654 Caring for older adults with mild cognitive impairment: an update for nurses. **2012**, 38, 22-35; quiz 36-7 7
- 653 Neuropsychiatric Aspects of Vascular Cognitive Impairment. **2013**, 237-251 1
- 652 Frontotemporale Demenzen. **2013**, 204-218
- 651 Elderly Care Cost Control using Observation, Assessment, and Decision-Making. **2013**, 320-329
- 650 Two-year follow-up study of patients with dementia in an NHS continuing care unit. **2013**, 37, 11-14
- 649 Health and Functional Status in Elderly Patients Living in Residential Facilities in Italy. **2013**, 361-370
- 648 Place du mēdecin gñfaliste dans le diagnostic et le suivi des patients atteints de maladie dāAlzheimer. **2013**, 63-73 1
- 647 Neurorehabilitation. **2013**, 879-894
- 646 Apathy. **2013**, 109-129 1
- 645 Apathy in Neuropsychiatric Disease: Diagnosis, Pathophysiology, and Treatment. **2013**, 67-79
- 644 Suivi mēdical du patient atteint de la maladie dāAlzheimer. **2013**, 403-414

- 643 Geriatric Psychiatry or Psychogeriatrics? Partnership at the CAGP/CCSMH 2012 Scientific Meeting. **2013**, 16, 3-5
- 642 La valutazione in psicologia gerontologica. **2013**, 225-238
- 641 The Logic and Ontology of Assessment of Conditions in Older People. **2014**, 391-400 1
- 640 Depression in Alzheimer's Disease. **2014**, 13, 27 1
- 639 Psychopathologie de la personne âgée. **2014**, 35, 16-22
- 638 Normal and Abnormal Aggressions: Definitions and Operational Approaches. **2014**, 1-31
- 637 Assessment with Non-cognitive Screening Instruments and Combinations of Scales. **2014**, 153-201
- 636 Assessment scales for geriatric patients. **2014**, 43-51
- 635 Non Cognitive Symptoms in Alzheimer's Disease. **1997**, 487-493
- 634 Neuropsychiatric Symptoms in Dementia Patients. **1999**, 195-221
- 633 Alzheimer's Disease. **1999**, 77-101
- 632 Aberrant Gray Matter Structure Associated with Sleep Disturbance in the Drug Naïve Subjects with Alzheimer's Disease. **2014**, 5, 43-48
- 631 «C'est un jeu pour la survie»: le syndrome de Godot dans la démence. **2015**, 9, 62 1
- 630 Rehabilitative Outcomes after Hip Fracture in a Special Care Unit for Persons with Dementia and Behavioral and Psychotic Symptoms. **2015**, 07, 1175-1182
- 629 Systematik organisch-symptomatischer Störungen. **2015**, 1-15
- 628 Vasculaire dementie. **2015**, 225-247
- 627 De ziekte van Parkinson. **2015**, 115-133
- 626 [Alzheimer's disease and the organization of visits to cultural sites]. **2015**, 39-42

- 625 Mapping the affective syndrome in Alzheimer's disease. **2015**, 73, 551-2
- 624 Gedragsproblematiek bij dementie. **2016**, 151-155
- 623 Neurocognitieve stoornissen. **2016**, 381-427
- 622 Padua Rehabilitation Tool: A Pilot Study on Patients with Dementia. **2016**, 292-301 1
- 621 Demenz. **2016**, 1-89
- 620 [Clinical and neuropsychological features of Alzheimer's disease in the combination with cerebrovascular disease]. **2016**, 116, 46-53 0
- 619 Comprehensive Geriatric Assessment. **2016**, 87-101 1
- 618 10 Neurocognitieve stoornissen. **2016**, 275-304 1
- 617 [Identifying and treating frailty in carers within a geriatric hospital]. **2016**, 45-7
- 616 Effects of Community Based Group Validation Therapy on Depression, Quality of Life, Behavioral Problems, and Cognitive Function in Patients with Dementia. **2016**, 18, 22-31 3
- 615 Factors Affecting Agitation in Nursing Home Patients with Dementia. **2016**, 18, 41-52 3
- 614 Assessments for the Practicing Clinician: Practical Tools. **2017**, 215-231
- 613 Psychosis in Dementia. **2017**, 237-249
- 612 Neuropsychiatric Symptoms in Cognitive Impairment and Dementia: A Brief Introductory Overview. **2017**, 1-7
- 611 Demenzen (F00 â€F03). **2017**, 231-248
- 610 Global Hypoactivity and Apathy. **2017**, 71-91 1
- 609 Encyclopedia of Clinical Neuropsychology. **2017**, 1-6
- 608 The Influence of Behavioral and Psychological Symptoms of Dementia on the Autonomic Nervous System. **2017**, 07, 383-390

607 Verubecestat. **2017**, 204-251

606 Behavioral and psychological characteristics of patients with different types of dementia in Mansoura, Egypt. **2017**, 38, 13

605 Encyclopedia of Clinical Neuropsychology. **2017**, 1-4

604 Encyclopedia of Clinical Neuropsychology. **2017**, 1-8

603 Design and Evaluation of an ICT Platform for Cognitive Stimulation of Alzheimer's Disease Patients. **2017**, 106-115

602 Encyclopedia of Personality and Individual Differences. **2017**, 1-3

601 Systematik organisch-symptomatischer Störungen. **2017**, 1351-1364

600 Evidence of compensation in the brain networks of Lewy body dementia and Alzheimer's disease patients.

599 Alzheimer's Genetic Risk Score linked to Incident Mild Behavioral Impairment.

598 EXPERIENCE OF CLINICAL APPLICATION OF THE METHOD OF INTEGRATED GRAPHIC GEOMETRICAL LOGARITHMIC EVALUATION OF COGNITIVE FUNCTIONS. **2018**, 20, 368-375

597 De arts en de niet-medicamenteuze behandeling van dementie. **2018**, 65-78

596 Neuropsychologie du vieillissement normal et des syndromes dmentiels. **2018**, 417-540

595 Factors Affecting Verbal Agitation in Dementia Patients Living in Nursing Homes, South Korea. **2018**, 08, 339-354

594 Hulp bij het handhaven van een emotionele balans. **2018**, 231-245

593 Altersprobleme. **2018**, 527-555

592 Encyclopedia of Clinical Neuropsychology. **2018**, 1493-1499

591 Neuropsychologische aspecten van neurodegeneratieve aandoeningen. **2018**, 423-470

590 Stand der Therapieforschung. **2018**, 15-25

- 589 Investigation of Factors Affecting Apathy in Three Major Types of Dementia. **2020**, 57, 120-125 1
- 588 Chapitre 19. Mme P. et le syndrôme de Benson. **2018**, 306-323
- 587 Characteristics of Conversation in Frontotemporal Dementia: Comparison with Dementia of the Alzheimer's Type. **2018**, 23, 146-159 1
- 586 Cas 9. Améliorer le contrôle de la colère après un traumatisme crânio-cérébral sévère : un programme d'interventions multiples. **2018**, 237-265
- 585 Maladie d'Alzheimer et maladies apparentées : symptômes psychocomportementaux dans la démence (SPCD). **2018**, 631-641
- 584 Age-related changes in social behaviours in the 5xFAD mouse model of Alzheimer's disease.
- 583 Clinical profile of early-onset dementia from a geriatric clinic in South India. **2019**, 6, 71 1
- 582 ViTA: Virtual Trainer for Aging. **2019**, 199-208 0
- 581 Behavioral, Psychotic and Affective Disorders in Dementia (BPSD). **2019**, 253-253
- 580 MARIO Project: Validation in the Hospital Setting. **2019**, 509-520 0
- 579 History Taking and Assessment. **2019**, 53-64
- 578 Dementia and Intellectual Disability: Prevalence, Assessment and Post-Diagnostic Support. **2019**, 965-986 0
- 577 Neuropsychiatry and Traumatic Brain Injury. **2019**, 227-301
- 576 Psychiatric Symptoms Comorbid with Neurological Syndromes. **2019**, 201-218
- 575 Agitation. **2019**, 331-347
- 574 [Current approaches to the treatment of fronto-temporal dementia]. **2019**, 119, 18-24
- 573 [Clinical and neuroimaging heterogeneity of dementia with Lewy bodies]. **2019**, 119, 25-31 1
- 572 Neurobiological Differences Between Aggression and Agitation in Persons with Dementia Affiliation. **2018**, 2, 28-36

- 571 Study on Correlation between Cognitive Impairment and Geriatric Depression or Geriatric Stress. **2019**, 51, 105-113 2
- 570 [Postanoxic encaphalopathy after and episode of resuscitated sudden death. Minimizing sequelae]. **2019**, 53, 111-115
- 569 Neurocognitive Disorders. **2019**,
- 568 Neurocognitive Disorders. **2019**,
- 567 Clinical-psychopathological structure of hallucinatory-paranoid disorders during vascular dementia of moderate degrees of severity. **2019**, 27, 63-67 1
- 566 [Utility of a Life-trouble Scale-based care planning tool for elderly patients living in a long-term care health facility: Effects of an intervention based on person-centered care]. **2019**, 56, 312-322
- 565 Organizational interventions for promoting person-centred care for people with dementia. 1
- 564 Papel del personal de enfermería especializado en el proceso de evaluación no motora dentro de la atención global de los pacientes con enfermedad de Parkinson. **2019**, 50, 2-11
- 563 Development of a Caregivers' Support Platform (Connected Health Sustaining Home Stay in Dementia): Protocol for a Longitudinal Observational Mixed Methods Study. **2019**, 8, 13280 3
- 562 A unified neurocognitive model of the anterior temporal lobe contributions to semantics, language, social behaviour & face recognition. 1
- 561 [Interest of extrahospital multidisciplinary unit of neuro-psycho-geriatric intervened in nursing home: Analysis of 288 interventions]. **2019**, 45, 327-332
- 560 A Conversational Robotic Approach to Dementia Symptoms. **2019**, 5
- 559 Efficacy of a Web App for Cognitive Training (MeMo) Regarding Cognitive and Behavioral Performance in People With Neurocognitive Disorders: Randomized Controlled Trial (Preprint).
- 558 Neurocognitive stoornissen. **2020**, 207-234
- 557 Major Neurocognitive Disorders and Violence. **2020**, 135-152
- 556 Dementia and usage of N-methyl-d-aspartate receptor antagonists. **2020**, 573-584
- 555 Die Demenz. **2020**, 15-63
- 554 Sleep Disorder Screeners. **2020**, 113-118

- 553 Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study. **2021**, 8, 199-209 2
- 552 Psychopathologie du sujet âgé. **2020**, 20, 67-82
- 551 Moderators of Cognitive Outcomes from an Exercise Program in People with Mild to Moderate Dementia. **2020**, 68, 2095-2100 0
- 550 Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI.
- 549 Vigilancia de los pacientes con demencia. Ejemplo del caso francés. **2020**, 24, 1-8
- 548 Stimulus-induced Gamma rhythms are weaker in human elderly with Mild Cognitive Impairment and Alzheimer's Disease.
- 547 Informativeness of the scales for assessing cognitive functions and psychometric questionnaires for moderate cognitive impairment and vascular genesis dementia. **2020**, 73-86
- 546 Exploring Bottom-Up Visual Processing and Visual Hallucinations in Parkinson's Disease with Dementia.
- 545 Tolcapone Treatment for Cognitive and Behavioral Symptoms in Behavioral Variant Frontotemporal Dementia: A Placebo-Controlled Crossover Study. **2020**, 75, 1391-1403 3
- 544 Clinical Trials for Cognitive Impairment and Dementia in Parkinson's Disease. **2021**, 193-225
- 543 Chapitre 5. L'examen psychologique du sujet vieillissant. **2020**, 201-253
- 542 Motion-Based Technology for People With Dementia Training at Home: Three-Phase Pilot Study Assessing Feasibility and Efficacy. **2020**, 7, e19495 2
- 541 Phenotyping Neuropsychiatric Symptoms Profiles of Alzheimer's Disease Using Cluster Analysis on EEG Power.
- 540 Genome-Wide Association Identifies the First Risk Loci for Psychosis in Alzheimer Disease. 1
- 539 Neuropsychiatric symptoms, quality of life and caregivers' burden in dementia. **2020**, 15, 905-914 0
- 538 Neuropsychiatric symptoms are associated with dementia in Parkinson's disease but not predictive of it.
- 537 Speech Paralinguistic Approach for Detecting Dementia Using Gated Convolutional Neural Network. **2021**, E104.D, 1930-1940 1
- 536 Demenzerkrankungen. **2020**, 295-321

535	The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer's disease. 2020 , 9, 1470	2
534	Daily garden use and quality of life in persons with advanced dementia living in a nursing home: A feasibility study. 2021 , 8, 1243-1253	0
533	Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD). 2021 , 69, 955-963	1
532	Diagnosis and treatment for frontotemporal degenerations. 2020 , 42-50	1
531	Effects of Rivastigmine on Brain Functional Networks in Patients With Alzheimer Disease Based on the Graph Theory. 2021 , 44, 9-16	1
530	Psychiatric Disorders in Dementia. 2021 , 317-385	
529	Psychosocial outcomes of dyadic arts interventions for people with a dementia and their informal caregivers: A systematic review. 2021 , 29, 1632-1649	1
528	Effectiveness of the Validation Method in Work Satisfaction and Motivation of Nursing Home Care Professionals: A Literature Review. 2020 , 18,	0
527	The relationship between perceived social support and psychological distress in carers of older relatives: A longitudinal cross-lagged analysis. 2022 , 297, 401-406	1
526	Behavioral and Psychiatric Symptoms in Dementia (BPSD). 2020 , 223-236	
525	Neurological, Psychiatric, and Affective Aspects of Dementia in Latinxs. 2020 , 119-130	
524	Encyclopedia of Personality and Individual Differences. 2020 , 1425-1427	
523	Memantine and Alzheimer's disease. 2020 , 511-527	1
522	Concurrent Validity of the ABC Dementia Scale with Other Standard Scales: A New Comprehensive Instrument for Assessing Dementia in Japan. 2020 , 49, 617-627	
521	Atrophy in Distinct Corticolimbic Networks Subserving Socioaffective Behavior in Semantic Variant Primary Progressive Aphasia. 2020 , 49, 589-597	0
520	Dramatic Performance by a Professional Actor for the Treatment of Patients with Behavioral and Psychological Symptoms of Dementia. 2020 , 252, 263-267	0
519	Gedragsproblematiek bij dementie. 2020 , 183-188	
518	Encyclopedia of Gerontology and Population Aging. 2020 , 1-6	

517 Mental Health of Older Adults. **2021**, 1379-1397

516 [Recognition of Psychiatric Symptoms in Inpatient Long-Term Care]. **2020**, 109, 301-308

0

515 AQUEDUCT Intervention for Crisis Team Quality and Effectiveness in Dementia: Protocol for a Feasibility Study (Preprint).

514 Acceptability and feasibility of a Japanese version of STrAtegies for RelaTives (START-J): A manualized coping strategy program for family caregivers of relatives living with dementia. **2021**, 20, 985-1004

1

513 Losartan to slow the progression of mild-to-moderate Alzheimer's disease through angiotensin targeting: the RADAR RCT. **2021**, 8, 1-72

0

512 Phantom boarder symptom in elderly Japanese. **2021**,

1

511 Long-term neuropsychiatric symptoms in spontaneous intracerebral haemorrhage survivors. **2021**,

2

510 Cognitive intervention programmes on patients affected by mild cognitive impairment: A promising intervention tool for MCI?.

509 Neuropsychiatric Symptoms in Alzheimer's Disease: Assessment and Management. **2002**, 327-346

508 Psychiatric Evaluation of the Neurological Patient. **2006**, 19-30

0

507 Tracking the Progression & Influence of Beta-Amyloid Plaques Using Percolation Centrality and Collective Influence Algorithm: A Study using PET Images.

506 Issues of diagnosis and treatment of frontotemporal degeneration. **2020**, 217-224

505 Chinese patients with Lewy body dementia had shorter survival and developed complications earlier than those with Alzheimer's disease. **2020**, 61, 551-558

0

504 Dropout from farm-based day care for people with dementia in Norway: a follow-up study. **2020**, 20, 428

503 Neuropsychiatric symptoms in brain diseases - historical foundations. **2020**, 14, 324-328

0

502 AQUEDUCT Intervention for Crisis Team Quality and Effectiveness in Dementia: Protocol for a Feasibility Study. **2020**, 9, e18971

1

501 Challenges in the management of psychotic symptoms in long-term care. **2003**, 4, H17-20

500 A biopsychosocial interpretation of the Neuropsychiatric Inventory - Nursing Home assessment: reconceptualising psychiatric symptom attributions. **2020**, 6, e137

0

499	Heterogeneous distribution of tau pathology in the behavioral variant of Alzheimer's disease.	
498	Correlations Between Facial Expressivity and Apathy in Elderly People With Neurocognitive Disorders: Exploratory Study (Preprint).	
497	Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. 2003 , 28, 13-26	30
496	Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease. 2008 , 33, 218-26	47
495	Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. 2008 , 3, 211-25	278
494	Development and psychometric properties of the Carer - Head Injury Neurobehavioral Assessment Scale (C-HINAS) and the Carer - Head Injury Participation Scale (C-HIPS): patient and family determined outcome scales. 2007 , 3, 389-408	2
493	Development and psychometric properties of the Patient-Head Injury Participation Scale (P-HIPS) and the Patient-Head Injury Neurobehavioral Assessment Scale (P-HINAS): patient and family determined outcomes scales. 2007 , 3, 373-88	2
492	Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer's disease. 2006 , 2, 105-10	111
491	Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. 2010 , 5, 1-6	15
490	Drugs for Alzheimer's disease: are they effective?. 2010 , 35, 208-11	88
489	Mild cognitive impairment: The dilemma. 2009 , 51 Suppl 1, S44-51	8
488	Progression to dementia in a population with amnesic mild cognitive impairment: clinical variables associated with conversion. 2012 , 27, 49-54	28
487	Estimating severity of illness and disability in Frontotemporal Dementia: Preliminary analysis of the Dementia Disability Rating (DDR). 2011 , 9, 141-153	4
486	Use of health and social care services in a cohort of Italian dementia patients. 2013 , 28, 265-73	12
485	Neuropathologic correlates of trial-related instruments for Alzheimer's disease. 2014 , 3, 45-9	1
484	Driving habits in patients with dementia: a report from Alzheimer's disease assessment units in northern Italy. 2014 , 29, 107-12	2
483	Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. 2014 , 3, 158-69	13
482	Dementia. 2015 , 84, 79-87	39

481	An Interdisciplinary Approach to Educating Medical Students About Dementia Assessment and Treatment Planning. 2020 , 37, 466-471	0
480	High frequency of psychosis in late-stage Parkinson's disease.. 2021 , 5, 100119	0
479	A pragmatic trial testing a tailored non pharmacologic therapies on nocturnal behavioral and psychological symptoms associated with dementia. 2021 , 43, 85-90	
478	ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods. 2021 ,	0
477	Neuroimaging Biomarkers Predicting the Efficacy of Multimodal Rehabilitative Intervention in the Alzheimer's Dementia Continuum Pathology. 2021 , 13, 735508	0
476	A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease. 2021 ,	8
475	Degree of personalisation in tailored activities and its effect on behavioural and psychological symptoms and quality of life among people with dementia: a systematic review and meta-analysis. 2021 , 11, e048917	1
474	Caregiver Tele-Assistance for Reduction of Emotional Distress During the COVID-19 Pandemic. Psychological Support to Caregivers of People with Dementia: The Italian Experience. 2021 ,	2
473	Measuring social cognition in frontotemporal lobar degeneration: a clinical approach. 2021 , 1	1
472	Gait changes over time in hospitalized older adults with advanced dementia: Predictors of mobility change. 2021 , 16, e0259975	1
471	Psychosocial interventions for older people with intellectual disabilities and the role of support staff: A systematic review. 2021 ,	2
470	A Home-Based Individual Cognitive Stimulation Program for Older Adults With Cognitive Impairment: A Randomized Controlled Trial. 2021 , 12, 741955	2
469	User experience and acceptance of a device assisting persons with dementia in daily life: a multicenter field study. 2021 , 1	2
468	Brain network modulation in Alzheimer's and frontotemporal dementia with transcranial electrical stimulation.. 2021 , 111, 24-34	2
467	The Psychiatric Misdiagnosis of Behavioral Variant Frontotemporal Dementia in a Colombian Sample. 2021 , 12, 729381	0
466	A feasibility study to assess the design of a multicentre randomized controlled trial of the clinical and cost-effectiveness of a caregiving intervention for people following hip fracture surgery. 2021 , 2, 909-920	0
465	Neuropsychiatric, cognitive and brain morphology characteristics of conversion from Mild Cognitive Impairment to Alzheimers Disease.	
464	Neuropsychiatric Symptoms and Caregiver's Burden in Parkinson's Disease Patients in a Tertiary Care Teaching Hospital in South India: A Cross-Sectional Study.. 2021 , 69, 1706-1710	

- 463 Effect of Multiple Medicines on Dementia Initial Treatment: Experience and Thinking. **2021**, 36, 15333175211053134
- 462 Development and assessment of a brief screening tool for psychosis in dementia.. **2021**, 13, e12254
- 461 [Non-cognitive psychopathological symptoms in mild cognitive impairment]. **2021**, 121, 41-51
- 460 Encyclopedia of Gerontology and Population Aging. **2021**, 611-616
- 459 Mindfulness-Based Cognitive Therapy for Stress Reduction in Family Carers of People Living with Dementia: A Systematic Review.. **2022**, 19, 3
- 458 Neuropsychological and neuroanatomical features of patients with behavioral variant Alzheimer's disease (AD): a comparison to behavioral variant frontotemporal dementia and amnesic AD groups.
- 457 The Role of Individual Characteristics in Predicting Short- and Long-Term Cognitive and Psychological Benefits of Cognitive Stimulation Therapy for Mild-to-Moderate Dementia.. **2021**, 13, 811127 0
- 456 Validation of the self-rated Dimensional Apathy Scale in community stroke survivors.. **2021**, 434, 120103 2
- 455 Bibliographie. **2018**, 289-298
- 454 Bibliographie. **2020**, 289-298
- 453 Apathy Classification by Exploiting Task Relatedness. **2020**, 2
- 452 The complex conundrum of geriatric depression and dementias: Revisiting the clinical ambiguity. **2021**, 8, 93
- 451 Conception des Interactions avec un Patient Virtuel Alzheimer pour la Formation du Personnel Soignant. **2021**,
- 450 The prevalence, predictors, associated symptoms, and outcomes of social disinhibition following moderate-to-severe TBI: A scoping review of quantitative evidence.. **2021**, 43, 716-736 0
- 449 Neuropsychiatric Manifestations of Wilson Disease: Correlation with MRI and Glutamate Excitotoxicity. **2021**, 58, 6020-6031 1
- 448 Comparative efficacy and acceptability of cholinesterase inhibitors and memantine based on dosage in patients with vascular cognitive impairment: a network meta-analysis.. **2022**, 2
- 447 Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials.. **2022**, 1 2
- 446 Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?. **2021**, 12, 808724 0

445	Factors Associated with Apathy in Alzheimer's Disease: A Cross-Sectional Analysis of the Texas Alzheimer's Research and Care Consortium (TARCC) Study.. 2022,	0
444	Neuropsychiatric Symptoms Mediated the Relationship Between Odor Identification and Cognition in Alzheimer's Disease Spectrum: A Structural Equation Model Analysis.. 2021, 13, 732840	0
443	Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology.. 2022, 1	1
442	Residential aged care staff perceptions and responses towards neuropsychiatric symptoms: a mixed methods analysis of electronic healthcare records.. 2022, 1-8	
441	Are there distinct dimensions of apathy? The argument for reappraisal.. 2022, 149, 246-256	1
440	Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson's Disease.. 2022,	0
439	Neuropsychiatric symptoms and subsyndromes in patients with different stages of dementia in primary care follow-up (NeDEM project): a cross-sectional study.. 2022, 22, 71	2
438	Managing neuropsychiatric symptoms in patients with dementia.. 2022, 376, e069187	1
437	Resilience in People with Lewy Body Disorders and Their Care Partners: Association with Mental Health, Relationship Satisfaction, and Care Burden.. 2022, 12,	0
436	Subjective clustering in patients with fronto-temporal dementia.. 2022, 1-11	
435	The Relationship Between Decision-making Capacity and the Domains of Awareness in Alzheimer Disease.. 2022, 36,	
434	Role of Apolipoprotein E in the Clinical Profile of Atypical Parkinsonian Syndromes.. 2022, 36,	0
433	Informant-based tools for assessment and monitoring of cognition, behavior, and function in neurocognitive disorders: Systematic review and report from a CCCDTD5 Working Group.. 2022, 37,	0
432	Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment.. 2022,	1
431	Incident epilepsy in the cognitively normal geriatric population, irrespective of seizure control, impairs quality of life. 2021, 126, 108457	0
430	Signature laminar distributions of pathology in frontotemporal lobar degeneration.. 2022, 143, 363	0
429	Non-Pharmacological Interventions for Wandering/Aberrant Motor Behaviour in Patients with Dementia.. 2022, 12,	0
428	The Calcium-free form of Atorvastatin inhibits amyloid- β (1-42) aggregation in vitro.. 2022, 101662	2

427	Decline of ergothioneine in frailty and cognition impairment.. 2022,	3
426	Brain pathology and cognitive scores prior to onset of late-life depression.. 2022, 37,	1
425	Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development.. 2021, 12, 788168	1
424	Predicted Cognitive Conversion in Guiding Early Decision-Tailoring on Patients With Cognitive Impairment.. 2021, 13, 813923	
423	Application of Repetitive Transcranial Magnetic Stimulation over the Dorsolateral Prefrontal Cortex in Alzheimer's Disease: A Pilot Study.. 2022, 11,	1
422	Dynamic structural equation modelling evaluating the progressively lowered stress threshold as an explanation for behavioural symptoms of dementia.. 2022,	1
421	MRI biomarkers for Alzheimer's disease: the impact of functional connectivity in the default mode network and structural connectivity between lobes on diagnostic accuracy.. 2022, 8, e08901	0
420	Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis.. 2022, 75, 101568	
419	Paranoid and Misidentification Subtypes of Psychosis in Dementia.. 2022, 134, 104529	0
418	Self-reported word-finding complaints are associated with cerebrospinal fluid amyloid beta and atrophy in cognitively normal older adults.. 2022, 14, e12274	0
417	Dissociable Functional Brain Networks Associated With Apathy in Subcortical Ischemic Vascular Disease and Alzheimer's Disease.. 2021, 13, 717037	1
416	Clinical Trajectories of Neuropsychiatric Symptoms in Mild-Moderate to Advanced Dementia.. 2022,	0
415	Economic and caregiver impact of Alzheimer's disease across the disease spectrum: a cohort study.. 2022, 14, 34	3
414	The Tuokko version of the Clock Drawing Test: A validation study in the Greek population.. 2022, 1-13	
413	Does Elevated Alcohol Consumption Delay the Diagnostic Assessment of Cognitive Impairment among Older Adults?. 2022, 12, 14-23	
412	Treatment of noncognitive neuropsychiatric disorders in Alzheimer's disease. 2021, 13, 132-138	3
411	Gamma-induction in frontotemporal dementia (GIFTeD) randomized placebo-controlled trial: Rationale, noninvasive brain stimulation protocol, and study design.. 2021, 7, e12219	0
410	Investigation of Structural Brain Changes in Charles Bonnet Syndrome.	

409	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.. 2022 , 9, 197-210	7
408	Olive polyphenols and bioavailable glutathione: Promising results in patients diagnosed with mild Alzheimer's disease.. 2022 , 8, e12278	
407	The Frequency of Neuropsychiatric Sequelae Following Traumatic Brain Injury in the Global South: A Systematic Review and Meta-Analysis.	
406	Neuropsychiatric Symptoms in Patients with Neurocognitive Disorder and Their Performance Between Mild and Major Stages.. 2021 ,	1
405	Increased retention of tau PET ligand [F]-AV1451 in Alzheimer's Disease Psychosis.. 2022 , 12, 82	1
404	Prediction of Institutionalization for Patients With Dementia in Taiwan According to Condition at Entry to Dementia Collaborative Care.. 2022 , 7334648211073129	0
403	Reduction of physical activity during the COVID-19 pandemic is related to increased neuropsychiatric symptoms in memory clinic patients.. 2022 ,	0
402	Multidimensional Clinical Assessment in Frontotemporal Dementia and Its Spectrum in Latin America and the Caribbean: A Narrative Review and a Glance at Future Challenges.. 2021 , 12, 768591	3
401	Music moves â€”Ettlingen dementia study: Protocol of a pragmatic randomised controlled trial. 1-16	0
400	The Effect of the NorGeP-NH on Quality of Life and Drug Prescriptions in Norwegian Nursing Homes: A Randomized Controlled Trial.. 2022 , 10,	
399	Active music therapy in dementia: results from an open-label trial.	
398	Education level is associated with neuropsychiatric symptoms in patients with amnesic-mild cognitive impairment.. 2022 ,	0
397	Profile of cognitive impairment in late-stage Parkinson's disease.. 2022 , e32537	0
396	A Single-Case Design Investigation for Measuring the Efficacy of Gestalt Therapy to Treat Depression in Older Adults with Dementia in Italy and in Mexico: A Research Protocol.. 2022 , 19,	
395	Detecting depression in persons living with mild cognitive impairment: a systematic review.. 2022 , 1-13	1
394	Association of Variation in Behavioral Symptoms With Initial Cognitive Phenotype in Adults With Dementia Confirmed by Neuropathology.. 2022 , 5, e220729	1
393	The Relationship Between Light Exposure before Bedtime and Daytime Sleepiness Among People Living With Cognitive Impairment.. 2022 , 7334648221083658	
392	Cognitive and Functional Abilities in an Older Adult Veteran Before and After Contracting COVID-19.. 2022 , 6, 115-120	

- 391 Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography.. **2022**, appineuropsych21050135 1
- 390 Drug-Induced Non-Motor Symptoms in Parkinson's Disease. **2022**, 212-223
- 389 Impact of Web-based CBT for Insomnia on Stress, Health, Mood, Cognitive, Inflammatory, and Neurodegenerative Outcomes in Rural Dementia Caregivers: Protocol for the NiteCAPP SM CARES & SHARES Randomized Controlled Trial (Preprint).
- 388 Eye-gaze Strategies During Facial Emotion Recognition in Neurodegenerative Diseases and Links With Neuropsychiatric Disorders.. **2022**, 35, 14-31 0
- 387 Palliative care for patients with advanced dementia.. **2022**, 52, 19-26
- 386 A prospective multicenter validation study of a machine learning algorithm classifier on quantitative electroencephalogram for differentiating between dementia with Lewy bodies and Alzheimer's dementia.. **2022**, 17, e0265484
- 385 The effect of Alzheimer's blanket activity program on behavioral symptoms, activities of daily living, and quality of life.. **2022**,
- 384 Multi-modality human phenotyping to examine subjective and objective health afflictions in former professional American-style football players: The In-Person Assessment (IPA) protocol.. **2022**, 17, e0265737
- 383 Cerebrospinal Fluid Proteome Alterations Associated with Neuropsychiatric Symptoms in Cognitive Decline and Alzheimer's Disease.. **2022**, 11, 1
- 382 Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem).. **2022**, 1
- 381 Spectrum of neuropsychiatric symptoms in chronic post-stroke aphasia.. **2022**, 12, 450-469 1
- 380 A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia.. **2022**, 22, 214 1
- 379 Exploring behavioural and cognitive dysexecutive syndrome in patients with focal prefrontal cortex damage.. **2022**, 1-21
- 378 Psychometric Properties of the Revised Dysexecutive Questionnaire in a Non-clinical Population.. **2022**, 16, 767367 1
- 377 Pet ownership supports quality of life in home-dwelling people with Alzheimer's disease.. **2022**, 37,
- 376 Apathy in UK Care Home Residents with Dementia: Longitudinal Course and Determinants.. **2022**,
- 375 Neuropsychiatric symptoms and caregiver relationship quality for older Mexican Americans.. **2022**, 1-8
- 374 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer's Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate Alzheimer's Disease (DRAMA).. **2022**,

373	Study Protocol for a Phase III Randomised Controlled Trial of Sailuotong (SLT) for Vascular Dementia and Alzheimer's Disease with Cerebrovascular Disease.	
372	Pharmacological and nonpharmacological approaches to reduce disinhibited behaviors in dementia: a systematic review.. 2022 , 1-17	3
371	Developing neuropalliative care for sporadic Creutzfeldt-Jakob Disease.. 2022 , 16, 23-39	2
370	Effect of COVID-19 quarantine on cognitive, functional and neuropsychiatric symptoms in patients with mild cognitive impairment and dementia.. 2022 , 1	3
369	Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease.. 2022 ,	1
368	Computer-aided cognitive training in patients with neurocognitive vascular impairment: effects on cognition, depression and behavior. 1-6	
367	The associations between unmet needs with protective factors, risk factors and outcomes among care partners of community-dwelling persons living with dementia.. 2022 , 1-9	0
366	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases.. 2022 , 115, 88-108	0
365	Algorithm-based pain management for people with dementia in nursing homes.. 2022 , 4, CD013339	1
364	Rehabilitation in dementia: CST and Sonas group interventions for people with moderate cognitive impairment. A pilot study. 2022 , ahead-of-print,	1
363	Concordance of self- and informant-rated depressive symptoms in nursing home residents with Dementia: cross-sectional findings.. 2022 , 22, 241	0
362	Sex differences in neuropsychiatric symptoms in Alzheimer's disease dementia: a meta-analysis.. 2022 , 14, 48	4
361	Exploring Network Properties Across Preclinical Stages of Alzheimer's Disease Using a Visual Short-Term Memory and Attention Task with High-Density Electroencephalography: A Brain-Connectome Neurophysiological Study.. 2022 ,	0
360	Mind-body therapies for older adults with dementia: a systematic review and meta-analysis.. 2022 , 1	1
359	Diagnosis of Subcortical Ischemic Vascular Cognitive Impairment With No Dementia Using Radiomics of Cerebral Cortex and Subcortical Nuclei in High-Resolution T1-Weighted MR Imaging.. 2022 , 12, 852726	0
358	Emotion Recognizing by a Robotic Solution Initiative (EMOTIVE Project).. 2022 , 22,	1
357	Diminished preparatory physiological responses in frontotemporal lobar degeneration syndromes.. 2022 , 4, fcac075	0
356	A transdiagnostic review of neuroimaging studies of apathy and disinhibition in dementia.. 2022 ,	0

- 355 Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up.. **2021**,
- 354 Case Report: Accessible Digital Musical Instrument Can Be Used for Active Music Therapy in a Person With Severe Dementia and Worsening Behavioral and Psychological Symptoms: A Case Study Over a Year and a Half.. **2022**, 13, 831523 1
- 353 Neuropsychiatric Inventory-Questionnaire Assessed Nighttime Behaviors in Cognitively Asymptomatic Patients with Pathologically Confirmed Alzheimer's Disease Predict More Rapid Cognitive Deterioration.. **2022**,
- 352 Mortality in nursing home residents stratified according to subtype of dementia: a longitudinal study over three years.. **2022**, 22, 282 1
- 351 Dual-task gait and mild behavioral impairment: The Interface between non-cognitive dementia markers.. **2022**, 111743 1
- 350 Assessment of Social Behavior Using a Passive Monitoring App in Cognitively Normal and Cognitively Impaired Older Adults: Observational Study.. **2022**, 5, e33856
- 349 Predictors of clinically significant quality of life impairment in Parkinson's disease.. **2021**, 7, 118 4
- 348 Apathy and Huntington's Disease: A Literature Review Based on PRISMA.. **2021**, appineuropsych21060154 0
- 347 Neuropsychiatric symptoms are associated with exacerbated cognitive impairment in covert cerebral small vessel disease.
- 346 An Individual Cognitive Stimulation Therapy App for People with Dementia and Carers: Results from a Feasibility Randomized Controlled Trial (RCT).. **2021**, 16, 2079-2094 1
- 345 PTSD Symptoms and Dementia in Older Veterans Who are Living in Long-Term Care.. **2021**, 10497323211061345
- 344 Cognitive Trajectories Following Acute Infection in Older Patients With and Without Cognitive Impairment: An 1-Year Follow-Up Study.. **2021**, 12, 754489 1
- 343 Interactive Associations of Neuropsychiatry Inventory-Questionnaire Assessed Sleep Disturbance and Vascular Risk on Alzheimer's Disease Stage Progression in Clinically Normal Older Adults.. **2021**, 13, 763264 0
- 342 Effectiveness and Safety of Aromatherapy in Managing Behavioral and Psychological Symptoms of Dementia: A Mixed-Methods Systematic Review.. **2021**, 11, 273-297 1
- 341 Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. **2021**, 21, 477 2
- 340 Pilot Study of the Effects of Bright Ambient Therapy on Dementia Symptoms and Cognitive Function.. **2021**, 12, 782160 2
- 339 Abordaje de la agitación en el anciano con demencia. **2021**, 28, 576-590
- 338 The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone. **2021**, 11, e054405 1

- 337 Exercise priming with transcranial direct current stimulation: a study protocol for a randomized, parallel-design, sham-controlled trial in mild cognitive impairment and Alzheimer's disease. **2021**, 21, 677 0
- 336 An Interdisciplinary Approach to Educating Medical Students About Dementia Assessment and Treatment Planning. **2020**, 37, 466-471 0
- 335 Interaction Between Affect and Cognition as a Function of Aging: Testing the Positivity Bias in Indian Population. **2022**, 81-99
- 334 The Effect of Deep Micro Vibrotactile Stimulation on Cognitive Function of Mild Cognitive Impairment and Mild Dementia.. **2022**, 19, 0
- 333 Alzheimer's Disease-Related Psychosis: An Overview of Clinical Manifestations, Pathogenesis, and Current Treatment.. **2022**,
- 332 The short-term effect of a modified comprehensive geriatric assessment and regularly case conferencing on neuropsychiatric symptoms in nursing homes: a cluster randomized trial.. **2022**, 22, 316
- 331 Reliability and Validity of the Traditional Chinese Version of the Mild Behavioral Impairment - Checklist Among Persons With Mild Cognitive Impairment - A Validation Study.. **2022**, 8919887221093363 0
- 330 Distinguishing Lewy Body Dementia from Alzheimer's Disease using Machine Learning on Heterogeneous Data: A Feasibility Study.
- 329 Establishing an individualized model of conversion from normal cognition to Alzheimer's disease after 4 years, based on cognitive, brain morphology and neuropsychiatric characteristics.. **2022**, 37, 1
- 328 Olfactory stimulation for people with dementia: A rapid review.. **2022**, 14713012221082377 1
- 327 Demenz aus psychologischer Sicht. **2008**, 141-172
- 326 Table_1.xls. **2018**,
- 325 Table_2.xls. **2018**,
- 324 Table_1.docx. **2018**,
- 323 Data_Sheet_1.docx. **2018**,
- 322 Table_1.docx. **2018**,
- 321 Table_2.DOCX. **2018**,
- 320 Table_1.docx. **2018**,

319 table_1.docx. **2018**,

318 Table_1.PDF. **2020**,

317 Table_1.pdf. **2019**,

316 DataSheet_1.pdf. **2020**,

315 Data_Sheet_1.docx. **2020**,

314 Data_Sheet_1.docx. **2020**,

313 Data_Sheet_1.docx. **2020**,

312 Table_1.docx. **2020**,

311 Data_Sheet_1.docx. **2020**,

310 Psychological treatments for depression and anxiety in dementia and mild cognitive impairment.. **2022**, 4, CD009125 0

309 Anxiety and depression in Alzheimer's disease: a systematic review of pathogenetic mechanisms and relation to cognitive decline.. **2022**, 1 3

308 Effect of Exposure to Socio-Political Violence and Abuse During Childhood on Executive Planning in Adult Life.. **2021**, 12, 693741

307 Long-Term Effects of a Behavioural Management Technique for Nurses on Aggressive Behaviour in Brain-Injured Patients.. **2019**, 16, 107-115

306 Effects of white matter hyperintensities, neuropsychiatric symptoms, and cognition on activities of daily living: Differences between Alzheimer's disease and dementia with Lewy bodies.. **2022**, 14, e12306

305 Impact of Web-based CBT for Insomnia on Stress, Health, Mood, Cognitive, Inflammatory, and Neurodegenerative Outcomes in Rural Dementia Caregivers: Protocol for the NiteCAPP CARES & SHARES Randomized Controlled Trial (Preprint). 0

304 Effects of a person-centred and thriving-promoting intervention on nursing home residents' experiences of thriving and person-centredness of the environment.. **2022**,

303 Exploration of Symptom Scale as an Outcome for Deprescribing: A Medication Review Study in Nursing Homes. **2022**, 15, 505 0

302 The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks.. **2022**, 0

- 301 Predictors of nursing home placement at 2 years in Alzheimer's disease: A follow-up survey from the THERAD study.. **2022**, 37,
- 300 Psychobiological Monitoring of a Home-Based Dyadic Intervention for People Living with Dementia and Their Caregivers: Added Value to Evaluate Treatment Success and Understand Underlying Mechanisms.. **2022**, ○
- 299 Responsive Behaviors and Pain Management in Hospital Dementia Care: A Before and After Comparison of the "Serial Trial Intervention" **2022**, 3,
- 298 Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.. **2022**, 11, 24 ○
- 297 Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.. **2022**, ○
- 296 Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the ONDRI study. ○
- 295 Association Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alfoscerate in the Treatment of Depression in Patients with Alzheimer's Disease. 1-9 1
- 294 What outcome measures are most useful in measuring the effectiveness of anti-dementia medication in people with intellectual disabilities and dementia?. **2022**, 16, 87
- 293 Exploring changes to resident thriving and associated factors in Swedish nursing homes: A repeated cross-sectional study.. **2022**, 37, ○
- 292 An intervention to promote self-management, independence and self-efficacy in people with early-stage dementia: the Journeying through Dementia RCT.. **2022**, 26, 1-152
- 291 Post-stroke apathy: A case series investigation of neuropsychological and lesion characteristics.. **2022**, 171, 108244 ○
- 290 Investigation of structural brain changes in Charles Bonnet Syndrome.. **2022**, 35, 103041 ○
- 289 Dementia neuropsychiatric symptom frequency, severity, and correlates in community-dwelling Thai older adults. **2022**,
- 288 Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis.. **2022**, 1-13 ○
- 287 Dohsa-hou for unexplained regression in Down syndrome in a 19-year-old man: A case report. **2022**, 10,
- 286 Bibliographie. **2014**, 177-212
- 285 Comparing Behavioral and Psychological Symptoms of Dementia and Caregiver Distress Caused Between Older Adults With Dementia Living in the Community and in Nursing Homes. **2022**, 13, ○
- 284 Tele-Mindfulness for Dementia's Family Caregivers: a Randomized Trial with a Usual Care Control Group.. **2022**,

- 283 Needs of patients with parkinsonism and their caregivers: a protocol for the PRIME-UK cross-sectional study.. **2022**, 12, e057947
- 282 A cluster-randomized trial of a complex intervention to encourage deprescribing antidepressants in nursing home residents with dementia: a study protocol.. **2022**, 23, 410
- 281 Decreased 5-HT binding in mild Alzheimer's disease - a PET study.. **2022**,
- 280 Analysing the use of music to facilitate social interaction in care home residents with dementia: Narrative synthesis systematic review.. **2022**, 14713012221100625 1
- 279 Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia.. *Neurology*, **2022**, 6.5
- 278 Synuclein Motor Dysfunction Composite Scale for the Discrimination of Dementia With Lewy Bodies From Alzheimer's Disease. **2022**, 14,
- 277 Assess of Combinations of Non-Pharmacological Interventions for the Reduction of Irritability in Patients with Dementia and their Caregivers: A Cross-Over RCT. **2022**, 12, 691
- 276 A Functional Assessment Tool to Distinguish Controls From Alzheimer's Disease in Lima, Peru. **2022**, 37, 153331752211043
- 275 Neuropsychiatric disorders after severe traumatic brain injury: An overview. **2022**, 71-83
- 274 Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study. **2022**, 8, 2
- 273 Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people. **2022**, 19, 0
- 272 The Oxford Brain Health Clinic: Protocol and Research Database. 0
- 271 Factors associated with change over time in quality of life of people with dementia: longitudinal analyses from the MODEM cohort study. **2022**, 22, 0
- 270 The Effect of a Tele-Health Intervention Program on Home-Dwelling Persons with Dementia or MCI and on Their Primary Caregivers during the Stay-at-Home-Order Period in the COVID-19 Pandemic Outbreak: Evidence from Taiwan. **2022**, 10, 969 0
- 269 Le « syndrome de glissement », du m'susage ^ la recherche de causes r'versibles': entre mythe et r'alit'. **2022**,
- 268 Neurosyphilis Mimicking Behavioral Variant of Frontotemporal Dementia in a 59-Year-Old Man. **2022**, 35, 140-146 0
- 267 A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease. 13, 1
- 266 Implementing a Personalized Integrated Stepped-Care Method (STIP-Method) to Prevent and Treat Neuropsychiatric Symptoms in Persons With Dementia in Nursing Homes: Protocol for a Mixed Methods Study (Preprint).

- 265 Accompagnement et prise en soins de la maladie d'Alzheimer et des affections apparentées. **2022**, 193-210
- 264 Troubles cognitifs et psycho-comportementaux dans la maladie de Parkinson idiopathique et les syndromes parkinsoniens atypiques. **2022**, 277-290
- 263 Évaluation des troubles ou perturbation du comportement. **2022**, 167-184
- 262 Histoire naturelle et diagnostic de la maladie d'Alzheimer. **2022**, 143-161
- 261 Resting state functional brain networks associated with emotion processing in frontotemporal lobar degeneration. 0
- 260 Automated High-Definition MRI Processing Routine Robustly Detects Longitudinal Morphometry Changes in Alzheimer's Disease Patients. 14,
- 259 Decreased frontal gamma activity in Alzheimer's disease patients. 0
- 258 Emergent visual creativity in frontotemporal dementia is associated with dorsomedial visual cortex enhancement.
- 257 Évaluer les effets du shiatsu. Réflexion à propos d'une étude sur les troubles du comportement chez des résidents vivant en Ehpad atteints de la Maladie d'Alzheimer. **2022**, N° 2, 109-119
- 256 Detecting Anxiety in Long-Term Care Residents: A Systematic Review. 1-10
- 255 Neurological Symptoms and Their Associations With Inflammatory Biomarkers in the Chronic Phase Following Traumatic Brain Injuries. 13, 0
- 254 Elevated Plasma Orexin-A Levels in Prodromal Dementia with Lewy Bodies. **2022**, 1, 1-12 1
- 253 CT-Detected MTA Score Related to Disability and Behavior in Older People with Cognitive Impairment. **2022**, 10, 1381
- 252 Plasma Oxytocin Is Not Associated with Social Cognition or Behavior in Frontotemporal Dementia and Alzheimer's Disease Syndromes. 1-8
- 251 Neuropsychiatric or Behavioral and Psychological Symptoms of Dementia (BPSD): Focus on Prevalence and Natural History in Alzheimer's Disease and Frontotemporal Dementia. 13, 4
- 250 Deep brain stimulation of the nucleus basalis of Meynert for Parkinson's disease dementia: a 36 months follow up study. 0
- 249 Informal Caregivers' Attitude Toward Dementia: The Impact of Dementia Knowledge, Confidence in Dementia Care, and the Behavioral and Psychological Symptoms of the Person with Dementia. A Cross-Sectional Study. **2022**, 1-14 0
- 248 Implementing a Personalized Integrated Stepped-Care Method (STIP-Method) to Prevent and Treat Neuropsychiatric Symptoms in Persons With Dementia in Nursing Homes: Protocol for a Mixed Methods Study. **2022**, 11, e34550 1

- 247 Biweekly fluctuations of neuropsychiatric symptoms according to the Neuropsychiatric Inventory: Erratic symptoms or scores?. **2022**, 37, 0
- 246 Risk factors for apathy in Alzheimer's disease: A systematic review of longitudinal evidence. **2022**, 79, 101672 1
- 245 Clinical and biological subtypes of late-life depression. **2022**, 312, 46-53 1
- 244 Menschen mit Frontotemporaler Demenz: Versorgungsbedarfe und Interventionen. **2022**, 155-168
- 243 Urinary AD7c-NTP Evaluates Cognition Impairment and Differentially Diagnoses AD and MCI. **2022**, 37, 153331752211152 0
- 242 Tailored Activity Program (TAP-BR): Proposition of an outpatient care version and evaluation of its impacts on dementia - A pilot study. 30,
- 241 Programa Personalizado de Atividades (TAP-BR): proposiçã de uma versã ambulatorial e avaliaçã dos seus impactos na demência - Estudo piloto. 30,
- 240 A systematic review on resting state functional connectivity in patients with neurodegenerative disease and hallucinations. **2022**, 35, 103112 0
- 239 A Multinational, Multicenter, Randomized, Double-Blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease. **2022**, 18, 428
- 238 The association of depression and apathy with Alzheimer's disease biomarkers in a cross-cultural sample. 1-17 0
- 237 Identification of risk factors for delirium, cognitive decline, and dementia after cardiac surgery (FINDER) and delirium risk factors): a study protocol of a prospective observational study. **2022**, 22, 0
- 236 Secular trends in the prevalence of dementia based on a community-based complete enumeration in Japan: the Nakayama Study.
- 235 Italian Dementia-Friendly Hospital Trial (IDENTIFY): efficacy of a dementia care intervention for hospital staff. 1-9
- 234 Behavioral and Psychological Symptoms and Associated Factors in Community-Dwelling Persons at the First Time of Dementia Diagnosis. **2022**, 19, 7765
- 233 Psychobiological Evaluation of Day Clinic Treatment for People Living With Dementia - Feasibility and Pilot Analyses. 14,
- 232 Estudio de sntomas neuropsiquiátricos y neuropsicolóxicos en pacientes con enfermedad de Parkinson seleccionados para la cirugía de estimulación cerebral profunda. **2022**,
- 231 Various courses of early post-stroke apathy symptoms are associated with different outcomes.
- 230 Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia. **2022**, 12, 1106 0

229	Association between the frailty index and vascular brain damage: The Treviso Dementia (TREDEM) registry. 2022 , 111894	0
228	Comparing Individuals With PPA to Individuals With AD: Cognitive and Linguistic Profiles. 7,	
227	Impact of the COVID-19 Pandemic and Lockdown on Anxiety, Depression and Nursing Burden of Caregivers in Alzheimer's Disease, Dementia With Lewy Bodies and Mild Cognitive Impairment in China: A 1-Year Follow-Up Study. 13,	1
226	Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. 2022 , 1-26	3
225	Th�rapie musicale individualis�e et sentiment d'identit� dans la maladie d'Alzheimer � un stade avanc�: protocole � cas-unique d'une dyade patient aid�/conjoint-aidant. 2022 ,	
224	Transcranial direct current stimulation in the treatment of visual hallucinations in Charles Bonnet syndrome: A randomized placebo-controlled crossover trial.. 2022 ,	
223	Latest Trends in Outcome Measures in Dementia and Mild Cognitive Impairment Trials. 2022 , 12, 922	
222	Effects of the use of autobiographical photographs on emotional induction in older adults: a systematic review.	
221	Relations of neuropsychiatric symptoms with disease stage, sex, and daily function in mild cognitive impairment and dementia due to Alzheimer's disease: A cross-sectional study. 2022 , 110994	0
220	Empirical and Authoritative Classification of Neuropsychiatric Syndromes in Neurocognitive Disorders.	0
219	Clinical and structural brain correlates of hypomimia in early-stage Parkinson's disease.	1
218	Quantitative susceptibility mapping demonstrates different patterns of iron overload in subtypes of early-onset Alzheimer's disease.	0
217	The Dementia Coding System (DeCS): Development and initial evaluation of a coding system to assess positive, challenging, and music-related behaviors of people with dementia. 1-17	1
216	The Characteristics and Outcomes of People with Dementia in Inpatient Mental Health Care: A Review. 1-20	0
215	Reliability and Validity of the Neuropsychiatric Inventory-Questionnaire Using a Rasch Analysis. JNM-2021-0008R2	
214	POISED: Protocol for a multi-site randomized controlled trial of the program of intensive support in emergency departments for care partners of cognitively impaired patients (Preprint).	
213	Neuropsychiatric Symptoms of Alzheimer's Disease and Caregiver Burden. 13,	
212	The gesture imitation test in dementia with Lewy bodies and Alzheimer's disease dementia. 13,	

- 211 Sleep Quality and Factors Affecting It in Caregivers of People with Dementia: A Cross Sectional Study. **2022**, 0-0
- 210 Episodic Memory, Hippocampal Volume, and Function for Classification of Mild Cognitive Impairment Patients Regarding Amyloid Pathology. **2022**, 1-12
- 209 Evaluating the effectiveness of a 6-week hybrid mindfulness-based intervention in reducing the stress among caregivers of patients with dementia during COVID-19 pandemic: protocol of a randomized controlled trial. **2022**, 10, 0
- 208 Early Identification of Different Behavioral Phenotypes in the Behavioral Variant of Frontotemporal Dementia with the Aid of the Mini-Frontal Behavioral Inventory (mini-FBI). **2022**, 1-10
- 207 Astrogliosis in aging and Parkinson's disease dementia: a new clinical study with 11C-BU99008 Positron Emission Tomography. 1
- 206 Tracking the Progression and Influence of Beta-Amyloid Plaques Using Percolation Centrality and Collective Influence Algorithm: A Study Using PET Images. 097275312211176
- 205 An integrated intervention of computerized cognitive training and physical exercise in virtual reality for people with Alzheimer's disease: The jDome study protocol. 13, 0
- 204 Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments. **2022**, 23, 0
- 203 Neuropsychological and Neuroanatomical Features of Patients with Behavioral/Dysexecutive Variant Alzheimer's disease (AD): A Comparison to Behavioral Variant Frontotemporal Dementia and Amnesic AD Groups. **2022**, 1-18 1
- 202 Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta-analysis.
- 201 Biological determinants of blood-based cytokines in the Alzheimer's disease clinical continuum. 0
- 200 Reproductive factors and cognitive impairment in natural menopausal women: A cross-sectional study. 13,
- 199 Pimavanserin for the Treatment of Alzheimer's Disease Psychosis: An Evaluation of the Clinical Importance of Efficacy Results.
- 198 Impaired recollection and initially preserved familiarity in a patient with bilateral fornix transection following third ventricle colloid cyst removal: A two-year follow-up study. 1-13
- 197 Dementia Disease Detection from Psychiatric Disorders Based on Automatic Speech Analysis. **2023**, 95-102
- 196 Effects of an essential amino acid mixture on behavioral and psychological symptoms of dementia and executive function in patients with Alzheimer's disease: A double-blind, randomized, placebo-controlled exploratory clinical trial. **2022**, 37,
- 195 White matter hyperintensities in dementia with Lewy bodies are associated with poorer cognitive function and higher dementia stages. 14,
- 194 Tailoring the therapeutic interventions for behavioral and psychological symptoms of dementia. 1-14

- 193 Complementary and integrative medicines for behavioral and psychological symptoms of dementia: Overview of systematic reviews. **2022,** ○
- 192 Why can spontaneous intracranial hypotension cause behavioral changes? A case report and multimodality neuroimaging comparison with frontotemporal dementia. **2022,**
- 191 Attention, Praxis, and Reasoning Are Associated with Risk of Undernutrition in Older People with Cognitive Impairment. **2022,** 1-8
- 190 Reliability and Validity of a Chinese Version of the CohenâMansfield Agitation Inventory-Short Form in Assessing Agitated Behavior. **2022,** 19, 9410
- 189 Pisa syndrome in dementia with Lewy bodies: A Chinese multicenter study. **2022,** 103, 50-55
- 188 Treatment of Lewy Body Dementia. **2003,** 608-614 ○
- 187 Different Trajectories of Depressive Symptoms in Alzheimerâ Disease Caregivers â Year Follow-Up. 1-10 ○
- 186 Effects of oral health intervention strategies on cognition and microbiota alterations in patients with mild Alzheimer's disease: A randomized controlled trial. **2022,** 48, 99-106 1
- 185 Peripheral inflammatory markers during an acute bacterial infection in older patients with and without cognitive dysfunction: A case control study. **2022,** 25, 100503 ○
- 184 Factors associated with the quality of life in family caregivers of people with dementia in Taiwan. **2022,** 36, 123 ○
- 183 Combined treatment with Ginkgo biloba extract EGb 761 plus acetylcholinesterase inhibitors improved cognitive function and neuropsychiatric symptoms in patients with mild cognitive impairment. **2022,** 8, ○
- 182 Factors Associated With Sleep Quality in Hospitalized Persons With Dementia. **2022,** 36, 253-258 ○
- 181 Distinguishing Lewy Body Dementia from Alzheimer's Disease using Machine Learning on Heterogeneous Data: A Feasibility Study. **2022,** ○
- 180 Musical Bridges to Memory. Publish Ahead of Print, ○
- 179 Neuropsychiatric symptoms are associated with exacerbated cognitive impairment in covert cerebral small vessel disease. 1-8 ○
- 178 A low dimensional cognitive-network space in Alzheimerâ disease and frontotemporal dementia. ○
- 177 Association between prevalence rate of dementia with Lewy bodies and sleep characteristics in Chinese old adults. 16, ○
- 176 Depression in multiple system atrophy: Views on pathological, clinical and imaging aspects. 13, ○

175	Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses. 2022 , 37,	2
174	Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial. 9,	0
173	Application of virtual reality for dementia management. 2022 , 8, 210-220	0
172	A multi-expert ensemble system for predicting Alzheimer transition using clinical features. 2022 , 9,	0
171	Plasma Myeloperoxidase as a Potential Biomarker of Patient Response to Anti-Dementia Treatment in Alzheimer's Disease. 2022 , 1-10	0
170	Neighborhood characteristics and dementia symptomology among community-dwelling older adults with Alzheimer's disease. 14,	0
169	Wrist accelerometry for monitoring dementia agitation behaviour in clinical settings: A scoping review. 13,	2
168	Neuropathological correlates of neuropsychiatric symptoms in dementia.	2
167	Neuropsychiatric symptoms of dementia and caregivers' burden: a study among Indian caregivers. 2022 , 16, 332-340	1
166	Neural correlates of delusion in Alzheimer's disease and Mild Cognitive Impairment.	1
165	Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients. 14,	0
164	Non-pharmacologic and pharmacologic treatments for anxiety in long-term care: a systematic review and meta-analysis. 2022 , 51,	0
163	Effects of Reminiscence Therapy on Cognition, Depression and Quality of Life in Elderly People with Alzheimer's Disease: A Systematic Review of Randomized Controlled Trials. 2022 , 11, 5752	1
162	Case Report: A neurolinguistic and neuroimaging study on a Chinese follow-up case with logopenic-variant of primary progressive aphasia. 13,	0
161	The presence and co-incidence of geriatric syndromes in older patients with mild-moderate Lewy body dementia. 2022 , 22,	0
160	Survival and Causes of Death among People with Clinically Diagnosed Dementia with Lewy bodies: A Multicenter Cohort Study.	0
159	Assessing the wellbeing of family caregivers of multimorbid and homebound older adults's scoping literature review.	0
158	An Integrative Stress Reduction Program for Family Caregivers of Persons With Advanced Dementia: A Pilot Study. 2022 , 48, 26-32	0

- 157 Strengths and weaknesses of the vascular apathy hypothesis: a narrative review. **2022**, 0
- 156 Sex differences in clinical cognitive impairment with Lewy bodies: a Chinese multicenter study. **2022**, 13, 0
- 155 Magnetic resonance imaging Locus Coeruleus abnormality in amnesic Mild Cognitive Impairment is associated with future progression to dementia. 1
- 154 Neuropsychiatric symptoms in patients with possible vascular cognitive impairment, does sex matter?. **2022**, 3, 100152 0
- 153 Estimation of the epidemiology of dementia and associated neuropsychiatric symptoms by applying machine learning to real-world data. **2022**, 15, 167-175 0
- 152 Development of a Home-Based Stress Management Toolkit for Dementia Caring Dyads: Protocol for A Pilot Intervention Development and Feasibility Study (Preprint). 0
- 151 Signs and symptoms associated with a need for supervision in patients with Alzheimer's disease. 0
- 150 Temporal Variation in Disease Onset and Clinical Features of Lewy Body Disease in China. **2022**, 1-13 0
- 149 Neuropsychiatric outcomes and caregiver distress in primary progressive aphasia. 0
- 148 Diagnostic and Management Strategies for Common Neurobehavioral and Psychiatric Disturbances Among Patients with Cognitive Impairment and the Dementias. **2022**, 0
- 147 Health literacy of informal caregivers of older adults with dementia: results from a cross-sectional study conducted in Florence (Italy). 0
- 146 Association between Cerebral Coordination Functions and Clinical Outcomes of Alzheimer's Disease. **2022**, 12, 1370 0
- 145 Factors associated with the grief among family caregivers of patients with dementia in China. 0
- 144 Older Adults with Dementia: Association of Prayer with Neuropsychiatric Symptoms, Cognitive Function, and Sleep Disturbances. **2022**, 13, 973 2
- 143 Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial. 0
- 142 Utility of the 20-Item Noise Pareidolia Task (NPT -20) for Assessing Visuo-perceptual Disturbances Associated with Complex Visual Hallucinations in Parkinson's Disease. 0
- 141 Long-Term EEG Monitoring in Patients with Alzheimer's Disease Using Ear-EEG: A Feasibility Study. **2022**, 1-11 0
- 140 High frequency of Depressive Disorders and Suicidal Phenomena in Late-Stage Parkinson's Disease - A Cross-Sectional Study. 089198872211355 0

- 139 Doll Therapy Intervention Reduces Challenging Behaviours of Women with Dementia Living in Nursing Homes: Results from a Randomized Single-Blind Controlled Trial. **2022**, 11, 6262 ○
- 138 Clinical Data Interchange Standards in Clinical Trials on Alzheimer's Disease. **2022**, 19, 814-823 ○
- 137 Plasma P-Tau181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. 10.1212/WNL.0000000000000000 ○
- 136 Genetic analysis of and clinical characteristics associated with ANXA11 variants in a Chinese cohort with amyotrophic lateral sclerosis. **2022**, 175, 105907 ○
- 135 Rationalising Antipsychotic Prescribing in Dementia (RAPID) complex intervention: A mixed-methods feasibility intervention study. **2022**, 8, 100190 ○
- 134 Memory Clinics: A Guide to Implementation and Evaluation. **2003**, 828-843 ○
- 133 Reaching a Diagnosis of a Dementia Subtype. **2003**, 106-193 1
- 132 Classes of Psychotropics: An Overview of Evidence from Clinical Trials. **2003**, 675-694 ○
- 131 Polypharmacy and medicine regimens in older adults in residential aged care. **2023**, 105, 104849 ○
- 130 Sex-dependent worsening of NMDA-induced responses, anxiety, hypercortisolemia, and organometry of early peripheral immunoendocrine impairment in adult 3xTg-AD mice and their long-lasting ontogenic modulation by neonatal handling. **2023**, 438, 114189 ○
- 129 Development of a Home-Based Stress Management Toolkit for Dementia Caring Dyads: Protocol for A Pilot Intervention Development and Feasibility Study (Preprint). ○
- 128 Individual differences among older adults with mild and moderate dementia in social and emotional loneliness and their associations with cognitive and psychological functioning. **2022**, 22, 1 1
- 127 Association of Psychotropic Education with Quality of Life: A Before-After Study in Residential Aged Care Facilities. ○
- 126 Brain metabolic correlates of Locus Coeruleus degeneration in Alzheimer's Disease: A multimodal neuroimaging study. **2022**, ○
- 125 Frontal and temporal lobe correlates of verbal learning and memory in aMCI and suspected Alzheimer's disease dementia. 1-17 ○
- 124 The Costs of Dementia in Europe: An Updated Review and Meta-analysis. ○
- 123 Genetic and clinical characteristics of ALS patients with NEK1 gene variants. **2022**, ○
- 122 Frequency and Pathophysiology of Apathy in Huntington Disease: A Systematic Review and Meta-Analysis. ○

121	The unrecognized role of fidelity in effectiveness-implementation hybrid trials: simulation study and guidance for implementation researchers.	○
120	The Central and Peripheral Nervous System. 2001 ,	○
119	Evaluation of virtual caregiver support groups for young-onset dementia family caregivers. 1-14	○
118	What factors contribute to the need for physical restraint in institutionalized residents in Taiwan?. 2022 , 17, e0276058	○
117	Baseline characterization of the ARMADA (Assessing Reliable Measurement in Alzheimer’s Disease) study cohorts.	○
116	Involvement of inflammation in the medial temporal region in the development of agitation in Alzheimer’s disease: an in vivo positron emission tomography study.	○
115	Feasibility and acceptability of cognitive behavioural therapy in older Japanese people with cognitive decline: a single-arm intervention. 2022 , 15,	○
114	Systematic review of arts and culture-based interventions for people living with dementia and their caregivers. 2023 , 83, 101793	○
113	Deprescribing for older people living in residential aged care facilities: Pharmacist recommendations, doctor acceptance and implementation. 2023 , 107, 104910	○
112	The healthcare trajectories of older people in foster families: protocol for an Observational Study (Preprint).	○
111	Diagnóstico da demência frontotemporal: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. 2022 , 16, 40-52	○
110	Diagnosis of frontotemporal dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. 2022 , 16, 40-52	○
109	Diencephalic versus Hippocampal Amnesia in Alzheimer’s Disease: The Possible Confabulation-Misidentification Phenotype. 2022 , 1-26	○
108	Reporting of outcomes and measures in studies of interventions to prevent and/or treat delirium in older adults resident in long-term care: a systematic review. 2022 , 51,	○
107	How patients with dementia influence caregiver burden using the Dementia Assessment Sheet for Community-based Integrated Care System-21 items (DASC -21) and Zarit Caregiver Burden Interview (ZBI).	1
106	The neurocognitive disorder cohort RIFADE: Aims, methods, first results showing cognitive improvement in a subgroup.	○
105	Dance-Specific Activity in People Living With Dementia: A Conceptual Framework and Systematic Review of Its Effects on Neuropsychiatric Symptoms. 089198872211302	○
104	Examining Voting Capacity in Older Adults with and without Cognitive Decline. 2022 , 12, 1614	○

- 103 Association of right precuneus compression with apathy in idiopathic normal pressure hydrocephalus: a pilot study. **2022**, 12, ○
- 102 Effects of telehealth on functional capacity, mental health and quality of life among older people with dementia: LAPESI telehealth protocol for a randomized controlled trial. ○
- 101 Blood MAPT expression and methylation status in Alzheimer's disease. **2022**, 1, ○
- 100 Tailoring a complex intervention to reduce antidepressants in institutionalized older persons with dementia. **2022**, 22, ○
- 99 Associations between neuropsychiatric symptoms and incident Alzheimer's dementia in men versus women. ○
- 98 Applying Apriori algorithm to explore long-term care services usage status—Variables based on the combination of patients with dementia and their caregivers. 13, ○
- 97 Soundscape Awareness Intervention Reduced Neuropsychiatric Symptoms in Nursing Home Residents With Dementia: A Cluster-Randomized Trial With MoSART+. **2022**, ○
- 96 Unraveling the role of relative telomere length and CAG expansion on initial symptoms of juvenile Huntington disease. ○
- 95 Determinants of cognitive impairment in multiple system atrophy: Clinical and genetic study. **2022**, 17, e0277798 ○
- 94 Awareness impairment in Alzheimer's disease and frontotemporal dementia: a systematic MRI review. 1
- 93 Cause and place of death in Norwegian nursing home residents. 140349482211401 ○
- 92 Hospitalizations and Emergency Room Admissions by Mexican American Older Adults with and without Dementia and Caregiver Mental Health. **2022**, 1-11 ○
- 91 Prosopagnosia, Other Specific Cognitive Deficits, and Behavioral Symptoms: Comparison between Right Temporal and Behavioral Variant of Frontotemporal Dementia. **2022**, 6, 75 ○
- 90 Disrupted topological organization of functional brain networks in Alzheimer's disease patients with depressive symptoms. **2022**, 22, 1
- 89 Cognitive Impairments Predict the Behavioral and Psychological Symptoms of Dementia. ○
- 88 Stepwise Dual-target MR-guided Focused Ultrasound in Tremor-dominant Parkinson's Disease: a Feasibility Study. **2022**, ○
- 87 What are the factors associated with people with advanced dementia refusing assistance with personal care?. **2023**, 38, ○
- 86 Comparative efficacy and acceptability of treatments for depressive symptoms in cognitive impairment: A systematic review and Bayesian network meta-analysis. 14, ○

85	Persistent depressive symptoms are associated with frontal regional atrophy in patients with Alzheimer's disease. 2023 , 38,	1
84	QUALITY OF LIFE AND MENTAL HEALTH IN MULTIPLE SCLEROSIS PATIENTS DURING THE COVID-19 PANDEMIC.. 2022 , 104487	1
83	Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART.	0
82	Development of a simple screening tool for determining cognitive status in Alzheimer's disease. 2023 , 18, e0280178	0
81	The role of the clinical psychologist in deep brain stimulation surgery for Parkinson's disease. 2011 , 1, 29-34	0
80	A 76-Year-Old Male Patient who Has Been Receiving Cognitive Intervention for 10 Years: A Case Report. 2022 , 1, 8	0
79	Impact of Palliative Care for Dementia Patients in Tertiary Hospitals among Saudi Arabia: A Systemic Review. 2022 , 13, 134-140	0
78	The association of depression and quality of life in patients with neurocognitive disorder in a tertiary care center: An observational study. 2022 , 36, 170	0
77	Evaluating the treatment outcomes of repetitive transcranial magnetic stimulation in patients with moderate-to-severe Alzheimer's disease. 14,	0
76	Molecular Imaging of the Association between Serotonin Degeneration and Beta-Amyloid Deposition in Mild Cognitive Impairment. 2023 , 103322	0
75	The Rossy Progressive Supranuclear Palsy Centre: creation and initial experience. 1-28	0
74	Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance. 1-14	0
73	Transcranial alternating current stimulation combined with sound stimulation improves cognitive function in patients with Alzheimer's disease: Study protocol for a randomized controlled trial. 14,	0
72	Examining the association between neuropsychiatric symptoms among people with dementia and caregiver mental health: are caregiver burden and affiliate stigma mediators?. 2023 , 23,	0
71	Mild behavioral impairment linked to progression to Alzheimer's disease and cortical thinning in amnesic mild cognitive impairment. 14,	0
70	R4Alz-Revised: A Tool Able to Strongly Discriminate "Subjective Cognitive Decline" from Healthy Cognition and "Minor Neurocognitive Disorder" 2023 , 13, 338	0
69	Different peripheral expression patterns of the nicotinic acetylcholine receptor in dementia with Lewy bodies and Alzheimer's disease. 2023 , 20,	0
68	Feasibility, Acceptability, and Efficacy of Home-Based Transcranial Direct Current Stimulation on Pain in Older Adults with Alzheimer's Disease and Related Dementias: A Randomized Sham-Controlled Pilot Clinical Trial. 2023 , 12, 401	0

- 67 Service evaluation: Exploring the usefulness of modified, group-based cognitive stimulation therapy for people with advanced dementia on inpatient wards. **2020**, 1, 48-57 ○
- 66 Twenty-one years of creativity and development: The evolving Newcastle Model. **2020**, 1, 62-69 ○
- 65 A low-dimensional cognitive-network space in Alzheimer's disease and frontotemporal dementia. **2022**, 14, ○
- 64 Does Multicomponent Physical Exercise Training Work for Dementia? Exploring the Effects on Cognition, Neuropsychiatric Symptoms, and Quality of Life. 089198872211491 ○
- 63 Factors that Make It Difficult to Live at Home Due to Social Behavior Disorders. **2022**, 42, 459-465 ○
- 62 Kan bruk av atferd- og d̄nrytmeregistreringsskjema predikere aggresjon og irritasjon hos pasienter innlagt i en alderspsykiatrisk d̄nnavdeling?. **2023**, 13, 1-23 ○
- 61 Apathy as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Texas Alzheimer's Research and Care Consortium (TARCC) Cohort-Based Analysis. **2023**, 1-11 ○
- 60 Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. **2023**, 1-12 ○
- 59 Leisure-Related Social Work Interventions for Patients with Cognitive Impairment: A Systematic Review and Meta-Analysis. **2023**, 20, 1906 ○
- 58 Apathy and depression in mild cognitive impairment: distinct longitudinal trajectories and clinical outcomes. 1-10 ○
- 57 Behavioral and Psychological Symptoms of Dementia: Prevalence, Symptom Severity, and Caregiver Distress in South-Western Uganda's Quantitative Cross-Sectional Study. **2023**, 20, 2336 ○
- 56 Frailty Improvement by Multicomponent Drug, Ninjin'soeito, in Mild Cognitive Impairment and Mild Alzheimer's Disease Patients: An Open-Label Exploratory Study (FRAMINGO). **2023**, 7, 107-117 ○
- 55 Addition of the FTD Module to the Neuropsychiatric Inventory improves classification of frontotemporal dementia spectrum disorders. ○
- 54 Prevalence, Timing, and Network Localization of Emergent Visual Creativity in Frontotemporal Dementia. **2023**, 80, 377 ○
- 53 Automated Video Analysis of Audio-Visual Approaches to Predict and Detect Mild Cognitive Impairment and Dementia in Older Adults. **2023**, 92, 875-886 ○
- 52 Les unit's de soins sp'cialis's Alzheimer': une seconde peau psychique?. **2023**, 7, 100335 ○
- 51 A systematic review and meta-analysis of depression and apathy frequency in adult-onset Huntington's disease. **2023**, 149, 105166 ○
- 50 Histone deacetylase 1 regulates haloperidol-induced motor side effects in aged mice. **2023**, 447, 114420 ○

49	Valutazione neuropsicologica negli adulti. 2023 , 30, 1-12	0
48	Distinguishing apathy from depression: A review differentiating the behavioral, neuroanatomic, and treatment-related aspects of apathy from depression in neurocognitive disorders. 2023 , 38,	0
47	An Intervention on Anxiety Symptoms in Moderate Alzheimer’s Disease through Virtual Reality: A Feasibility Study and Lessons Learned. 2023 , 20, 2727	2
46	A data-driven examination of apathy and depressive symptoms in dementia with independent replication. 2023 , 15,	0
45	Outcome measures for Alzheimer’s disease: A global inter-societal Delphi consensus.	0
44	Resting-State Functional Connectivity Changes in Older Adults with Sleep Disturbance and the Role of Amyloid Burden.	0
43	Lower cognitive function attenuates the convergence between self-ratings and observer ratings of depressive symptoms in late-life cognitive impairment. 2023 , 13,	0
42	Neuropsychiatric Symptoms and Caregiver Stress in Parkinson’s Disease with Cognitive Impairment, Alzheimer’s Disease, and Frontotemporal Dementia. 2023 , 13, 243-254	0
41	The Possible Role of Apathy on Conflict Monitoring: Preliminary Findings of a Behavioral Study on Severe Acquired Brain Injury Patients Using Flanker Tasks. 2023 , 13, 298	1
40	Impact of behavioral and psychological symptoms of dementia (BPSD) in institutionalized people. 2019 , 4, 233-239	0
39	Validation study of the Persian version of behavioral pathology in Alzheimer’s Disease Rating scale (BEHAVE-AD) and the empirical BHAVE-AD (E-BEHAVE-AD). 1-11	0
38	Italian guidance on Dementia Day Care Centres: A position paper. 2023 , 35, 729-744	0
37	Physical Exercise as a Nonpharmacological Intervention for the Treatment of Neuropsychiatric Symptoms in Persons With Dementia. 2023 , 37, 73-81	0
36	Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer’s disease in individuals with mild cognitive impairment: The NORFACE cohort. 17,	0
35	Efficacy of acupuncture in patients with mild Alzheimer’s disease and its impact on gut microbiota: Study protocol for a randomized sham-controlled trial. 10,	0
34	The limitations and challenges in the assessment of executive dysfunction associated with real-world functioning: The opportunity of serious games. 1-17	0
33	Association of Religious Service Attendance and Neuropsychiatric Symptoms, Cognitive Function, and Sleep Disturbances in All-Cause Dementia. 2023 , 20, 4300	0
32	Characterization of Depressive Symptoms in Dementia and Examination of Possible Risk Factors. 2023 , 7, 213-225	0

31	Collaborative Care and Geriatric Psychiatry. 2023 , 1-15	0
30	Correlation between white matter hyperintensity and delusional symptoms in Alzheimer's disease.	0
29	Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition. 1-13	1
28	Assessing and managing agitation as a symptom of dementia.	0
27	Factors Associated with ADL Dependence in Nursing Home Residents with Korsakoff's Syndrome and Other Alcohol-Related Disorders: An Explorative Cross-Sectional Study. 2023 , 12, 2181	1
26	Effects of Mindfulness-Based Interventions (MBIs) in Patients with Early-Stage Alzheimer's Disease: A Pilot Study. 2023 , 13, 484	0
25	Aromathérapie et troubles anxieux de la personne âgée. 2023 ,	0
24	Study protocol for a phase III randomised controlled trial of Salluotong (SLT) for vascular dementia and Alzheimer's disease with cerebrovascular disease. 2023 , 18, e0265285	0
23	Statistical harmonization of everyday functioning and dementia-related behavioral measures across nine surveys and trials. 2023 , 15,	0
22	A digital health home intervention for people within the Alzheimer's disease continuum: results from the Ability-Telerehabilitation pilot randomized controlled trial. 2023 , 55, 1080-1091	0
21	Cutoff scores for the "Interest game" an application for the assessment of diminished interest in neurocognitive disorders. 14,	0
20	Cognitive Impairment in Neurodegenerative Movement Disorders. 2023 , 43, 081-094	0
19	Sleep Disturbances Predict Cognitive Decline in Cognitively Healthy Adults. 2023 , 92, 1427-1438	0
18	Cognitive evaluation in Parkinson's disease: applying the Movement Disorder Society recommendations in a population with a low level of formal education. 2023 , 81, 119-127	0
17	Body mass index in nursing home residents during the first year after admission. 2023 , 9,	0
16	Effects of Early- and Late-Onset Alzheimer's Disease on Caregiver Burden. 79-86	0
15	Influence of affective states on informant impression of neuropsychiatric symptoms in people living with MCI. 1-6	0
14	Association between advance care planning and depressive symptoms among community-dwelling people with dementia: An observational cross-sectional study during the COVID-19 pandemic in Japan. 11,	0

- 13 Effets à long terme d'une remédiation de la reconnaissance des émotions faciales et de ses conséquences cliniques dans la maladie d'Alzheimer. **2023**, ○
- 12 Altered nucleus accumbens functional connectivity precedes apathy in Parkinson's disease. ○
- 11 PROTOCOL: The effectiveness of sensory interventions targeted at improving occupational outcomes, quality of life, well-being and behavioural and psychological symptoms for older adults living with dementia: A systematic review and meta-analysis. **2023**, 19, ○
- 10 Abnormal functional connectivity of the habenula in mild cognitive impairment patients with depression symptoms revealed by resting-state functional magnetic resonance imaging. **2023**, 38, ○
- 9 Persistence of Neuropsychiatric Symptoms and Dementia Prognostication: A Comparison of Three Operational Definitions of Mild Behavioral Impairment. ○
- 8 Combined multidisciplinary in/outpatient rehabilitation delays definite nursing home admission in advanced Parkinson's disease patients. 14, ○
- 7 Neuroprotective, neurogenic, and anticholinergic evidence of Ganoderma lucidum cognitive effects: Crucial knowledge is still lacking. ○
- 6 Protocol of a randomized controlled trial investigating Deep Brain Stimulation for Motor symptoms in patients with Parkinson's disease Dementia (DBS-MODE). **2023**, 23, ○
- 5 Methods to Identify Cognitive Alterations from Animals to Humans: A Translational Approach. **2023**, 24, 7653 ○
- 4 Evaluación neuropsicológica en adultos. **2023**, 44, 1-13 ○
- 3 Impact of pharmaceutical care integrated at a psychosocial intervention to reduce caregiver's burden in Alzheimer's disease or related dementias: Negative results at 18 months and difficulties to conduct PHARMAID RCT. **2023**, 101146 ○
- 2 Prevalences and Indications of Psychotropic Drug Prescriptions in Nursing Home Residents with Korsakoff Syndrome. **2023**, 12, 3133 ○
- 1 The Effect of Cannabidiol 3% on Neuropsychiatric Symptoms in Dementia – Six-Month Follow-Up. 1-8 ○